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ZUSAMMENFASSUNG 
Obwohl es nur circa 1-2% der Köpermasse ausmacht, verbraucht das Gehirn im 
Ruhezustand 20% des gesamten Sauerstoffes und 25% aller Glucose im Körper. Dieser 
außerordentliche Nährstoffverbrauch erfordert eine ständige Wiederauffüllung der 
Nährstoffreserven und eine strikte Kontrolle der Homöostase im Gehirn, was in erster Linie 
durch die Zellen der Bluthirnschranke (BHS) gewährleistet wird. Die BHS befindet sich auf 
der Ebene der Kapillaren und postkapillaren Venolen und setzt sich aus Endothelzellen, 
benachbarten perivaskulären Perizyten und Astrozyten sowie einer Basallamina zusammen. 
Aufgrund seines hohen Nährstoffverbrauches reagiert das Gehirn besonders empfindlich auf 
Hypoxie und Ischämie, welche sich durch eine unzureichende Sauerstoffversorgung 
beziehungsweise eine kombinierte Sauerstoff- und Nährstoffknappheit auszeichnen. Sowohl 
Hypoxie als auch Ischämie beeinträchtigen die Integrität der BHS und sind eng mit 
verschiedenen neurologischen Erkrankungen wie Schlaganfall, Alzheimer und Multipler 
Sklerose verknüpft. Ziel dieser Arbeit war es die molekularen Zusammenhänge einer 
Dysfunktion der BHS in Bezug auf Hypoxie und Ischämie besser zu verstehen, wobei hier vor 
allem die individuellen Reaktionen der verschiedenen Zelltypen im Vordergrund standen. 
Der Transkriptionsfaktor HIF-1 (Hypoxie induzierbarer Faktor 1) ist der zentrale Regulator  
Hypoxie vermittelter Antworten, seine Rolle bezüglich der Beeinträchtigung der BHS unter 
diesen Bedingungen ist allerdings weitgehend unklar. Aus diesem Grund haben wir die 
direkte Auswirkung von HIF-1 auf die Integrität der BHS untersucht. Als in vitro Modell wurde 
die Ratten Endothelzelllinie RBE4 auf Transwellplatten kultiviert. Unsere Ergebnisse zeigten, 
dass die Stabilisierung von HIF-1 unter normalen Sauerstoffbedingungen eine vergleichbare 
Beeinträchtigung der BHS zur Folge hat wie unter Hypoxie. Wenn hingegen die Aktivität von 
HIF-1 unter Hypoxie gehemmt wurde, hatte dies einen protektiven Effekt auf die Integrität der 
BHS. Interessanterweise wurde der negative Effekt des HIF-1 Signalweges hauptsächlich 
durch eine Zerstörung der Schlussleiste (tight junctions) vermittelt, insbesondere einer 
Verlagerung der assoziierten Proteine weg von der Zellmembran, wobei eine Verminderung 
der Proteinexpression nur eine untergeordnete Rolle spielte. Zusätzlich sprechen unsere 
Ergebnisse dafür, dass die erhöhte Phosphorylierung von Tyrosinresten von Occludin und in 
geringerem Maße auch Claudin-5 durch HIF-1 und wahrscheinlich auch VEGF (Vascular 
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endothelial growth factor) verursacht wird und zu der beobachteten Dysfunktion der BHS 
führt.  
Unter hypoxischen und ischämischen Stressbedingungen spielen die generelle Toleranz der 
einzelnen Zelltypen sowie ihre spezifischen Antworten eine entscheidende Rolle für die 
Regulierung der BHS. In einer früheren Studie konnte unsere Gruppe die Bedeutsamkeit der 
Astrozyten und Perizyten für die Aufrechterhaltung der BHS unter mildem (1% O2) sowie 
erheblichem (0.1%O2) Sauerstoffentzug aufzeigen. Abhängig vom Schweregrad der Hypoxie 
beeinflussten die Zelltypen die BHS in unterschiedlicher Weise - Perizyten waren in der Lage 
die BHS unter akuter Hypoxie aufrecht zu erhalten was Astrozyten nicht gelang. Diese 
Ergebnisse legen nahe, dass die individuellen Antworten der BHS Zellen eine zentrale Rolle 
in ihrer Regulierung erfüllen. Aus diesem Grund hat sich der zweite Teil dieser Arbeit mit 
einer vergleichenden Studie befasst, in der die Hypoxie und Ischämie vermittelten Antworten 
von RBE4 Zellen, Perizyten und Astrozyten charakterisiert wurden. Indem generelle zelluläre 
Parameter wie Expression von Hypoxie gesteuerten Genen und Proteinen, die Dynamik des 
Zytoskeletts, Zellteilung und Zellviabilität untersucht wurden, konnten Endothelzellen klar als 
derjenige Zelltyp charakterisiert werden, der am stärksten reagierte und am sensibelsten war;  
Astrozyten hingegen waren am tolerantesten. Endothelzellen zeigten schon bei Hypoxie eine 
hohe Verletzlichkeit, wobei Astrozyten und Perizyten hier kaum reagierten und eine 
vergleichbare Toleranz zeigten. Ischämie hingegen tolerierten Astrozyten interessanterweise 
sehr viel besser als Perizyten. Diese Unterschiede in Bezug auf die Sensitivität sowie 
Genexpression untermauern die besondere Relevanz der resistenten perivaskulären Zellen 
für die Unterstützung der Endothelzellenfunktion. Die Tatsache, dass im Generellen die 
zellspezifischen Antworten sehr unterschiedlich sind, wirft die Frage auf, wie Hypoxie- 
regulierte Genexpression gesteuert wird.  
Mit Hilfe von Flüssigchromatographie gekoppelter Massenspektrometrie haben wir die Frage 
weiterverfolgt, ob eine differentielle Aktivität metabolischer Stoffwechselwege die 
unterschiedliche Toleranz von Endothelzellen und Astrozyten gegenüber Hypoxie und 
Ischämie erklären kann. In der Tat haben wir tiefgreifende Unterschiede im basalen sowie 
ischämischen Stoffwechsel zwischen Astrozyten und Endothelzellen beobachtet, welche sehr 
wahrscheinlich entscheidend dazu beitragen in Zeiten von Nährstoffmangel zu überleben. Wir 
 5 
konnten den Schluss ziehen, dass der basale Stoffwechsel von Astrozyten darauf 
programmiert ist Metaboliten anzureichern, die unter Stressbedingungen helfen den Energie- 
und Redoxhaushalt aufrecht zu erhalten, wie zum Beispiel Glykogen, Phosphokreatin oder 
Glutathion. Endothelzellen hingegen schienen diese Stoffe nicht zu speichern. Die Folgen 
dieser Unterschiede konnten wir vor allem unter ischämischen Bedingungen im 
Kohlenhydratstoffwechsel beobachten. In Astrozyten war dieser Stoffwechselweg nach 24 
Stunden nur geringfügig beeinträchtigt, wohingegen in Endothelzellen sehr viele Metaboliten 
stark erniedrigt waren, was nahelegt, dass sie bereits die meisten ihrer Zuckerreserven 
verbraucht haben. Solchen zellspezifischen und charakteristischen Anpassungen wie diesen 
liegen komplexe Antworten zugrunde, die maßgeblich zur Regulierung der BHS Stabilität 
beitragen. Zusammenfassend beleuchtet diese Arbeit die vielschichtigen Reaktionen und 
unterschiedliche Toleranz der verschieden BHS Zellen in Bezug auf hypoxische 
Stresssituationen. Aufgrund der komplexen Struktur der BHS beleuchtet diese Arbeit, dass 
der Erkenntnisgewinn in Bezug auf die individuellen zellulären Antworten uns eine zentrale 
Grundlage bietet, um die Regulation der BHS unter Normalsituationen sowie 
Stressbedingungen besser zu verstehen.  
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SUMMARY 
Of the whole body expenditure the brain consumes about 20% of oxygen (O2) and 25% of 
glucose although it accounts for only 1-2% of the total body mass. This extraordinary nutrient 
demand requires continuous replenishment and very well coordinated regulation of brain 
homeostasis - that is primarily mediated by the cells of the blood-brain barrier (BBB). The 
BBB is located at the level of brain capillaries and postcapillary venules being composed of 
endothelial cells, surrounded by perivascular pericytes and astrocytes as well as basement 
membranes. Due to its high nutrient demand, the brain is particularly vulnerable to insults like 
hypoxia or ischemia that are characterized by insufficient O2 supply or combined O2 and 
nutrient shortage, respectively. Hypoxia and ischemia both disturb BBB integrity, and are 
closely associated with various neurological disorders such as stroke, Alzheimer’s disease 
and multiple sclerosis. This work was directed towards a better understanding of the 
molecular relationships of hypoxic/ischemic BBB impairment with a special focus on the 
individual responses of the different barrier cells.  
Hypoxia-inducible factor-1 (HIF-1) transcription factor is the predominant regulator of hypoxic 
responses but its impact on hypoxia-mediated barrier impairment remains poorly defined, 
thus we investigated the direct consequence of HIF-1 induction on barrier function. Using the 
rat brain endothelial cell line RBE4 cultured on transwells as in vitro model our data 
demonstrated that normoxic HIF-1 stabilization results in similar disturbance of BBB function 
like hypoxic exposure, whereas hypoxic HIF-1 inhibition had a positive effect on barrier 
integrity. Interestingly the barrier compromising effects of HIF-1 were predominantly regulated 
via tight junction disruption and translocation of tight junction proteins from the plasma 
membrane and only to a minor extent through reduction of tight junction protein expression. In 
addition our data advocates that increased tyrosine phosphorylation of occludin and to a 
lesser extent claudin-5, likely induced through vascular endothelial growth factor (VEGF), is a 
mechanism by which HIF-1 mediates BBB dysfunction.  
During hypoxic and ischemic stress the general tolerance of the individual cell types and the 
adaptive responses initiated are very important for barrier outcome. Previously our group was 
able to highlight the importance of astrocytes and pericytes for barrier function maintenance 
under mild (1% O2) and severe (0.1% O2) hypoxia. Importantly depending on the severity of 
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the insult the cell types differentially modulated barrier function - showing that pericytes were 
able to maintain barrier function under severe O2 deprivation whereas astrocytes could not. 
These data suggested that the individual hypoxic responses of the BBB cells crucially 
regulate barrier function. As a consequence the second part of this thesis focused on 
performing a comprehensive study to better characterize the hypoxic/ischemic responses of 
RBE4 cells, primary astrocytes and pericytes. Comparing general cellular parameters like 
hypoxic target gene/protein induction, cytoskeletal rearrangements, proliferation and cell 
survival, endothelial cells were clearly defined as the most responsive and sensitive cell type 
amongst the three, whereas astrocytes proved to be the most tolerant.  Importantly the 
endothelial cells were vulnerable during O2 deprivation alone, whereas astrocytes and 
pericytes were hardly affected and exhibited quite similar responses. However astrocytes 
resisted extended severe oxygen-glucose deprivation much better than pericytes. These 
differences in terms of overall sensitivity and target gene induction corroborate the 
importance of support of endothelial function by the more resistant perivascular cells. With 
their overall responses being quite different raises an important and intriguing question of how 
hypoxic cell-specific gene induction is regulated.  
Using liquid chromatography-mass spectrometry (LC-MS) we pursued the question whether 
different activity of metabolic pathways could account for differential tolerance of endothelial 
cells and astrocytes to hypoxic and ischemic treatment. Indeed profound differences in the 
basal and ischemic metabolism of astrocytes and endothelial cells were identified that are 
likely crucial to survive periods of nutrient depletion. We concluded that basal astrocyte 
metabolism is programmed to accumulate metabolites that help maintain energy and redox 
state in times of distress including glycogen, phosphocreatine and glutathione, whereas in 
contrast endothelial cells do not seem to accumulate these compounds. During ischemia the 
consequences of these differences were particularly seen in central carbohydrate 
metabolism, wherein the pathway appeared to be only mildly affected after 24h of treatment 
in astrocytes, while in endothelial cells a large number of metabolites were reduced 
suggesting that the latter have consumed most of their sugar stores. Specific and differential 
characteristics of adaptation such as these can clearly underlie the complex responses of the 
different cells and modulate their contribution to BBB stability.  
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Taken together this work highlights the diverse reaction and tolerance of the individual barrier 
cell types to stress conditions. Due to the complex structure of the BBB this work emphasizes 
that an increase of our knowledge about the individual cell responses will provide a 
foundation to understand barrier regulation under normal and injury conditions.    
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1 INTRODUCTION 
Note: Sections marked with * have been adapted from our very recent review (Engelhardt et 
al., 2014b) and were originally written by S. Engelhardt. The sections have been updated with 
additional recent information where required. 
 
1.1 THE BLOOD-BRAIN BARRIER (BBB) - GENERAL CONSIDERATIONS 
1.1.1 Function and anatomy of the BBB  
In 1885 Paul Ehrlich discovered the presence of a specialized anatomical barrier between the 
brain and the blood circulation when dyes injected into the peripheral blood stream stained all 
organs except the brain and the spinal cord (Ehrlich, 1885). 15 years later Lewandowsky first 
introduced the term Bluthirnschranke (blood-brain barrier) (Lewandowsky, 1900). The blood-
brain barrier (BBB) crucially supports brain function by maintaining brain homeostasis, 
controlling cerebral nutrient uptake and molecular traffic, excluding potentially harmful 
substances from the brain, and strictly regulating immune surveillance (Abbott, 2013). In 
addition the BBB is also implicated in regulation of local blood flow and neuronal development 
(Iadecola and Nedergaard, 2007; Stenman et al., 2008; Takano et al., 2006).  
Brain capillary endothelial cells form the core of the BBB and are supported by surrounding 
pericytes, perivascular astrocytes and the basal lamina to fulfill their unique function (Abbott 
et al., 2006; Engelhardt et al., 2014b). Subsequently, the importance of intercellular signaling 
between the BBB and neurons, microglia and immune cells led to a more integrated view of 
cellular interactions within the brain and its vascular beds, referred to as the neurovascular 
unit (NVU) (Abbott, 2013; Neuwelt et al., 2011) (Fig. 1.1). Importantly the barrier function of 
the BBB acts on various levels, firstly as a physical barrier via expression of tight junction 
proteins and low pinocytic activity, secondly as a transport barrier by strictly limiting transport 
from the blood into the brain and vice versa through expression of specialized transporter 
systems, and finally as a metabolic barrier that converts molecules in transit through 
expression of specialized enzyme systems (Abbott et al., 2010).  
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Figure 1.1: The BBB protects neurons and glial cells from systemically circulating agents as brain 
microvessels form a very tight barrier clearly distinct from vessels in other organs. The barrier is formed 
by ECs (red), that line the blood vessels, surrounded by pericytes (light blue), basement membrane 
(grey) and astrocytic (dark blue) end-feet. Astrocytes provide the cellular link to the adjacent neurons 
(pink). The illustration also shows microglial cells (grey) in contact with astrocytes. Inset (black box) 
shows the cell–cell contact that takes place between two adjacent ECs at the BBB and demonstrates 
the basic organization of the BBB tight and adherens junctional proteins. Note the interactions of the 
junctional proteins with the cytoskeleton. Adapted from (Engelhardt et al., 2014b).  
 
Endothelial junctions - tight and adherens junction complexes 
At the junctional complex of polarized epithelia and endothelia three different structures are 
found: the tight junction (TJ) and adherens junction (AJ) complexes and desmosomes 
(Niessen, 2007). TJ and AJ together physically connect neighboring cells, participate in 
endothelial cell polarization and mechanotransduction and provide intercellular signaling 
platforms (Baum and Georgiou, 2011; Gulino-Debrac, 2013) (Fig 1.1 box). Although AJ 
participate in limiting paracellular passage between the adjacent cells, TJ are the major 
structures according for paracellular tightness, which is one of the most, if not the single most 
important feature of a tight BBB (Luissint et al., 2012). Both TJ and AJ complexes are 
composed of transmembrane proteins, cytoplasmic scaffold proteins associated with the 
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cytoskeleton and signaling/polarity molecules (Niessen, 2007). The nectin-afadin and 
cadherin-catenin complexes represent the central structures of the AJ. In addition PECAM-1 
(platelet endothelial cell adhesion molecule), a member of the immunoglobulin (Ig) 
superfamily of cell adhesion molecules localizes to endothelial AJ and participates in cell-cell 
adhesion and signal transmission (Ilan and Madri, 2003; Niessen, 2007). Nectins are 
members of the Ig-like adhesion receptor family forming lateral homodimers that interact 
either homophilically or heterophilically with the extracellular domains of neighboring cells. 
Nectins connect to the actin cytoskeleton via the actin-binding protein afadin (AF-6) (Niessen, 
2007) and represent the first scaffold for formation of AJ and TJ (Takai et al., 2003; Takai and 
Nakanishi, 2003). The cadherins constitute a family of roughly 20 members that 
homophilically interact with each other between adjacent cells in a Ca2+-dependent manner 
(Meng and Takeichi, 2009). The different cadherin family members are expressed in a tissue 
and cell specific manner, with VE-cadherin (vascular endothelial) being specific for 
endothelial cells (Vestweber, 2008). In addition to its adhesive functions VE-cadherin has 
been implemented in regulation of proliferation, apoptosis and paracellular permeability via 
regulation of TJ proteins, like claudin-5 and occludin (Taddei et al., 2008; Walsh et al., 2011). 
The cytoplasmic adaptor proteins of the catenin family, like β-catenin or p120-catenin connect 
cadherins to the actin cytoskeleton and microtubules (Baum and Georgiou, 2011; Meng and 
Takeichi, 2009). More than just functioning as linker molecules catenins fulfill important roles 
in cellular signaling. β-catenin binds to EGF receptor and tyrosine phosphatases but also is a 
central modulator of the wnt signaling pathway thus linking cellular adhesion to cell fate 
determination signaling, whereas p120-catenin has been implemented in regulation of 
endocytosis (Niessen, 2007).  
At the TJ at least three different types of transmembrane proteins are located that mediate 
cell-cell adhesion: the proteins of the claudin, occludin and junctional adhesion molecules 
family (JAMs) (Bauer et al., 2011; Luissint et al., 2012). Claudins and the members of the 
occludin family belong to the superfamily of MARVEL (Mal and related proteins for vesicle 
trafficking and membrane link) proteins that contain a conserved four-transmembrane 
MARVEL domain (Sanchez-Pulido et al., 2002). The claudins constitute a family of more than 
24 members and are separated by sequence homology into classical (Claudins 1-10, 14, 15, 
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17, 19) and non-classical claudins (Claudins 11-13, 16, 18, 20-24) (Krause et al., 2008). All 
claudins share the common function of paracellular sealing, which is tissue-, size- and charge 
selective (Krause et al., 2008). Indeed the tightness of a tissue appears to be crucially 
dependent on the combination of expressed claudin isoforms and as such tightening claudins 
(claudins 1, 5, 11, 14) and pore forming (claudins 2, 7, 15, 16) claudins have been identified 
(Krause et al., 2008). Both homo- and heterophilic interactions have been observed for 
claudins. Endothelial cells at the BBB express the claudin isoforms 1, 3, 5 and 12 (Goncalves 
et al., 2013). Knockout studies using transgenic mouse models have revealed the particular 
importance of TJ proteins for BBB function. Claudin-5-/- mice showed normal development 
and morphology of the vasculature, but exhibited increased BBB permeability to molecules 
smaller than 800 Da and died within 10h after birth (Nitta et al., 2003). In contrast, the 
occludin knockout did not cause vascular impairment or disturbed tight junction morphology, 
but resulted in increased calcification of the cerebellum and basal ganglia (Saitou et al., 
2000). However a complex histological phenotype with chronic inflammation and poor TJ 
integrity in various epithelial tissues suggests a role for occludin in TJ stability rather than TJ 
assembly (Cummins, 2012; Saitou et al., 2000).  
The integral membrane proteins of the TJ interact with adaptor/scaffolding proteins, signaling 
molecules and transcriptional regulators (Bauer et al., 2011). Scaffolding proteins such as 
zonula occludens (ZO-1) proteins 1-3, AF-6 or cingulin provide the physical link between the 
TJ transmembrane proteins and the actin cytoskeleton and confer stability (Bauer et al., 2011; 
Gonzalez-Mariscal et al., 2003).  
 
Regulation and posttranslational modifications of tight junction complexes 
Through interaction with kinases and small GTPases, TJ directly participate in cell signaling 
events and are able to transmit extracellular information into the cells (Gonzalez-Mariscal et 
al., 2003). Particularly the small GTPases of the Rho family, RhoA, Rac1 and Cdc42 and 
protein kinases like PI3K, PKC and MAPK have been attributed an important function in 
signaling events at the TJ and similarly TJ regulation (Bauer et al., 2011; Gonzalez-Mariscal 
et al., 2008). Importantly TJ are not rigid structures but constantly undergo dynamic changes 
(Niessen, 2007; Steed et al., 2010). A study by Shen and co-workers used fluorescently-
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tagged tight junction proteins to follow their dynamics by fluorescence recovery after 
photobleaching (FRAP) and showed that claudin-1 stably localized to the tight junctions, 
whereas about 70% of the occludin diffused rapidly within the cellular membranes and about 
70% of ZO-1 molecules translocated between a membrane associated state and the 
cytoplasm (Shen et al., 2008). Besides diffusion and translocation, tight junctions also 
undergo degradation and posttranslational alterations that affect overall barrier tightness 
(Luissint et al., 2012). Indeed many TJ-associated proteins can be phosphorylated at serine, 
threonine and tyrosine residues (Luissint et al., 2012). The phosphorylation pattern in the end 
affects TJ protein conformation and their interaction with each other and thus crucially 
regulates BBB tightness (Gonzalez-Mariscal et al., 2008; Luissint et al., 2012). In MDCK cells 
strong Ser/Thr-phosphorylation of occludin triggers its localization to TJ whereas non or 
weakly phosphorylated occludin is mainly distributed across basolateral membranes 
(Sakakibara et al., 1997). However in brain cells Ser/Thr phosphorylation of occludin and 
claudin-5 by Rho/ROCK has been correlated to BBB breakdown (Persidsky et al., 2006). 
Similarly increased Tyr-phosphorylation of occludin has been observed during BBB 
impairment (Cummins, 2012; Engelhardt et al., 2014a; Gonzalez-Mariscal et al., 2008). These 
studies show that the effect of phosphorylation on barrier function cannot be generalized 
because depending on the tissue, cell type, the kinase involved and on the type of stimulus 
the outcome on barrier integrity can be very distinct (Cummins, 2012; Gonzalez-Mariscal et 
al., 2008). Importantly proteins localized at the AJ have also been implicated in TJ control. AJ 
facilitate formation of TJ by recruitment of ZO-1 to cadherin complexes, which then forms a 
scaffold for TJ formation (Itoh et al., 1997; Niessen, 2007). β-catenin has been shown to 
regulate maintenance of BBB phenotype during embryonic and postnatal development in vivo 
and its inactivation causes decreased claudin-3 expression coincidentally with BBB 
breakdown (Liebner et al., 2008). Similarly VE-cadherin was shown increase barrier tightness 
via upregulation of claudin-5 expression and suppression of occludin phosphorylation (Taddei 
et al., 2008; Walsh et al., 2011).  
Overall these studies highlight the highly dynamic nature of the TJ and the multifaceted 
possibilities of TJ regulation through signaling cascades as well as cellular structures like the 
cytoskeleton or AJ.  
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1.1.2 Contribution of perivascular cells to BBB regulation*  
Endothelial cells certainly represent the core of the BBB. However it has become very evident 
that the inductive environment of the brain crucially contributes to the tightness of brain 
endothelial cells (Ballabh et al., 2004).  Many in vitro studies revealed that upon co-culture 
with perivascular cells, particularly astrocytes and pericytes, endothelial cells exhibit a state of 
significant tightness and tight junction expression (Abbott et al., 2006; Ballabh et al., 2004; 
Ogunshola, 2011). In the following two chapters the current state of research on the impact of 
astrocytes and pericytes on physiological BBB function will be discussed. 
1.1.2.1 Astrocytes*  
Similar to neurons and other glial cells, astrocytes originate from the neuroectoderm (Allen 
and Barres, 2009). To date 11 different types of astrocytes are classified based on their 
structural and functional interaction with their environment, of which 8 are specifically 
associated with blood vessels (Abbott et al., 2006). Astrocytes are crucially involved in control 
of neuronal function through regulation of brain homeostasis, supply of neurons with energy 
and substrates for neurotransmission and recycling of neurotransmitters. Furthermore they 
represent the connection between neurons and the brain vasculature, which they cover with 
their end-feet. Almost 50 years ago the close proximity of the astrocytic end-feet to the brain 
endothelium raised the hypothesis that astrocytes contribute to BBB regulation (Davson and 
Oldendorf, 1967). Since then a number of in vivo (Janzer and Raff, 1987; Stewart and Wiley, 
1981; Willis et al., 2004b) and particularly in vitro studies have demonstrated the importance 
of astrocytes to BBB induction and regulation. Deletion of astrocytes in vivo using 3-
chloropropandiol results in increased vascular permeability to 10 kDa dextran and 300 kDa 
fibrinogen, implying a major disruption of the BBB. Moreover a loss of claudin-5, occludin and 
ZO-1 from the cellular junctions is observed, whereas astrocytic repopulation reverses tight 
junction protein loss and restored BBB function (Willis, 2011; Willis et al., 2004a). Studying 
the contribution of astrocytes to BBB function in vivo is highly complex due to technical 
challenges and as such in vitro studies have crucially contributed to our understanding about 
astrocytic modulation of BBB tightness. Model systems using astrocyte-endothelial co-
cultures (Al Ahmad et al., 2009; Dehouck et al., 1990; Fischer et al., 2000; Rist et al., 1997) 
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as well as astrocyte-conditioned media (Raub et al., 1992; Rubin et al., 1991) demonstrated 
the inductive potential of astrocytes on barrier tightness by increased transendothelial 
electrical resistance (TEER) and reduced permeability to low molecular weight tracers (for 
detailed review refer to the excellent article by (Deli et al., 2005)). There is now good 
evidence that barrier induction through astrocytes is mainly mediated via changes in the 
number, length and complexity of endothelial TJs (Tao-Cheng et al., 1987), expression levels 
of TJ and associated-proteins like occludin and ZO-1 (Colgan et al., 2008; Siddharthan et al., 
2007) and the redistribution of junctional proteins such as platelet endothelial cell adhesion 
molecule-1 (PECAM-1), ZO-1 and claudin-5 at endothelial junctions (Al Ahmad et al., 2011; 
Colgan et al., 2008). In addition astrocytes modulate expression and polarized localization of 
endothelial transporters, such as P-glycoprotein (P-gp) or multi drug resistance protein (MRP) 
(Al Ahmad et al., 2011; Berezowski et al., 2004) as well as BBB-specific enzyme-systems 
such as γ-glutamyl transpeptidase (Hayashi et al., 1997; Meyer et al., 1991) and thus crucially 
regulate EC function. Major efforts have been made to unravel how astrocytes modulate TJs, 
transporters and enzyme systems. Astrocytes are known to secrete a large number of 
substances including peptides, growth factors and chemokines (Nico and Ribatti, 2012) 
several of which modulate barrier function, such as basic fibroblast growth factor (bFGF), 
transforming growth factor-β1 (TGF-β1), glial cell-derived neurotrophic factor and src-
suppressed C-kinase substrate (SSeCKS) (Dohgu et al., 2004; Igarashi et al., 1999; Lee et 
al., 2003; Reuss et al., 2003; Shimizu et al., 2012; Sobue et al., 1999; Walshe et al., 2009). 
For instance bFGF has demonstrated barrier-tightening effects in vitro by reducing barrier 
permeability (Sobue et al., 1999) and increasing endothelial γ-glutamyl-transpeptidase and 
alkaline phosphatase activity (el Hafny et al., 1996). In vivo bFGF knockout increases BBB 
permeability to albumin and reduces expression of ZO-1 and occludin, and coincides with 
reduced astrocyte differentiation (Reuss et al., 2003). The effect of astrocyte-secreted TGF-
β1 on barrier function is discussed controversially. While some studies observed reduced 
BBB permeability and increased TJ expression in presence of TGF-β1/TGF-β (Dohgu et al., 
2005; Dohgu et al., 2004; Walshe et al., 2009) others reported adverse effects (Shen et al., 
2011). This discrepancy may be explained by the fact that TGF-β effects on the endothelium 
are highly dependent on the endothelial activation state and the tissue environment, 
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especially the extracellular matrix as it mediates TGF-β activation (Cambier et al., 2005). 
Table 1.1 summarizes the discussed barrier inducing properties of astrocytes.  
Over the past 20 years our understanding of the importance of astrocytes as regulators of 
BBB physiology and how they modulate barrier characteristics has dramatically increased 
but, realistically, unraveling of the complex pathways has just begun. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: Stabilizing effects of astrocytes and pericytes during physiological BBB regulation. 
 
1.1.2.2 Pericytes* 
The origin of CNS pericytes remains unclear with derivation from the mesoderm and 
neuroectoderm as well as from the monocyte lineage under general discussion (Sa-Pereira et 
al., 2012). Diverse functions within the brain have been attributed to pericytes including 
regulation of brain homeostasis, angiogenesis, blood flow, immune and phagocytic activity, as 
well as being a source of pluripotent stem cells (Sa-Pereira et al., 2012). The impact of 
pericytes on BBB induction and maintenance is less well characterized than astrocyte-
induced responses. During development pericytes fulfill central roles in vessel stabilization 
through inhibition of EC proliferation and migration as well as regulation of vessel maturation 
Induc&ve)eﬀects)of)perivascular)cells)on)normal)BBB)func&on)
Astrocytes) •  &ght)junc&on)(TJ))integrity)
•  increased)number)and)length)of)TJ)
•  elevated)TJ)protein)expression)
•  stabilized)localiza9on)of)TJ)proteins)at)the)cellular)junc9ons)
•  polarized)expression)of)endothelial)transporter)and)
enzyme)systems)
•  p;glycoprotein)
•  γ;glutamyl)transpep9dase)
•  secreted)factors)increasing)BBB)func&on)
•  basic)ﬁbroblast)growth)factor)(bFGF))
•  transforming)growth)factor;β)(TGF;β))
•  glial)cell;derived)neurotrophic)factor)(GDNF))
•  src;suppressed)C;kinase)substrate)(SSeCKS)))
Pericytes) •  increased)&ght)junc&on)protein)expression)
•  inhibi&on)of)endothelial)transcytosis)(via)Mfsd2a))
•  secreted)factors)increasing)BBB)func&on)
•  angiopoie9n;1)(ANG;1))
•  transforming)growth)factor;β)(TGF;β))
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(Al Ahmad et al., 2011; Antonelli-Orlidge et al., 1989; Hellstrom et al., 2001; Sa-Pereira et al., 
2012). Recent in vivo studies using platelet-derived growth factor receptor β (PDGF-Rβ) 
knockout mice have significantly improved our understanding. During embryonic 
angiogenesis pericytes are recruited to the vessels via EC-derived platelet-derived growth 
factor β (PDGF-β). The impaired recruitment of pericytes to the brain microvasculature 
through abrogation of PDGF-β signaling either by PDGF-β or PDGF-Rβ knockout resulted in 
severe vascular consequences such as increased vessel diameter, formation of 
microaneurysms, endothelial hyperplasia and increased vessel permeability (Daneman et al., 
2010; Hellstrom et al., 2001; Lindahl et al., 1997). These alterations in vessel tightness were 
attributed to enhanced caveolae formation and transcytosis, abnormal TJ alignment and 
increased expression of permeability inducing factors like vascular endothelial growth factor 
(VEGF) and angiopoietin (ANG)-2 (Daneman et al., 2010; Hellstrom et al., 2001). 
Corresponding studies in adult mice revealed that pericytes are also crucial for adult BBB 
maintenance as reduced pericytic vessel coverage resulted in increased BBB permeability, 
altered endothelial gene expression and loss of astrocyte end-feet polarization (Armulik et al., 
2010). Age-dependent pericyte-loss in PDGF-Rβ+/- mice elevated parenchymal accumulation 
of blood proteins and leakage of neurotoxic and vasculotoxic substances into the brain 
parenchyma and reduction of ZO-1 and occludin protein expression (Bell et al., 2010). A very 
recent study by Ben-Zvi and co-workers demonstrated the importance of pericyte-mediated 
signaling on BBB tightness (Ben-Zvi et al., 2014). Mfsd2a (major facilitator super family 
domain containing 2a) is selectively expressed in BBB endothelial cells and its ablation 
results in increased BBB permeability due to increased transcytotic activity. Interestingly 
pericyte-deficient mice similarly showed increased transcytotic activity and reduced vascular 
Mfsd2a expression, suggesting a crucial role in pericyte-mediated signaling in regulating 
Mfsd2a expression and reducing endothelial transcytotic activity.  
In vitro studies using cells of human, murine, bovine, and porcine origin further underlined the 
positive effect of pericytes on BBB tightness (Al Ahmad et al., 2009; Daneman et al., 2010; 
Dohgu et al., 2005; Hayashi et al., 2004; Nakagawa et al., 2007). Similar to astrocytes, 
pericytes are capable of secreting factors that modulate BBB permeability under normal 
conditions, like ANG-1 (Hori et al., 2004; Wang et al., 2007), TGF-β1 (Dohgu et al., 2005) and 
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GDNF (Shimizu et al., 2012) that increase ZO-1, claudin-5 or occludin in vitro (Hori et al., 
2004; Shimizu et al., 2011; Wang et al., 2007). Therefore similar to astrocytes, pericytes 
seem capable of modulating TJs. In contrast a few in vitro studies report that co-culture of 
ECs with pericytes reduces TEER via induction of matrix metalloproteinases (MMP) -2 and -9 
activity and activation of VEGF-mediated signaling (Thanabalasundaram et al., 2010; Zozulya 
et al., 2008). Interestingly this negative impact of pericytes seems to be dependent on their 
differentiation state (Thanabalasundaram et al., 2011). The discussed effects of pericytes on 
barrier function are shown in Table 1.1.  
 
1.2 HYPOXIA AND ISCHEMIA 
Hypoxia develops when the blood stream fails to supply the oxygen demand of tissues and 
often acts as an initial trigger for pathophysiological changes at the BBB (Zepeda et al., 
2013). Hypoxic events can be divided into two major groups: non-vascular mechanisms, like 
high altitude, anemia, carbon monoxide poisoning or suffocation and pathologies affecting the 
vasculature either acutely or chronically. Atherosclerosis, and hypertension are important 
pathologies associated with reduced blood supply through vascular defects, which ultimately 
result in tissue hypoxia (Stanimirovic and Friedman, 2012). Ischemia is characterized by 
impaired blood supply ultimately resulting in combined tissue hypoxia and impaired nutrient 
supply, thus representing a more severe injury than hypoxia alone and is a hallmark of 
pathologies like ischemic and hemorrhagic stroke, traumatic brain injury, severe hypotension 
or cardiac arrest (Hawkins and Davis, 2005; Zoppo and Hallenbeck, 2000). Overall similar 
effects on cellular function like metabolic dysregulation, oxidative stress, inflammatory 
responses and BBB impairment are observed in both hypoxia and ischemia (Stanimirovic and 
Friedman, 2012) and responses to both injuries are regulated via hypoxic transcription 
factors, such as the HIF-1 pathway (Singh et al., 2012).  
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1.2.1 The HIF-1 signaling pathway*  
Hypoxia requires an immediate response of the affected tissues/cells to sustain their function 
and prevent cell death. The most important tasks of the adaptation process are to decrease 
energy consumption and increase oxygenation. This is mainly achieved through metabolic 
adaptation and temporal cell cycle arrest as well as induction of angiogenic and erythropoietic 
genes (Wenger et al., 2005). Different signaling pathways are involved in these events 
including the unfolded protein response, mTOR (mammalian target of rapamycin) signaling 
and hypoxia-inducible factor (HIF)-mediated gene regulation (Majmundar et al., 2010). HIFs 
are considered master regulators of the hypoxic response and are heterodimeric transcription 
factors composed of an oxygen sensitive α-subunit and a constitutively expressed β-subunit. 
Under normoxia the HIFα subunits are constitutively transcribed but constantly targeted for 
proteasomal degradation through a cascade of hydroxylation of conserved proline residues 
via prolyl hydroxylases (PHDs), subsequent recognition by the Von Hippel Lindau (VHL) 
protein, ubiquitination and degradation by the proteasome. As oxygen tension drops, the PHD 
enzymes are inhibited and the lack of hydroxylation results in cytoplasmic stabilization of the 
α-subunits. After phosphorylation HIFαs translocate to the nucleus and dimerize with ARNT 
(Aryl hydrocarbon receptor nuclear translocator, also known as HIF-β) and co-activators 
forming a functional HIF transcription factor (Fandrey and Gassmann, 2009; Wenger et al., 
2005). By binding to hypoxia responsive elements in promoter regions HIFs induce 
expression of target genes involved in cellular adaptation to hypoxic stress regulating 
erythropoiesis, angiogenesis, proliferation, and cellular metabolism (Ogunshola and Al-
Ahmad, 2012) (Fig. 1.2).  
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Figure 1.2: Schematic diagram illustrating the mechanism of HIF-1 regulation under normoxic and 
hypoxic conditions. HIFs are heterodimeric transcription factors composed of an oxygen-sensitive α-
subunit and a constitutively expressed β-subunit (also known as ARNT). Under normoxia (white 
gradient), the HIF-1α subunit is constitutively transcribed but constantly targeted degradation through 
hydroxylation of conserved proline residues by PHDs leading to recognition by VHL protein, 
ubiquitination and subsequent degradation by proteasome. As oxygen tension drops (red gradient), the 
PHD enzymes are inhibited and the lack of hydroxylation results in cytoplasmic stabilization of the α-
subunits. After phosphorylation, HIF-1α translocates to the nucleus and dimerizes with HIF-1β and co-
activators such as p300/CBP forming a functional HIF-1 transcription factor. HIF-1 then binds to 
hypoxia-responsive elements (HREs) in the promoter regions of its many targets inducing expression of 
genes involved in cellular adaptation to hypoxic stress by regulating erythropoiesis, angiogenesis, 
proliferation and cellular metabolism in order to reduce O2 consumption and increase O2 delivery to 
tissues. Adapted from (Engelhardt et al., 2014b). 
 
Three different HIFs have been identified namely HIF-1, -2 and -3 of which HIF-1 is the most 
widely studied. More than 100 HIF-1 target genes are known to date (Semenza, 2003) and as 
a consequence HIF-1 signaling is considered essential for cellular adaptation and survival 
during acute hypoxia. Mice with constitutive HIF-1α -/- die at E11 due to vascular and cardiac 
defects (Iyer et al., 1998; Ryan et al., 1998). Underlining the crucial contribution of HIF-1 in 
brain development it was further reported that HIF-1α knockout causes a lack of cerebral 
vessel formation (Ryan et al., 1998) 
Several HIF-1 target genes are neuroprotective and act as pro-survival factors such as 
erythropoietin and VEGF. Moreover HIF-1 signaling regulates the expression of several 
proteins implicated in glycolysis such as phosphofructokinase or enolase-1 and glucose 
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transporter 1 (GLUT-1) thus regulating metabolic adaptation to low oxygenation. Besides its 
positive effects HIF-1 also accounts for detrimental effects observed during hypoxia/ischemia 
by activation of pro-death genes, such as BNIP3 (BCL2/adenovirus E1B 19 kDa protein-
interacting protein 3), COX2, or p53 stabilization (Singh et al., 2012). The potential dual 
outcome of HIF-1 signaling has also been documented in various in vivo disease studies. A 
study by Helton and colleagues reported that late-stage brain deletion of HIF-1α in adult mice 
protects from ischemic cell death and that decreased HIF-1 levels are neuroprotective (Helton 
et al., 2005). Similarly in neonatal hypoxic-ischemic injury in rats it was shown that inhibition 
of HIF-1 signaling using 2-methoxyestradiol (2ME2) exerts a neuroprotective effect through 
reduction of infarct volume and brain edema, whereas HIF-1 stabilization via PHD inhibition 
using dimethyloxalylglycine (DMOG) had opposite effects (Chen et al., 2008b). In contrast 
two other studies observed positive effects of HIF-1 signaling on injury outcome. Using a rat 
middle cerebral artery occlusion ischemic stroke model Yan et al. showed that inhibition of 
HIF-1 signaling using 3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole (YC-1) results in 
increased infarct volumes and mortality rates albeit reduced permeability to Evans blue was 
observed (Yan et al., 2011). Neuronal-specific HIF-1α depletion in a mouse model transient 
focal ischemia led to increased tissue damage and cell death (Baranova et al., 2007). At 
present it is not clear what determines whether the initiated HIF-1 mediated response is 
protective or detrimental. However it is likely that the severity of the insult and its duration, as 
well as cell type-specific differences and paracrine signaling play a critical role. Thus HIF-1 
signaling is a key determinant of functional outcome. In contrast less is known about HIF-2 
signaling. HIF-2α knock down in mice is lethal around day E16.5 due to complications 
including bradycardia and incomplete lung maturation (Compernolle et al., 2002; Tian et al., 
1998). In contrast to HIF-1α, that is expressed constitutively in all tissues, HIF-2α shows a 
tissue-specific restricted expression pattern, which is limited to the endothelium, brain, kidney, 
lung, heart and small intestine (Loboda et al., 2010; Zepeda et al., 2013). Structurally HIF-1α 
and HIF-2α are very closely related, have an amino acid sequence homology of 48% and 
similar protein structures (Koh and Powis, 2012). Although they activate common target 
genes, both HIF-α isoforms also activate individual, specific genes due to disparities in their 
transactivation domains (Loboda et al., 2010). In contrast to HIF-1α, HIF-2α does not induce 
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glycolytic enzymes but instead specifically controls erythropoietin and oct4 (transcription 
factor regulating stem cell proliferation) expression. HIF-2α also predominantly regulates 
cyclin D4 and transforming growth factor α induction, whereas HIF-1α does not (Loboda et 
al., 2010). Generally HIF-1α is considered to particularly mediate acute adaptation to hypoxia, 
whereas HIF-2α is predominantly involved in chronic adaptation (van Patot and Gassmann, 
2011).  
HIF-2α is highly expressed in embryonic vasculature controlling target genes involved in 
regulation of vascular function and angiogenesis (Skuli et al., 2009). Indeed endothelial cell-
specific HIF-2α knockdown causes severe vascular defects including increased vessel 
permeability, abnormal vessel ultrastructure and pulmonary hypertension (Skuli et al., 2009), 
implicating its crucial role in vessel function. Unfortunately the role of HIF-2 signaling on BBB 
function has been largely neglected so far and therefore will not be further discussed.  
 
1.2.2 Consequences of hypoxic injury on cell state 
1.2.2.1 Adaptive hypoxic responses 
As discussed above hypoxic and ischemic signaling leads to the up-regulation of a large 
number of genes that critically modulate cellular adaptation and determine functional 
outcome. With regard to an entire organism adaptive responses include adaptation of 
metabolism, increase of local blood flow, induction of erythropoiesis and angiogenesis in 
order to decrease reduce O2 consumption and increase O2 delivery to the issues (Fandrey 
and Gassmann, 2009; Ogunshola and Al-Ahmad, 2012). At the cellular level the major 
requirement for survival is to reach a balance between energy consumption and energy 
production, as depletion of ATP ultimately results in bioenergetic collapse, and to keep 
oxidative stress levels low in order to reduce damage (Wheaton and Chandel, 2011). The 
cellular responses mediating these adaptations are discussed in detail below. 
 
Adaptations to maintain cellular energy balance 
Hypoxia decreases mitochondrial electron transport chain through HIF-1 mediated gene 
regulation leading to a reduction of ATP production (Wheaton and Chandel, 2011), thus an 
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adaptation of cell metabolism is indispensable in order to enable sufficient production of ATP 
(discussed in detail in Section 1.2.2.3).  
Another important mechanism used by cells to maintain energy balance is the reduction of 
energy and O2 consumption via inhibition of highly energy demanding processes like protein 
synthesis, Na-K-ATPase activity and proliferation (Semenza, 2011; Tracy and Macleod, 2007; 
Wheaton and Chandel, 2011). Indeed mRNA translation is a major consumer of cellular 
energy and many studies have shown that during hypoxia mRNA translation is inhibited via 
mTOR and PERK (pancreatic eIF2α kinase) signaling (Arsham et al., 2003; Bi et al., 2005; 
Koritzinsky et al., 2006; Wheaton and Chandel, 2011). It is note-worthy however that many 
HIF-1 target genes are translated in a cap-independent manner and thus continue to be 
translated even if general translation is inhibited. (Tracy and Macleod, 2007). Inhibition of the 
Na-K-ATPase during hypoxia is another very efficient way to reduce cellular energy 
consumption as this pump has been reported to consume between 30-50% of total cellular 
energy demand (Murphy and Crewther, 2013; Wheaton and Chandel, 2011). Indeed hypoxic 
phosphorylation of the Na-K-ATPase results in its internalization in an AMPK/PKC ς 
dependent manner (Gusarova et al., 2009) and chronic hypoxia triggers HIF-1 induced 
degradation of the Na-K-ATPase by the proteasome (Zhou et al., 2008). Appropriate 
regulation of cell cycle similarly represents a fundamental characteristic to adapt to altered O2 
levels (Semenza, 2011). Most cell types reduce their proliferative rate through a hypoxia-
mediated arrest in the G1 phase in an HIF-1 dependent fashion, although some specialized 
cells like endothelial cells undergo mitosis in hypoxia as an adaptive mechanism (Semenza, 
2011). A significant reduction of proliferation has been measured by BrdU incorporation in 
primary mouse fibroblasts and B-lymphocytes after 24h of hypoxic exposure (0.5% O2) (Goda 
et al., 2003). Importantly the reduction in proliferation was abolished in HIF-1α knock out 
fibroblasts, thus implying a HIF-1α- dependent regulation of cell cycle. A similar observation 
has also been made for embryonic mouse stem cells (Carmeliet et al., 1998). Interestingly 
both studies observed a correlation between HIF-1α stabilization and increased mRNA 
expression of cyclin dependent kinase (CDK) inhibitor p21 (Carmeliet et al., 1998; Goda et 
al., 2003).  
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A correlation between HIF-1α, c-myc - that has been shown to promote proliferation via 
inhibition of p21 - and p21 was also demonstrated. Under normoxic conditions c-myc binds 
the p21 promoter, inhibits its transcription and consequently promotes proliferation, whereas 
under hypoxic conditions HIF-1α directly interacts with c-myc and displaces it from p21 
promoter, thus allowing its transcription and inhibition of cell proliferation (Koshiji et al., 2004; 
Semenza, 2011). In addition HIF-1α regulates proliferation through interaction with the mini-
chromosome maintenance (MCM) helicase. MCM assembles at the replication origin and is 
essential for DNA replication. Two of its subunits MCM7 and MCM3 have been shown to 
crucially affect HIF-1 signaling by targeting HIF-1α for degradation via promoting its 
hydroxylation and inhibiting its transactivation domain in an asparaginyl-dependent manner, 
respectively (Hubbi et al., 2011). However during prolonged hypoxia MCM mRNA decreases 
in a HIF-1α dependent manner implying a mutual regulation between MCM helicases and 
HIF-1α in control of cell proliferation (Semenza, 2011).  
Induction of autophagy was considered for a long time as a cell death preceding mechanism, 
however growing experimental evidence suggests a survival promoting action by clearing of 
damaged organelles and proteins, energy generation through catabolism of macromolecules 
and reduction of oxidative stress (Balduini et al., 2012; Tracy and Macleod, 2007; Zhang et 
al., 2008). A study by Bellot and coworkers demonstrated the survival-promoting role of 
hypoxia-induced autophagy as knock-down of BNIP3/BNIP3L (Nix, a closely related protein of 
BNIP3) and Beclin-1 results in increased hypoxic cell death rates (Bellot et al., 2009). 
Furthermore their data shows that double knockdown of BNIP3 and BNIP3L leads to a 
significant reduction of hypoxia-induced autophagy, whereas its ectopic overexpression under 
normoxic conditions stimulates autophagy (Bellot et al., 2009). They propose a model in 
which BNIP3 acts as initiator of Beclin-1 and LC3 mediated autophagy via displacement of 
Beclin-1 from its inhibitory interaction with Bcl-2 (B-cell lymphoma 2) (Bellot et al., 2009).  
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Reduction of oxidative stress  
Due to its high O2 consumption and oxidative metabolism the brain is prone to accumulate 
reactive oxygen species (ROS) and experience oxidative stress (Chong et al., 2005; Warner 
et al., 2004). In addition some particular anatomical features, like high amounts of 
unsaturated fatty acids, high iron levels and a relatively low catalase activity similarly account 
for the high vulnerability of the brain to oxidative damage (Chong et al., 2005). Cells 
constantly generate ROS. A major ROS source is electron leak in the electron transport chain 
but also certain enzymes such as nitric oxide synthases, cyclooxygenase, lipooxygenase, or 
L-amino acid oxidase account for ROS production (Chong et al., 2005; Erecinska and Silver, 
2001). Oxidative stress only develops when ROS outbalance the cellular anti-oxidative 
capacity (Warner et al., 2004). Indeed low levels of ROS may have a positive effect on 
initiation of adaptive responses and contribute to initiation of hypoxic signaling via HIF 
stabilization (Hamanaka and Chandel, 2010). However excessive ROS generation causes 
lipid peroxidation, protein, nucleic acid and carbohydrate damage ultimately resulting in 
irreversible cellular injury (Erecinska and Silver, 2001; Hamanaka and Chandel, 2010). 
Hypoxia and ischemia are characterized by increased ROS production and reduction of 
oxidative stress represents another crucial parameter modulating survival or cell death in 
these injuries (Chandel et al., 2000; Guzy et al., 2005; Hamanaka and Chandel, 2010; 
Warner et al., 2004; Zepeda et al., 2013). Superoxide is the major factor causing oxidative 
stress (Warner et al., 2004) and brain cells have developed different scavenging 
mechanisms. Enzymatic antioxidants like superoxide dismutase, peroxidases and catalase, 
convert superoxide to H2O2, water and water and oxygen, respectively (Warner et al., 2004). 
In addition dietary and endogenous antioxidants like glutathione, ascorbate or α-tocopherol 
function as potent superoxide scavengers (Warner et al., 2004). However the most important 
direct adaptation of cells experiencing oxidative stress is probably the inhibition of the 
mitochondrial electron transport chain to actively reduce ROS formation per se (Erecinska 
and Silver, 2001; Wheaton and Chandel, 2011). Interestingly it was shown that in mouse 
embryonic fibroblasts BNIP3-mediated autophagy via Beclin-1 and autophagy protein 5 
(Atg5) functions as an adaptive mechanism by reduction of ROS formation and inhibition of 
cell death during prolonged hypoxia (Zhang et al., 2008). 
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1.2.2.2 Detrimental hypoxic responses 
Besides numerous positive adaptation mechanisms, adverse responses are similarly 
observed during hypoxia/ischemia when a sufficient adaptation cannot be achieved. Due to 
their importance for this project the adverse effects of hypoxia on BBB function are discussed 
in a separate chapter (see Section 1.3). On a cellular level insufficient adaptation or too 
severe injury conditions ultimately results in initiation of cell death due to depletion of energy 
stores or irreversible cellular damage, e.g. through ROS as discussed above. 
Induction of apoptosis in response to hypoxic exposure is quite well characterized. Apoptosis 
represents an energy dependent process thus a combination of severe hypoxia and presence 
of ATP is required for its induction (Greijer and van der Wall, 2004). In contrast hypoxia 
combined with nutrient depletion prevents apoptosis and provokes necrosis (Greijer and van 
der Wall, 2004). Hypoxia has been shown to trigger apoptosis via three different mechanisms: 
1. Inhibition of the mitochondrial electron transport chain causes a reduction in membrane 
potential leading to reduced mitochondrial ATP production resulting in activation of the pro-
apoptotic proteins Bak and Bax (Altman and Rathmell, 2012; Greijer and van der Wall, 2004). 
These trigger increased release of cytochrome C from the mitochondria, which in the end 
activates the caspase signaling cascade and ultimately results in apoptosis (Greijer and van 
der Wall, 2004; Wei et al., 2001). 
2. Elevated ROS levels trigger cytochrome C independent activation of caspase-3 and -12 
finally resulting in activation of the initiator caspase-9 that mediates apoptosis (Greijer and 
van der Wall, 2004). In addition ROS have also been shown to mediate apoptosis via p53 
induced cytochrome C release in a number of different tissues (Altman and Rathmell, 2012).  
3. Hypoxic activation of the c-Jun NH2 terminal kinase (JNK) has been reported to mediate 
cell death in melanoma cells, as its depletion protected the cells from hypoxia-induced cell 
death (Greijer and van der Wall, 2004; Kunz et al., 2001). 
Importantly HIF-1 signaling has been shown to promote hypoxia-induced apoptosis by two 
different mechanisms - p53 stabilization that results in Bak/Bax activation triggering 
mitochondrial cytochrome C release (Altman and Rathmell, 2012; Greijer and van der Wall, 
2004) and via BNIP3/BNIP3L mediated inhibition of the anti-apoptotic proteins Bcl-2 and Bcl-
xL (Kubli et al., 2007; Renault and Manon, 2011).  
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Necrotic cell death primarily occurs when cells cannot meet their minimal energy demand to 
maintain electrochemical potential resulting in osmotic stress, cell swelling and cell rupture 
(Altman and Rathmell, 2012; Zong and Thompson, 2006). Ischemia/reperfusion, which is 
characterized by nutrient depletion with subsequent excessive ROS production, is frequently 
associated with necrosis (Altman and Rathmell, 2012; Zong and Thompson, 2006). Induction 
of necrosis has been further observed in various cells types, including neurons, particularly 
after anoxic or near anoxic events (O2<0.1%) (Lenihan and Taylor, 2013; Niquet et al., 2003; 
Steinbach et al., 2003).  
 
1.2.3 Normoxic versus hypoxic/ischemic cellular metabolism  
Normoxic energy metabolism - a focus on brain cells 
Under normal conditions the major energy source of the brain is glucose, that is transported 
from the blood stream via the BBB into the brain parenchyma (Duelli and Kuschinsky, 2001; 
Hertz, 2008; Hertz et al., 2007; Wiesinger et al., 1997). Glucose can be metabolized via 
various metabolic pathways including glycolysis, pentose phosphate pathway (PPP), the 
glucuronic acid pathway and glycogen synthesis (Wamelink et al., 2008; Wiesinger et al., 
1997). Importantly glycolysis and its further metabolism represents the major pathway for 
ATP generation. Under normoxic conditions glycolysis produces pyruvate, which then is 
transported to the mitochondria, converted to acetyl coenzyme A (acetyl-CoA) and further 
metabolized in via oxidative metabolism in the TCA (Tricarboxylic acid) cycle (Fig. 1.3) 
(Wheaton and Chandel, 2011). The TCA cycle intermediates are then further used for 
biosynthetic processes, e.g. lipid synthesis, whereas the produced reducing equivalents 
NADH and FADH2 are used in the electron transport chain to generate large amounts of ATP 
(Wheaton and Chandel, 2011). Importantly complete mitochondrial oxidation of glucose 
feeding the electron transport chain yields about 17 times more ATP than glycolysis alone 
(30-34 ATP versus 2 ATP respectively) (Belanger et al., 2011). In the brain particularly the 
energy metabolism of neurons and astrocytes has been a focus of research. Astrocytes 
appear to have a very efficient and versatile metabolism for oxidative metabolism as well as 
aerobic glycolysis (Bouzier-Sore and Pellerin, 2013). Although under normal conditions 
oxidative metabolism accounts for major energy production in astrocytes and in conditions of 
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high energy demand astrocytes strongly induce aerobic glycolysis and glycogenolysis to 
compensate the increased energy demand (Hertz et al., 2007).  
Based on estimated energy expenditures neurons have been predicted to account for about 
70% of cerebral glucose consumption, whereas astrocyte metabolism would only account for 
30% (Bouzier-Sore and Pellerin, 2013). However astrocytes have a higher glycolytic activity 
than neurons and glucose transport/utilization studies have revealed that they also consume 
more glucose than neurons (Bouzier-Sore and Pellerin, 2013). It has been shown that as a 
result of their high glycolytic activity astrocytes predominantly convert pyruvate to lactate via 
lactate dehydrogenase (LDH) that is then released to serve as a neuronal energy source, 
explaining the relatively high rate of glucose consumption (Bouzier-Sore and Pellerin, 2013). 
Neurons in general exhibit a high rate of oxidative metabolism and a low glycolytic rate 
compared to astrocytes (Belanger et al., 2011). Interestingly increased induction of neuronal 
glycolysis under normal conditions induces cell death and oxidative stress (Belanger et al., 
2011), which clarifies why they prefer lactate as energy substrate over glucose (Bouzier-Sore 
et al., 2006). In neurons lactate is converted back to pyruvate and directly metabolized via in 
the TCA cycle to generate NADH/FADH2 for efficient ATP generation via the mitochondrial 
electron transport chain (Dienel, 2012; Pellerin, 2010). In total contrast data on the cellular 
metabolism of endothelial cells information is very rare. However cultured HUVECs were 
shown to display a preference for glycolytic metabolism (Harjes et al., 2012) and additionally 
glutamine utilization and fatty acid oxidation capacity was reported for endothelial cells, 
particularly during stress conditions (Harjes et al., 2012).  
In summary brain cells have clear dispositions towards particular substrates and pathways for 
energy production. Whereas neurons clearly prefer oxidative metabolism, endothelial cells 
appear to be mainly glycolytic and astrocytes exhibit a versatile metabolism efficiently using 
both pathways.  
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Figure 1.3: Overview of glycolysis and oxidative glucose metabolism. Under normoxic conditions 
glucose is transported via glucose transporters (GLUTs) into the cell and converted to pyruvate during 
glycolysis. Pyruvate is transported into the mitochondria and converted to Acetyl-CoA. In the 
tricarboxylic acid cycle acetyl-CoA gets further metabolized finally yielding NADH and FADH2 for 
electron transport chain. HIF-1 promotes a metabolic shift from oxidative metabolism to glycolysis 
through induction of lactate dehydrogenase A, which produces lactate from pyruvate and up-regulation 
of pyruvate dehydrogenase kinase 1 (PDK1) inhibiting conversion of pyruvate into acetyl-CoA. Adapted 
from (Wheaton and Chandel, 2011). 
 
Hypoxic/ischemic modulation of energy metabolism 
As discussed previously hypoxic conditions significantly influence cellular metabolism, mainly 
because oxidative metabolism is reduced (Wheaton and Chandel, 2011). After prolonged 
hypoxia carbon flux into the TCA cycle diminishes because of reduced conversion of pyruvate 
into acetyl-CoA (Wheaton and Chandel, 2011). HIF-1 signaling directly affects pyruvate 
conversion via induction of lactate dehydrogenase A (LDH-A) and pyruvate dehydrogenase 
kinase 1 (PDK1) (Wheaton and Chandel, 2011) (Fig. 1.3). PDK1 inactivates pyruvate 
dehydrogenase (PDH), the enzyme that mediates conversion of pyruvate into acetyl-CoA 
(Kim et al., 2006; Papandreou et al., 2006). LDH-A directly converts pyruvate into lactate 
using NADH (Wheaton and Chandel, 2011). In consequence the lack of acetyl-CoA reduces 
TCA cycle activity and the mitochondrial electron transport chain because of NADH and 
FADH2 reduction and ultimately inhibits oxidative glucose metabolism (Wheaton and Chandel, 
2011). As a consequence the cells need to find a way to feed their energy needs through 
other metabolic pathways. During hypoxia/ischemia lactate accumulates in the brain (Dienel, 
2012) indicating that glycolysis increases. It has been well reported that HIF-1 up-regulates 
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glycolysis associated genes, such as glucose transporters and glycolytic enzymes including 
aldolase A, LDH, endolase 1 and others (Wenger et al., 2005). 
Astrocytes are particularly resistant to hypoxia and ischemia (Hertz, 2008) because their 
metabolism exhibits some particular features: 1. Astrocytes are well-known to rapidly switch 
from oxidative metabolism to increase their glycolytic rate under hypoxia as well as ischemia 
(Hertz, 2008; Prebil et al., 2011), likely accounting for the increase in brain lactate 
concentrations. 2. Astrocytes are the major stores of glycogen in the brain (Cataldo and 
Broadwell, 1986a; Cataldo and Broadwell, 1986b), that is utilized during hypoxic but 
particularly ischemic conditions to replenish cellular energy stores (Kahlert and Reiser, 2004; 
Niitsu et al., 1999). Importantly glycogen can be more rapidly degraded than glucose during 
anoxic conditions, as here initiation of glycolysis does not require ATP (Belanger et al., 2011; 
Hertz, 2008).  
Cultured neurons adapt their energy metabolism in response to hypoxia by up-regulation of 
glycolysis and inhibition of oxidative metabolism (Malthankar-Phatak et al., 2008). However 
they only possess minor amounts of glycogen and their preferred pathway, oxidative 
metabolism, is less active during hypoxia (Cataldo and Broadwell, 1986a; Cataldo and 
Broadwell, 1986b; Wheaton and Chandel, 2011) thus they suffer much more from hypoxic 
and ischemic injuries than astrocytes. 
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1.3 HYPOXIC/ISCHEMIC BBB MODULATION 
1.3.1 Mechanisms of hypoxic barrier disruption* 
Hypoxia, when the oxygen demand of tissues is not met, acts as an initial trigger for 
pathophysiological changes at the BBB such as altered distribution of water and ions, 
inflammatory events and oxidative stress, edema formation, infiltration of peripheral immune 
cells and leakage of blood proteins into the brain. In addition, hypoxia induces major 
alterations in vessel structure as it stimulates proliferation of ECs leading to formation of new 
blood vessels and furthermore promotes activation and proliferation of astrocytes (Ogunshola 
and Al-Ahmad, 2012; Stanimirovic and Friedman, 2012). A large number of in vivo and in vitro 
studies have demonstrated that hypoxia is a major stress factor inducing BBB disruption (Al 
Ahmad et al., 2009; Kaur et al., 2006; Lochhead et al., 2010; Schoch et al., 2002). Regarding 
the temporal course of hypoxic barrier opening detailed in vivo studies are rare. Increased 
BBB permeability to evans blue has been observed in mice already 6h after onset of hypoxia 
(7% O2) (Li et al., 2011). Also after 24 and 48h of hypoxic exposure to 8% O2 an increased 
BBB leakage to sodium fluorescein was demonstrated in mice (Bauer et al., 2010; Schoch et 
al., 2002). An interesting study by Witt and colleagues demonstrated in a rat model that 
exposure to 6% O2 for 1h with subsequent re-oxygenation results in a biphasic opening of the 
BBB within the first hour and again after 6-24h of re-oxygenation (Witt et al., 2008). In vitro a 
decrease in endothelial tightness has been observed between the first 30 min of hypoxic 
exposure for up to 48h (Abbruscato and Davis, 1999b; Al Ahmad et al., 2009; Fischer et al., 
1999; Fleegal et al., 2005; Kuhlmann et al., 2007; Yamagata et al., 2004). Hypoxic exposure 
of rat brain microvascular endothelial cell line RBE4 to 1% O2 only induced significant 
reduction of transendothelial electrical resistance (TEER) after 48h, in contrast in near anoxic 
conditions (0.1% O2) a rapid loss of TEER was observed after 4-8h (Al Ahmad et al., 2009). 
Similarly a study using primary bovine microvascular endothelial cells showed increased 
permeability to radiolabeled sucrose only after 48h of hypoxic exposure (Abbruscato and 
Davis, 1999a). In porcine brain endothelial cells TEER was significantly impaired already at 
8h of hypoxic exposure (1% O2) (Yamagata et al., 2004). Overall these results demonstrate 
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that the time point of barrier impairment in vitro is highly dependent on severity of O2 
deprivation, cell sources and culture systems used as well on the read out applied.  
The mechanisms of hypoxic barrier disruption have been studied intensively in vitro and in 
vivo and it is evident that disruption of the BBB occurs on many different molecular levels. TJ 
complexes are major targets of hypoxic BBB disruption. At the molecular level hypoxia 
modulates protein expression levels and subcellular redistribution of occludin, ZO-1 and 
claudin-5 (Bauer et al., 2010; Fischer et al., 2002; Koto et al., 2007; Mark and Davis, 2002; 
Willis et al., 2010) that determines their localization at the plasma membrane and interaction 
with other proteins at the TJ (Luissint et al., 2012). This redistribution critically compromises 
TJ integrity and is likely mediated via phosphorylation changes at serine, threonine and 
tyrosine residues and by caveolae-mediated endocytosis. Protein kinase C enzymes, myosin 
light chain kinase, and RhoA alter TJ protein phosphorylation and contribute to hypoxic or 
inflammatory barrier disruption (Luissint et al., 2012). Increased transcellular and pinocytic 
activity of brain ECs are additional events that contribute to augmented barrier permeability 
during hypoxia (Cipolla et al., 2004; Plateel et al., 1997). Hypoxia-mediated alterations and 
breakdown of the basement membrane also aggravate BBB opening and are particularly 
important during ischemic events (Candelario-Jalil et al., 2009; Stanimirovic and Friedman, 
2012). Direct and indirect contribution of pericytes and astrocytes to hypoxic-mediated BBB 
permeability is discussed below. 
1.3.2 HIF-1 regulates BBB permeability* 
Growing evidence suggests that HIF-1 could play a pivotal role in the changes that occur at 
the BBB during hypoxia. Good insights have been obtained from cerebral ischemia and 
reperfusion studies as well as in vitro work (Ogunshola and Al-Ahmad, 2012). The HIF-1 
inhibitors 2ME2 and YC-1 reduce edema formation (directly correlating to BBB permeability) 
and infarct volumes in rat models of ischemia/reperfusion and neonatal hypoxic-ischemic 
brain injury (Chen et al., 2008a; Yeh et al., 2007) whereas rapid DMOG-induced HIF-1α 
stabilization increased edema formation. In both studies these effects were attributed to 
modulation in VEGF production (Chen et al., 2008a). In a rat model of cerebral ischemia 
using middle cerebral artery occlusion, HIF-1 inhibition using YC-1 remarkably reduced BBB 
impairment as indicated by reduced evans blue extravasation, nonetheless overall a negative 
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outcome of HIF-1 inhibition on infarct volume and mortality was observed (Yan et al., 2011). 
Our own in vitro work using brain ECs also suggests that HIF-1 stabilization is directly linked 
with barrier disruption and that inhibition of HIF-1 can significantly improve barrier stability 
(Engelhardt et al., 2014a) (see Section 3.1). We were able to correlate HIF-1 induced barrier 
permeability to translocation of claudin-5 and ZO-1 from the plasma membrane, whereas total 
expression of tight junction proteins was only slightly affected. Importantly we also observed 
increased tyrosine phosphorylation of occludin and to a minor extent of claudin-5. Overall this 
implicates that rearrangements at the TJ and posttranslational modifications primarily account 
for HIF-1 mediated barrier impairment. Likewise HIF-1 inhibition using siRNA in a rat focal 
ischemia model showed less BBB disruption and a better outcome for the animals in 
correlation with decreased VEGF levels, as well as reduction of caspase-3 and p53 
expression (Chen et al., 2009). These studies highlight that HIF-1 stabilization likely triggers 
increased BBB permeability through activation of its multiple target genes and signaling 
cascade.  
 
1.3.3 Contribution of astrocytes and pericytes to hypoxic BBB regulation* 
The next section discusses the response of BBB cells to hypoxia/ischemia and their 
subsequent impact on BBB function. 
1.3.3.1 Astrocytes* 
Knowledge of the basal responses of astrocytes to reduced oxygenation is limited and far 
from complete. We know that astrocytes are more resistant to hypoxia and ischemia than 
neurons. As discussed above this is likely due to their higher capacity to metabolically adapt 
to hypoxia/ischemia by using alternate energy sources and switching to anaerobic glycolysis 
thereby ensuring maintenance of the ATP levels (Schmid-Brunclik et al., 2008; Turner and 
Adamson, 2011). Astrocytes are activated in vivo (Kaur et al., 2006) and in vitro (Schmid-
Brunclik et al., 2008) following hypoxic/ischemic injury and secrete elevated levels of a large 
number of factors that can be neurotoxic as well as neuroprotective (Trendelenburg and 
Dirnagl, 2005; Vangeison and Rempe, 2009). Modulation of a variety of proteins by these 
cells suggests a highly complex tempering of their function and subsequent barrier status. 
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Indeed a microarray study recorded more than 1100 hypoxia-responsive genes in human 
astrocytes with 5 times more genes up-regulated than suppressed. Notably many of the up-
regulated genes were glycolytic enzymes and angiogenic molecules (Mense et al., 2006). 
Astrocyte co-culture with ECs results in mutual up-regulation and preservation of anti-oxidant 
enzymatic activity and reduced radical-induced endothelial cell injury (lipid peroxidation) 
compared to endothelial monocultures (Ogunshola and Al-Ahmad, 2012; Schroeter et al., 
1999). Different in vitro studies have shown that astrocyte co-culture or treatment of ECs with 
astrocyte-conditioned media improves endothelial cell performance and maintenance of 
barrier function during hypoxic insults (Al Ahmad et al., 2009; Brown et al., 2003; Fischer et 
al., 2000). Coinciding with these observations astrocytes/astrocyte-conditioned media 
preserve the junctional localization of TJ proteins, like ZO-1 or claudin-5 (Al Ahmad et al., 
2011; Fischer et al., 2000) and hypoxia/glycaemia-dependent down-regulation of the 
adherens junction protein VE-cadherin is partially reversed in the presence of astrocytes 
(Abbruscato and Davis, 1999b). Media from hypoxic and re-oxygenated astrocytes contains 
ANG-1 that increases occludin expression and reduces endothelial proliferation thereby 
stabilizing the vasculature (Song et al., 2002). In addition co-culture with astrocytes abrogates 
endothelial caspase-3 activation during hypoxia (Al Ahmad et al., 2009) thereby reducing cell 
death and caspase-3 mediated TJ disruption (Zehendner et al., 2011).  
Astrocytes are also the major source of VEGF in the brain and respond to hypoxic stimuli with 
increased induction and secretion of VEGF that acts as an endothelial survival factor (Chow 
et al., 2001; Kaur et al., 2006; Mense et al., 2006; Schmid-Brunclik et al., 2008). However 
VEGF is also a prominent angiogenic molecule and thus a strong inducer of vascular 
permeability in vitro and in vivo (Fischer et al., 1999; Schoch et al., 2002). Our group has 
shown that despite a beneficial effect of astrocyte co-cultures on hypoxic barrier 
maintenance, inhibition of VEGF signaling (with the VEGF receptor inhibitor SU1498) further 
improved maintenance of barrier characteristics (Al Ahmad et al., 2011). In agreement, 
astrocyte-derived VEGF was also shown to drive BBB disruption after hypoxic exposure 
(Kaur et al., 2006) and in CNS inflammatory disease (Argaw et al., 2012). Thus the impact of 
VEGF secretion during insult is multi-faceted. VEGF binds and activates two tyrosine kinase 
receptors namely VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). Hypoxia-induced endothelial 
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hyper permeability seems to be mediated predominantly by activation of Flt-1 (Vogel et al., 
2007) in agreement with the finding that hypoxia up-regulates both the expression of Flt-1 and 
binding of VEGF to Flt-1 (Fischer et al., 1999). Excellent reviews on hypoxia- and HIF-1- 
mediated VEGF permeability have been published (Fan et al., 2009; Nakayama and Berger, 
2013). However it has also been shown that VEGF splicing can occur in the terminal exon 
resulting in variants, termed VEGFxxxb, that act as anti-angiogenic dominant negative splice 
isoforms (Ladomery et al., 2007; Nowak et al., 2008). Notably, high homology means these 
anti-angiogenic isoforms may have been mistakenly identified as the more canonical species 
in many studies. Although the ratio of the b-isoforms to the canonical species could be highly 
relevant, investigations on the effects of stimuli such as hypoxia on these splice variants are 
yet to be performed.  
Astrocytic secretion of MMPs during hypoxia also causes BM reorganization and weakens 
barrier function. Increased activity of MMP-2, MMP-9 and MMP-13 was detected in hypoxic 
astrocyte supernatants and treatment of ECs with those supernatants led to MMP-13-
dependent delocalization and proteolysis of ZO-1 and disruption of VE-Cadherin (Lu et al., 
2009). Astrocytes additionally express various cytokines in response to hypoxic stimulation. 
For example IL-1β is a HIF-1 target gene (Zhang et al., 2006) that can in a feedback loop 
activate HIF-1α and VEGF expression in an NFκB-dependent manner in astrocytes and 
cause down-regulation of the vessel-stabilizing factor SSeCKs (Argaw et al., 2006). Also 
large amounts of chemokine ligand 2 (CCL2, also referred to as monocyte chemoattractant 
protein 1 (MCP-1)) and CCL12 (MCP-5) are produced by hypoxic astrocytes in a HIF-1 
dependent manner (Mojsilovic-Petrovic et al., 2007). Apart from its main function of recruiting 
leukocytes at sites of inflammation, CCL2 was shown to increase the paracellular 
permeability of endothelial monolayers via TJ redistribution mediated by Rho signaling 
(Stamatovic et al., 2003) and is involved in formation of vasogenic edema in vivo (Stamatovic 
et al., 2005). Altogether, these studies suggest that the hypoxic responses of astrocytes are 
critical during injury and disease and particularly impact on the stability of the BBB. A 
summary of the discussed effects of astrocytes on hypoxic barrier function is presented in 
Table 1.2.  
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Table 1.2: Summary of astrocytic and pericytic signaling on hypoxic barrier tightness 
 
1.3.3.2 Pericytes* 
Only few studies have investigated the survival of pericytes after hypoxic and ischemic 
insults. Our in vitro data suggests that pericytes have comparable sensitivity to astrocytes 
(see Section 3.2). We did not observe any impairment of mitochondrial activity in pericytes 
exposed for up to 48h in 0.2% oxygen reflecting no loss of viability, whereas ischemic 
conditions reduced mitochondrial function only after 24h of exposure (see Section 3.2). 
Likewise it was shown that ECs are much more susceptible to ischemia than astrocytes and 
pericytes in vitro (Ceruti et al., 2011). In vivo pericytes were observed to migrate away from 
microvessels in response to traumatic brain injury (Dore-Duffy et al., 2000) and hypoxic 
stimuli already 2h after onset of the insult and preceding any changes in vessel structure 
(Gonul et al., 2002). Furthermore a reduction of pericyte-to-endothelial cell ratio was reported 
after 1 week of hypobaric hypoxia (Dore-Duffy and LaManna, 2007). Although the cell status 
during these events remains unclear, the fact that the changes occurred during pathologies 
associated with increased BBB permeability suggest that pericyte loss per se could augment 
barrier leakage. Indeed in vitro models highlight that pericyte presence protects endothelial 
monolayers from hypoxic barrier disruption particularly during prolonged and severe oxygen 
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deprivation by maintaining TJ protein localization (Al Ahmad et al., 2009; Hayashi et al., 2004) 
and reducing endothelial caspase-3 activation (Al Ahmad et al., 2009; Al Ahmad et al., 2011). 
Interestingly, under severe conditions co-culture of pericytes with ECs maintained TEER and 
reduced paracellular flux of labeled substances better than astrocyte co-cultures (Al Ahmad et 
al., 2009).  
Like astrocytes, pericytes respond to hypoxia with up-regulation of various growth factors. 
Park et al. demonstrated that in retinal pericytes ANG-1, but not ANG-2 mRNA is significantly 
elevated (Park et al., 2003) again suggesting a vessel stabilizing effect. Interestingly the 
induction of ANG-1 could be mimicked through treatment of the pericytes with recombinant 
VEGF (Park et al., 2003). An in vivo study suggested that hypoxic pericytes rapidly increase 
VEGF levels within 24h, whereas astrocytic VEGF production was observed after 4 days 
(Dore-Duffy and LaManna, 2007). In our studies we observed differential outcome when 
inhibiting VEGF signaling using SU1498 wherein beneficial effects were observed in 
endothelial cell pericyte co-cultures during 1% O2 but not during more severe oxygen 
deprivation (0.1% O2) (Al Ahmad et al., 2009). Although temporal-spatial VEGF-mediated 
induction of ANG-1 may be a plausible explanation for some of the barrier stabilizing effects 
of pericytes during hypoxia it is unlikely that elevated VEGF expression does not largely 
contribute to hypoxic barrier disruption, indeed VEGF signaling by other brain cells may also 
have an impact. Like astrocytes pericytes also secrete MMPs and their expression is 
augmented through pro-inflammatory cytokines like tumor necrosis factor (TNF) -α (Takata et 
al., 2011). Additionally pericytes can induce MMP expression in ECs although the link 
between pericyte MMP expression and hypoxic barrier disruption is still to be properly 
demonstrated.  
Taken together however the data highlights that timing, severity and cellular crosstalk is likely 
to be very complex. Overall despite limited information, similar to astrocytes, pericytes appear 
to fulfill important barrier-stabilizing functions but in response to stress also secrete molecules 
that can cause BBB remodeling and increased permeability. Thus more studies are required 
to understand the multiple roles of this elusive perivascular cell. A summary of the discussed 
effects of pericytes on hypoxic barrier function is presented in Table 1.2. 
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2 AIM OF THE THESIS 
The BBB fulfills a fundamental role in controlling brain function during health and disease. 
Hypoxic and ischemic injuries represent a state of increased BBB permeability and thus 
disturbance of brain homeostasis. Therefore pathological disruption of BBB stability can have 
dire consequences. Although a physiologically tight and intact BBB is a required for normal 
brain function, it inhibits drug delivery and retention in the brain and therefore is often 
considered a bane in such contexts. Researchers are desperately looking for ways of 
modulating BBB integrity and increasing drug delivery into the brain. As such better 
understanding of the mechanisms contributing to barrier opening are valuable in two different 
ways. Firstly a profound knowledge of the molecular mechanisms of BBB impairment is 
indispensable to develop novel counteracting therapies for disease treatment; secondly this 
knowledge can be applied to develop new strategies by which the barrier could be transiently 
opened for drug delivery.  
This work addressed three major questions to deepen our knowledge of hypoxic/ischemic 
BBB regulation and to better understand how the different cells at the BBB function together 
in order to control its tightness, as follows: 
 
1. DOES HIF-1 MEDIATED SIGNALING CONTRIBUTE TO HYPOXIC BBB DISRUPTION AT 
THE LEVEL OF ENDOTHELIAL TIGHT AND ADHERENS JUNCTIONS? 
The rat brain microvascular endothelial cell line RBE4 was used to determine the 
outcome of HIF-1 signaling on BBB function. As such the effects of normoxic HIF-1α 
stabilization and hypoxic HIF-1 inhibition, on barrier tightness as well as tight and 
adherens junction modulation were compared to events that occur during hypoxic BBB 
impairment.  
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2. HOW COMPARATIVELY RESISTANT ARE THE DIFFERENT BBB CELL TYPES TO HYPOXIC 
AND ISCHEMIC INSULTS? DO INDIVIDUAL RESPONSES IN THESE INJURY MODELS 
CORRELATE TO THEIR ROLES IN BARRIER MODULATION? 
A comparative study of the hypoxic and ischemic response of RBE4 cells, primary rat 
brain astrocytes and pericytes was performed. A number of characteristics were 
assessed including HIF-1α stabilization, hypoxia-induced gene and protein expression, 
proliferation and cell survival. 
 
3. WHAT DETERMINES THE SENSITIVITY OF CELLS TO HYPOXIC AND ISCHEMIC INJURIES? 
IS THERE A GENERAL DIFFERENCE IN CELLULAR METABOLISM BETWEEN 
ENDOTHELIAL CELLS AND ASTROCYTES?  
An untargeted liquid-chromatography-mass spectrometry (LC-MS) approach was used to 
investigate the metabolic changes occurring during O2 deprivation and ischemia in 
primary rat brain microvascular endothelial cells and astrocytes. The subsequent analysis 
focused on identifying pathways and metabolites that confer increased tolerance to 
astrocytes compared to endothelial cells during such injury conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
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Hypoxia Selectively Disrupts Brain
Microvascular Endothelial Tight
Junction Complexes Through a
Hypoxia-Inducible Factor-1 (HIF-1)
Dependent Mechanism
SABRINA ENGELHARDT,1 ABRAHAM J. AL-AHMAD,2 MAX GASSMANN,1
AND OMOLARA O. OGUNSHOLA1*
1Vetsuisse Faculty, Institute of Veterinary Physiology & Zurich Center Integrative Physiology (ZIHP), University of Zurich, Zurich,
Switzerland
2Department of Chemical & Biological Engineering, College of Engineering, University of Wisconsin-Madison, Wisconsin
The blood–brain barrier (BBB) constitutes a critical barrier for the maintenance of central nervous system homeostasis. Brain
microvascular endothelial cells line the vessel walls and express tight junction (TJ) complexes that restrict paracellular passage across the
BBB, thereby fulfilling a crucial role in ensuring brain function. Hypoxia, an impairedO2 delivery, is known to cause BBB dysfunction but the
mechanisms that drive this disruption remain unclear. This study discloses the relevance of the master regulator of the hypoxic response,
hypoxia-inducible factor-1 (HIF-1), in hypoxia-induced barrier disruption using the rat brain endothelial cell line RBE4. Hypoxic exposure
rapidly induced stabilization of the HIF-1 oxygen-dependent alpha subunit (HIF-1a) concomitantly with BBB impairment and TJ disruption
mainly through delocalization and increased tyrosine phosphorylation of TJ proteins. Similar observations were obtained by normoxic
stabilization of HIF-1a using CoCl2, deferoxamine, and dimethyloxalylglycine underlining the involvement of HIF-1 in barrier dysfunction
particularly via TJ alterations. In agreement inhibition of HIF-1 stabilization by 2-methoxyestradiol and YC-1 improved barrier function in
hypoxic cells. Overall our data suggests that activation of HIF-1-mediated signaling disrupts TJ resulting in increased BBB permeability.
J. Cell. Physiol. 229: 1096–1105, 2014. ! 2013 Wiley Periodicals, Inc.
The blood–brain barrier (BBB) constitutes a pivotal structure
of the neurovascular unit and is primarily formed of specialized
brain microvascular endothelial cells that are surrounded and
supported by cerebral astrocytes, pericytes, microglia,
neurons, and a defined extracellular matrix (Hawkins and
Davis, 2005; Daneman, 2012). Microvascular endothelial cells
are “gatekeepers” controlling transport of substances between
the blood and brain tissue via formation of tight junction (TJ)
complexes (Wolburg and Lippoldt, 2002). Notably, proper
arrangement and function of TJ complexes is critical for
maintenance of BBB integrity.
At least three different types of transmembrane proteins
are located at the TJ namely proteins of the claudin family,
occludin, and junctional adhesion molecules (Wolburg and
Lippoldt, 2002). Integral TJ proteins are linked to each other
as well as to the cytoskeleton by cytoplasmic adaptor
proteins, such as zonula occludens (ZO), that provide
structural stability for the TJ (Gonzalez-Mariscal et al., 2003).
All endothelial cells also express adherens junction proteins
(AJ), such as VE-Cadherin, PECAM-1, and the cytoplasmic
adaptor protein b-catenin, which similarly to TJ physically
connect neighboring cells and participate in defining the
apical–basal axis of cells (Baum and Georgiou, 2011). Data
suggests that AJs can influence TJ organization and function
and particularly VE-Cadherin was shown to modulate
paracellular permeability via regulation of claudin-5
expression (Taddei et al., 2008) and suppression of occludin
phosphorylation (Walsh et al., 2011). As the structural and
functional integrity of TJs is a prerequisite for an intact BBB it
is not surprising that alterations in these components is a key
event in barrier impairment. During the last decades it has
become increasingly apparent that BBB disruption
contributes to the pathophysiology of many neurological
diseases including AIDS, Alzheimer’s disease, chronic pain,
multiple sclerosis, Parkinson’s disease, and stroke
(Rosenberg, 2012) although the mechanisms involved remain
largely unknown. Hypoxia characterizes many of these
diseases and is a major stress factor that induces BBB
disruption in vivo and in vitro (Witt et al., 2008; Al Ahmad
et al., 2009; McCaffrey et al., 2009; Lochhead et al., 2010;
Kimura et al., 2011). The cellular response to hypoxia is
predominantly driven through the activation of the hypoxia-
induced factor-1 (HIF-1) pathway (Fandrey and Gassmann,
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2009). Under normal conditions, the oxygen regulated HIF-
1a subunit is rapidly degraded via prolyl hydroxylation that
targets its degradation in the proteasome. Hypoxia inhibits
prolyl hydroxylase activity resulting in HIF-1a subunit
stabilization in the cytoplasm and translocation to the
nucleus, where it dimerizes with the aryl-hydrocarbon
receptor nuclear translocator (ARNT) to form HIF-1. HIF-1
then binds to hypoxia responsive elements in promotor
regions of target genes involved in cellular adaptation to
hypoxic stress and induces their expression. To date about
100 HIF-1 target genes have been identified that participate in
the control of a variety of different cellular processes such as
erythropoiesis, angiogenesis, proliferation, cellular
metabolism, survival, and apoptosis (Wenger et al., 2005).
Since HIF-1 is a key determinant for adaptation to oxygen
deprivation and is thus crucial for cell survival, it seems likely
that this key transcription factor also plays a central role in
hypoxia-mediated barrier permeability. This study aimed to
directly assess the consequence of HIF-1 induction on
barrier integrity using an in vitro model of the BBB. We
show that stabilization of HIF-1 rapidly compromises barrier
stability predominantly through the disruption of TJ
complexes.
Materials and Methods
Materials
Cell culture media and reagents were purchased from Gibco1
(Life Technologies, Zug, Switzerland). Basic fibroblast growth
factor was obtained from Pepro Tech (Rocky Hill, NJ). 2-
methoxyestadiol (2ME2) was ordered from Tocris (Bristol, UK),
cobalt chloride (CoCl2), dimethyloxalylglycine (DMOG), and
deferoxamine mesylate salt (DFO) from Sigma–Aldrich (Buchs,
Switzerland). YC-1 was purchased from Cayman Chemicals
(Tallinn, Estonia) and TranswellsTM from Corning (Schiphol, The
Netherlands). Radiolabeled 14C-Sucrose was purchased from
Hartmann Analytic GmbH (Braunschweig, Germany) and 40 kDa
FITC-Dextran from Sigma–Aldrich. RIPA lysis buffer was
obtained from Cell Signaling Technology (Danvers, MA),
protease inhibitor cocktail Set III from Calbiochem (Merck,
Darmstadt, Germany). Membrane protein extraction kit was
obtained from BioChain (Newark, NJ). Pierce BCA Protein Assay
was from Thermo Fisher Scientific Inc. (Rockford, IL). For
protein detection by Western blotting and immunofluorescence
antibodies directed against occludin, claudin-5, and ZO-1 from
Invitrogen (Basel, Switzerland), b-actin antibody from Sigma–
Aldrich (Buchs, Switzerland), HIF-1a antibody from Novus
Biologicals (Littleton, CO), and b-catenin antibody was from
Chemicon (Millipore, Billerica, MA) were used. The PECAM-1
antibody was a gift from Dr. P.J. Newman (BloodCenter of
Wisconsin, Milwaukee, WI). Anti-phosphotyrosine antibody
agarose conjugate was purchased from Milipore. Secondary
antibodies for Western blotting were obtained from Jackson
ImmunoResearch (Suffolk, UK) and Alexa-488 conjugated
antibodies from Invitrogen were used for immunofluorescence.
Quantikine VEGF ELISA kits were from R&D Systems Europe
(Abingdon, UK).
Cell culture & reagents
The rat brain endothelial cell line RBE4 was used for all
experiments (Roux et al., 1994). Cells were cultivated in 50:50 a-
MEM/Ham’s F-10 medium mixture supplemented with 10% FBS,
300mg/ml Geneticin, and 1 ng/ml basic fibroblast growth factor on
rat tail collagen coated petri dishes and coverslips. Rat tail collagen
was isolated as described (Roll et al., 1980). CoCl2 and DFO were
dissolved directly in RBE4media. All other solutions weremade up
in DMSO. Diluted working concentrations did not exceed a
maximal concentration of 0.1% DMSO.
Barrier function assessment
Barrier function of RBE4 monolayers was assessed by real-time
measurement of transendothelial electrical resistance (TEER) as
well as paracellular permeability to radiolabeled sucrose and
40 kDa FITC-dextran. Experiments were performed using RBE4
monolayers grown on rat tail collagen-coated TranswellsTM as
previously described (Al Ahmad et al., 2009). All measurements
were normalized to the 0 h time point of the corresponding
treatment.
Hypoxic exposures
Hypoxic experiments were carried out in a purpose-built hypoxic
glove-box chamber (InVivO2 400, Ruskinn Technologies, Pencoed,
UK) maintained at 37˚C with 5% CO2. O2 concentration was
constantly monitored internally with an O2 sensor. In all
experiments cells were exposed to hypoxia (1% O2).
Immunoblots
Confluent monolayers were washed with ice-cold PBS and
homogenized in RIPA lysis buffer supplemented with protease
inhibitor cocktail. Fractionation of membrane and cytoplasmic
proteins was performed using the membrane protein extraction
kit from BioChain according to the manufacturer’s protocol.
Accurate protein concentration was determined using Pierce BCA
Protein Assay. Twenty-five microgram of total protein were
separated by denaturing SDS–Page and subsequently transferred
onto nitrocellulose membranes. Membranes were blocked in 5%
non-fat dry milk dissolved in TBS or PBS followed by incubation at
4˚C overnight in the presence of antibodies directed against b-
actin (1:5,000), b-catenin (1:1,000), PECAM-1 (1:7,000) HIF-1a
(1:1,000), occludin (1:500), claudin-5 (1:300), or ZO-1 (1:250).
Membranes were washed with 0.1% Tween-20 in TBS or PBS and
incubated in presence of horseradish peroxidase (HRP) conjugated
secondary antibody. Band detection was performed by enhanced
chemiluminescent substrate and visualized using luminescent
image analyzer LAS-3000 (Fujifilm, Dielsdorf, Switzerland). Blot
quantification was performed using ImageJ software (ImageJ, NIH,
Bethesda, MD).
Immunoprecipitation (IP)
Cell cultures were washed with cold phosphate-buffered saline
containing 1mM sodium orthovanadate and 50mM NaF then
scraped into lysis buffer (see above). One milligram of protein was
suspended in IP buffer (50mM Tris–HCl pH 7.4, 150mM EDTA
and 0.5% NP-40, 1mM NaVO3, 1mM PMSF) and 30ml of anti-
phosphotyrosine antibody agarose conjugate (4G10, Millipore)
was added. Samples were then incubated at 4˚C in a circular
rotator for 3 h prior to centrifugation at 800g for 1min.
Supernatant was removed and beads were washed 3! with IP
buffer. Captured proteins were eluted from the beads by adding
2! Laemmli buffer, boiling at 80˚C for 2min and centrifugation at
16,000g for 2min. Samples were then run on 15% SDS–Page gel as
above.
Cell viability
Cell viability was assayed using a propidium iodide automated cell
counter (ADAM, Digital Bio, Witec AG, Littau, Switzerland)
according to the manufacturers protocol.
Microscopy and immunofluorescence
Cells were cultured on rat tail collagen coated glass coverslips.
After treatments cells were briefly washed with ice-cold PBS,
fixed with 4% paraformaldehyde solution then permeabilized
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using 0.1% Triton-X100. After blocking with 10% normal goat
serum the cells were incubated with primary antibodies against
claudin-5 (1:100), ZO-1 (1:100), and b-catenin (1:100) at 4˚C
overnight. Cells were washed with PBS and incubated in
presence of Alexa488-conjugated secondary antibody (1:500).
Coverslips were mounted on microscopic slides and
micrograph pictures were taken using an inverted fluorescence
microscope coupled to an 8-bit CCD camera (Axiocam HR,
Carl Zeiss, Feldbach, Switzerland).
Vascular endothelial growth factor Enzyme-Linked
Immunosorbent Assay (ELISA)
Intracellular vascular endothelial growth factor (VEGF)
measurements in 50mg of total protein were performed using
Quantikine VEGF ELISA kits according to the manufacturers
instructions. Optical density was measured at 450 nm, with
wavelength correction at 570 nm (Muliskan RC; Thermo
Labsystems, Helsinki, Finnland).
Statistical analysis
All results are expressed as mean! SD from three or more
independent experiments. Statistical significance was assessed by
one-way ANOVA for comparison of different time points within a
group, two-way ANOVA for comparison between different
groups. A P-value below 0.05 was considered significant.
Results
Hypoxia-driven HIF-1a protein stabilization correlates
with barrier disruption in endothelial cells
To observe the effect of hypoxic exposure on HIF-1
stabilization in RBE4 monolayers, we investigated time-
dependent changes in HIF-1a protein levels by immunoblot
(Fig. 1A). As expected under normoxic conditions HIF-1a was
hardly detected, however hypoxia induced significant
stabilization within 2 h. HIF-1a levels peaked at 8 h of hypoxic
exposure and subsequently declined. Next, we assessed
changes in RBE4 monolayer barrier function by TEER (Fig. 1B).
Interestingly, we noted a significant decrease in electrical
resistance at 8 h, when HIF-1a stabilization was maximal, that
remained stable for up to 24 h. Further exposure to hypoxia
resulted in complete loss of resistance indicating major barrier
disturbance. To further confirm this readout, we measured
paracellular permeability to sucrose (342Da) and 40 kDa
FITC-dextran (Fig. 1C). After 24 h we noted a significant
increase in sucrose permeability but not of the higher
molecular weight FITC-dextran, whereas both molecules
showed a significant increase at 48 h.
Hypoxia induces barrier disruption by tight junction
rearrangement
Next we investigated the effect of hypoxic exposure on TJ
proteins by immunoblotting and immunofluorescence (Fig. 2).
Surprisingly no significant change in claudin-5 or occludin
protein expression was noted (Fig. 2A,B), although ZO-1
protein levels were significantly down-regulated after
prolonged hypoxic exposure (Fig. 2C). Similarly expression of
the adherens junction protein VE-cadherin as well as associated
proteins b-catenin and PECAM-1 were not significantly
affected by hypoxic exposure although a trend for increased
protein expression of PECAM-1 was observed (Supplementary
Fig. 1A–C). It is well documented that not only absolute TJ
protein levels but also their organization and localization is of
particular relevance for barrier function (Harhaj and Antonetti,
2004; Johnson et al., 2008). To further investigate these
changes we performed immunofluorescence staining after 48 h
Fig. 1. Hypoxia induces HIF-1a stabilization and barrier disruption in
RBE4 monolayers. (A) Upper panel: representative HIF-1a
immunoblot of RBE4 cells exposed to 1% O2 at different time points.
Lower panel: Densitometric quantification of HIF-1a protein levels.
N¼ 3; #P< 0.05 and ###P< 0.001 compared to 0h time point. (B) TEER
measurements of RBE4 monolayers exposed to hypoxia. Resistance
values were normalized to normoxic control (0h time point). N¼ 6,
##P< 0.01 and ###P< 0.001. (C) Permeability measurements of
normoxic and hypoxic monolayers to 14C-sucrose (342Da) and FITC-
dextran (40kDa). Values were normalized to normoxic control (0h
time point). N¼ 4, #P< 0.05 and ##P< 0.01 versus normoxic group,
##P< 0.01 in comparison between sucrose and FITC-dextran.
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of hypoxic exposure. In hypoxic cells ZO-1 immunoreactivity
was discontinuous and heterogeneous (arrows, Fig. 2D)
compared to the normoxic control and at some areas we
observed formation of intercellular gaps (asterisk, Fig. 2D).
Although hypoxic exposure did not affect the localization of
either b-catenin or PECAM-1 disruption of VE-cadherin
localization was observed (Supplementary Fig. 1D).
HIF-1a stabilization alters TJ protein integrity and
barrier function
To determine the direct impact of HIF-1 on barrier disruption
we stabilized HIF-1a in normoxic RBE4 cells by treating them
with cobalt chloride (CoCl2, 100mM), dimethyloxalylglycine
(DMOG, 100mM) or deferoxamine (DFO, 100mM). Firstly, we
confirmed HIF-1a stabilization by performing immunoblot of
RBE4 cell lysates (Fig. 3A). DFO was the strongest inducer
producing the highest HIF-1a levels, followed by CoCl2.
Interestingly, DMOG only modestly stabilized HIF-1a
compared to the other inhibitors. Similar to results from
hypoxic exposure (Fig. 1A) HIF-1a protein levels were strongly
elevated at early time points for up to 8 h and then decreased
(Fig. 3A). As seen under hypoxic conditions no differences
were observed in protein levels for either TJ proteins (claudin-
5 and occludin) or AJ proteins (b-catenin and VE-cadherin)
after 24 h although DFO did down regulate AJ proteins after
Fig. 2. Effect of hypoxia on TJ protein expression and localization. In all experiments, confluent RBE4 cells were exposed for up to 48h to 1%
O2. Immunoblots for claudin-5 (A), occludin (B) and ZO-1 (C) (upper panels) were performed and protein levels were quantified by
densitometry (lower panels). N¼ 3, ""P< 0.01 compared to 0 h time point. (D) Representative micrograph pictures of ZO-1 immunostaining
of RBE4 monolayers during normoxia and after 48h of hypoxic exposure. White arrows highlight disrupted protein localization and asterisk
indicates gap formation.
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48 h (Fig. 3A). No changes in ZO-1 at 8 and 24 h were observed
despite strong HIF-1a induction but decreased levels were
observed after 48 h (Fig. 3B) again correlating nicely with the
hypoxic treatments suggesting a delayed action between HIF-
1a stabilization and ZO-1 down-regulation.
As normoxic HIF-1a stabilization did not induce major
changes in TJ protein levels we investigated changes in cell
junction localization (Fig. 3C). Treatment with CoCl2 did not
significantly alter b-catenin or VE-cadherin but DFO had a
stronger effect causing noticeable delocalization. In contrast
dramatic changes in claudin-5 and ZO-1 localization were
observed using all stabilizers such as stretched appearance of
the staining, gap formation (asterisk), increased cytoplasmic
localization as well as loss of continuous staining at cell–cell
Fig. 3. Pharmacological HIF-1a stabilization disrupts tight junction complexes and impairs barrier function. Immunoblots of RBE4 cell
monolayers treated at normoxia with 100mM CoCl2, 100mM DFO, or 100mM DMOG for 8, 24, and 48 h, untreated cells were used as control
C (A,B). Western blot analysis of ZO-1 protein expression (B) shows reduced levels after 48h of DFO and CoCl2 treatment. (C)
Representative micrograph pictures of claudin-5, ZO-1, b-catenin, and VE-cadherin localization (green) in endothelial monolayers either
untreated or following treatment with either 100mM CoCl2 or 100mM DFO for 48 h. Note the disruption of staining in areas marked by
arrows. Asterisk indicates gap formation. Blue: DAPI. (D) Western blot was performed after membrane fractionation of monolayers exposed
to normoxia (NX), hypoxia (HX), 100mM CoCl2 or 100mM DFO (both at normoxia) for 24 and 48 h. Note reduced claudin-5 protein levels in
the plasma membrane fraction after 24 and 48h, whereas occludin levels remain largely unaffected. (E) Barrier function of monolayers
exposed to 100mM CoCl2 or 100mM DMOG was assessed by TEER, !P< 0.05 and !!P< 0.01 compared to untreated control of corresponding
time point. (F) Measurement of paracellular permeability to 14C-sucrose and 40kDa FITC-dextran in RBE4 monolayers treated for 48h with
100mM CoCl2 or 100mM DFO. N¼ 3, !!!P< 0.001 compared to untreated control of corresponding time point.
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borders (Fig. 3C, arrows). These changes suggest that the TJ
proteins might be trafficked away from the plasma membrane
in response to HIF-1a stabilization. To further corroborate
this hypothesis we monitored protein levels of claudin-5 and
occludin at the plasma membrane following hypoxic exposure
and normoxic HIF-1a stabilization by performing membrane
fractionation (Fig. 3D). In both cases decreased abundance of
claudin-5 was detected in membrane fractions confirming that
HIF-1 stabilization reduces claudin-5 retention at TJ complexes
validating the immunofluorescence data (Fig. 3C). Surprisingly,
we did not observe significant changes in occludin protein
levels in the membrane fraction, suggesting that HIF-1 signaling
does not appreciably impact occludin localization (Fig. 3D). To
underline the relevance of the observed tight junction
rearrangements we assessed barrier integrity by TEER and
paracellular permeability (Fig. 3E,F). Both DMOG and CoCl2
treatment rapidly decreased barrier resistance within 4–6 h
and the disruption remained steady for up to 48 h (Fig. 3E).
These data were further confirmed by increased sucrose
permeability in cells treated with stabilizers for 48 h although
no significant increase in 40 kDa FITC-dextran permeability
was detected (Fig. 3F). Notably, neither drug affected cell
survival compared to control suggesting that loss of barrier
function is unlikely due to increased cell death (Supplementary
Fig. 2A). In conclusion the effects of normoxic HIF-1a
stabilization on TJ localization and barrier integrity mimicked
hypoxia-induced barrier opening.
Inhibition of hypoxic HIF-1a stabilization improves
barrier function
To further support our hypothesis that activation of HIF-1 per
se mediates hypoxic barrier disruption, we pharmacologically
inhibited HIF-1 signaling during hypoxic stress to test whether
loss of HIF-1 activity can improve barrier function. To this aim
we pretreated cells with 1mM methoxyestradiol (2ME2) or
10mMYC-1 [frequently used HIF-1 inhibitors (Yeh et al., 2007;
Chen et al., 2010; Yan et al., 2011)] prior to hypoxia (Fig. 4A).
HIF-1a stabilization was impaired in cells treated with either
inhibitor compared to hypoxic treatment only, especially after
8 h (Fig. 4A). Importantly neither 2ME2 nor YC-1 altered
expression of claudin-5, occludin, ZO-1, VE-cadherin, or b-
catenin protein levels compared to control underlining that
HIF-1 does not modulate TJ or AJ at the protein level (Fig. 4A).
Next immunofluorescence was used to investigate ZO-1,
b-catenin, and VE-cadherin localization in hypoxic cells treated
with 2ME2 or YC-1 for 48 h (Fig. 4B). A significant
improvement in ZO-1 protein localization compared to
control cells was noted by continuous staining at the cell-cell
borders and a decrease in frayed junctions. An improvement in
VE-cadherin staining was also seen, particularly with 2ME2
treatment, but in contrast no changes in b-catenin localization
were observed. We again assessed the relevance of these
observations for barrier function and although no
improvement in TEERwasmeasured during early time points, a
clear beneficial effect was observed after 48 h of exposure (Fig.
4C). Interestingly a differential inhibitor effect was observed as
2ME2-treated cells had better barrier function than those
treated with YC-1, displaying higher TEER at 48 h (Fig. 4C) that
correlated with decreased permeability to sucrose and 40 kDa
FITC-dextran (Fig. 4D). This differential effect was explained by
the fact that whereas 2ME2 treatment did not induce cell death
YC-1 had a tendency to impair cell survival, although not
significantly (Supplementary Fig. 2B).
HIF-1 modulates tight junction protein phosphorylation
Since alterations in BBB integrity are closely associated with TJ
phosphorylation, we monitored the tyrosine phosphorylation
status of claudin-5 and occludin proteins by
immunoprecipitation. Hypoxia strongly and rapidly increased
phosphorylation of both proteins (Fig. 5A). Increased occludin
phosphorylation was also strongly mimicked during normoxic
HIF-1 induction whereas claudin-5 phosphorylation was only
moderately affected (Fig. 5B). In contrast preventing hypoxic
HIF-1 stabilization via 2ME2 or YC1 had little effect on
phosphorylation status (Fig. 5B and data not shown).
Activation of HIF-1 signaling increases VEGF production
in RBE4 cells
VEGF is a well-documented HIF-1 target gene (Wenger et al.,
2005) mediating TJ alterations and hypoxic BBB disruption
Fig. 4. Inhibition of hypoxia-induced HIF-1a stabilization by 2ME2
and YC-1 partially restores barrier function. (A) Representative
immunoblot of HIF-1a, occludin, claudin-5, ZO-1, b-catenin, and
VE-cadherin in hypoxic cells treated with 1mM 2ME2, 10mM YC-1,
and 0.05% DMSO as control C. (B) Representative
immunofluorescence of ZO-1, b-catenin, and VE-cadherin (green) in
hypoxic RBE4 monolayers treated with 2ME2 or YC-1. Cells were
exposed to hypoxia for 48h, 0.05% DMSO served as control. Arrows
denote loss of continuous cell border staining. Blue: DAPI. (C) TEER
measurements of hypoxic endothelial monolayers following
treatment with 2ME2 or YC-1, compared to control. N¼ 3, "P< 0.05
and """P< 0.001 compared to control at corresponding time point.
(D) Paracellular permeability of 14C-sucrose and FITC-dextran in
cells exposed to hypoxia for 48h. N¼ 3, "P< 0.05 compared to
control at corresponding time point.
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(Fischer et al., 2002). For this reason we investigated whether
the normoxic barrier impairment through HIF-1a stabilizers
and hypoxic barrier maintenance through HIF-1 inhibitors was
mediated via modulation of VEGF levels. As expected hypoxic
exposure of RBE4 cells for up to 48 h resulted in robust and
sustained up-regulation of intracellular VEGF levels (Fig. 5C)
that correlated well with the observed onset of hypoxic barrier
disruption after 8 h (Fig. 1B,C). VEGF levels were also elevated
upon normoxic HIF-1 stabilization after 8 h of treatment
(Fig. 5D) correlating with previous observations (Fig. 3E). In
contrast 8 and 24 h of hypoxic exposure with 2ME2 or YC-1
treatment did not alter VEGF levels (data not shown).
Unexpectedly, no down-regulation of VEGF levels was
observed even after 48 h of HIF-1 inhibition (Fig. 5E) despite a
significant improvement of barrier function at this time point
(Fig. 4C).
Discussion
O2 deprivation compromises cerebral tissue integrity and
greatly disrupts neuronal function. Although changes in barrier
function during hypoxic and ischemic conditions have been
documented (Abbruscato and Davis, 1999; Witt et al., 2003;
Brown and Davis, 2005; Al Ahmad et al., 2009), until now the
relationship between activation of the HIF-1 pathway and
barrier function in brain endothelial cells has not been
thoroughly investigated. This study provides evidence that HIF-
1 signaling participates in hypoxia-driven BBB opening.
HIF-1a stabilization constitutes the key event in the
activation of the HIF-1 pathway. Under our experimental
conditions, endothelial monolayers demonstrated significant
stabilization of HIF-1a after 2 h of hypoxia similar to results in
primary rat brain endothelial cells as reported by Luo et al.
(2012) that decreased after 12 h of hypoxia suggesting the
presence of a negative feedback loop as already proposed for
other cells (Stiehl et al., 2006). HIF-1 stabilization is regulated
by activity of prolyl hydroxylase (PHD) enzymes that use
molecular oxygen to hydroxylate the a subunit and target it
for proteasomal degradation (Fandrey and Gassmann, 2009).
Inhibition of PHD activity by chelating Fe2þ and/or using 2-
oxoglutarate competitive substrate analogs (dimethyl-2-
oxoglutarate or dimethyloxalylglycine), is a common
mechanism for forcing HIF-1a stabilization in a normoxic
environment. We used three different HIF-1a stabilizers:
deferoxamine (DFO, an iron chelator), cobalt chloride
(CoCl2, a substrate analog to iron) and dimethyloxalylglycine
(DMOG, a 2-oxoglutarate competitor). Interestingly DFO and
CoCl2 were very effective in producing robust HIF-1a
stabilization, whereas DMOG effects were more discrete but
still induced changes in barrier integrity comparable to CoCl2.
Additionally we used 2ME2 and YC-1 to inhibit HIF-1a activity
in hypoxia. We again noted differential effects of the inhibitors
Fig. 5. HIF-1 stabilization increases tight junction protein tyrosine phosphorylation and modulates VEGF levels. (A) Representative
immunoblot of proteins immunoprecipitated with phosphotyrosine-specific beads after normoxic (NX) and hypoxic (HX) exposure. (B)
Representative immunoblot of occludin and claudin-5 immunoprecipitated with phosphotyrosine-specific beads after 24h of treatment with
HIF-1 stabilizers and inhibitors under normoxia and hypoxia, respectively. ELISA of intracellular VEGF induction of RBE4 cells (C) exposed to
normoxia and hypoxia for 8, 24, and 48 h. N¼ 5, ###P< 0.001; (D) treated with 100mM CoCl2, 100mM DFO, and 100mM DMOG for 8h. N¼ 6#P< 0.05, ##P< 0.01, ###P< 0.001 and (E) exposed to hypoxia and treated with 1mM 2ME2, 10mM YC-1, and 0.05% DMSO as control. N¼ 5.
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likely due to their modes of action (Mabjeesh et al., 2003; Xia
et al., 2012).
Both hypoxic HIF-1 induction and normoxic stabilization
induced endothelial barrier opening whereas HIF-1 inhibition
protected against hypoxic barrier disruption. Delayed opening
of the barrier, that is, only after HIF-1a was already stabilized,
suggested barrier stability is mediated via one or more HIF-1
effectors. VEGF, an important HIF-1 target gene and well-
known vascular permeabilizing factor (Minchenko et al., 1994;
Fischer et al., 1999) would be a prominent candidate. Hypoxia-
induced VEGF levels were shown to decrease ZO-1 protein
expression and induce ZO-1 rearrangements in brain
endothelial cells (Fischer et al., 2002; Yeh et al., 2007).
Moreover our previous study showed that the VEGF receptor
inhibitor SU1498 significantly improves barrier maintenance
under hypoxia (Al Ahmad et al., 2009). Thus the delay between
HIF-1a stabilization and decreased barrier function may
represent the lag time from induction of VEGF expression until
its biological efficacy, although other factors are also likely to
contribute. Indeed VEGF levels after normoxic HIF-1a
stabilization correlated well with VEGF levels during hypoxic
exposure, supporting our hypothesis. Although HIF-1
inhibition partially reversed the negative effects of hypoxia by
maintaining TJs and decreasing barrier permeability the
inhibitors surprisingly failed to reduce VEGF levels. Thus, 2ME2
and YC-1 likely protect BBB integrity by an as yet unidentified
mechanism. Of note YC-1 has been shown to prevent CoCl2-
induced VEGF expression in vitro (Yeh et al., 2007; Chen et al.,
2010; Yan et al., 2011) however we did not detect similar
changes in our system.
Structural and functional integrity of TJs is a prerequisite for
an intact BBB (Hawkins and Davis, 2005; Luissint et al., 2012).
Hypoxic and normoxic HIF-1a stabilization preferentially
caused TJ complex rearrangement rather than protein down-
regulation, with the exception of ZO-1. Reduced ZO-1 levels
following hypoxic exposure nicely correlates with previous
literature (Fischer et al., 2002; Koto et al., 2007). In contrast AJ
protein expression (VE-cadherin, PECAM-1, and b-catenin)
was altered only by DFO treatment although the reasons for
this remain largely unclear. A study on hypoxic human corneal
epithelial cells also demonstrated very similar effects of hypoxia
with decreased barrier function associated with ZO-1 down-
regulation whereas protein expression of occludin and the AJ
proteins E-cadherin and b-catenin were unaffected (Kimura
et al., 2010). In our model ZO-1 and claudin-5 were delocalized
from the plasma membrane upon hypoxia and normoxic HIF-1
activation, whereas occludin was unaffected correlating with in
vivo studies highlighting the importance of ZO-1 and claudin-5
for normal vascular development and barrier maintenance
(Nitta et al., 2003; Katsuno et al., 2008). Similarly, Liu et al.
(2012) observed that combined oxygen and glucose
deprivation (OGD) did not affect total claudin-5 levels in a
mouse endothelial cell line (bEND3) but caused a caveolin-1-
mediated redistribution away from cell borders. Interestingly,
OGD-induced relocation of ZO-1 and claudin-5 was shown to
be partially mediated by caspase-3 activation independently of
apoptotic events (Zehendner et al., 2011) and our previous
study also revealed a significant contribution of caspase-3
activation to barrier disruption in hypoxic RBE4 cells (Al
Ahmad et al., 2009). However, whether these mechanisms are
regulated directly by HIF-1 remains to be experimentally
addressed. Remarkably organization of the AJ protein VE-
cadherin was also disturbed by oxygen deprivation suggesting it
may also play a role in maintaining BBB stability in agreement
with other studies (Taddei et al., 2008; Walsh et al., 2011).
Although the disturbance in our system required a more
chronic exposure it is important that the previous studies were
not performed on brain microvascular cells and in most cases
involved OGD, a very severe insult that would expectedly give
rise to more rapid alterations. Transient inhibition of HIF-1
improved barrier function during hypoxic stress, by better
maintenance of TJ complexes as well as somewhat improved AJ
localization rather than protein up-regulation agreeing with
other stress models (Yan et al., 2011, 2012; Yeh et al., 2007).
This beneficial response was again observed after prolonged
exposure.
Generally post-translational modifications, and particularly
phosphorylation of TJ proteins control the biological function
of cellular junctions by determining their localization,
association with each other and interactions with regulatory
proteins (Fischer et al., 2002; Harhaj and Antonetti, 2004;
Krause et al., 2008; Blasig et al., 2011). In particular, increased
tyrosine phosphorylation of ZO-1 (Fischer et al., 2002) and
occludin (Kale et al., 2003; Takenaga et al., 2009; Du et al.,
2010) are suggested to participate in hypoxia-mediated barrier
breakdown as well as glutamate-mediated disruption (Andras
et al., 2007). Moreover, VEGF was also shown to promote
tyrosine phosphorylation of ZO-1 and occludin resulting in TJ
destabilization and increased permeability (Fischer et al., 2002;
Luissint et al., 2012). Although we did not investigate ZO-1
phosphorylation our data advocates that HIF-1, perhaps
partially via VEGF induction, mediates increased tyrosine
phosphorylation of occludin resulting in barrier dysfunction
whereas effects on claudin-5 are less significant. As the
Fig. 6. Proposed mechanism of HIF-1 action on barrier function.
Hypoxia (as well as chemical stabilization) stabilizes of HIF-1a and
its nuclear translocation where the functional HIF-1 binds target
genes and induces VEGF expression. VEGF is then secreted and, by
either autocrine or paracrine signaling, participates in disruption of
tight junction stability via increased tyrosine phosphorylation and
delocalization of tight junction proteins. Direct effects of other HIF-
1 targets on tight junction stability cannot be excluded.
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inhibitors failed to prevent hypoxia-induced TJ tyrosine
phosphorylation or suppress VEGF levels our data suggests
that phosphorylation occurs prior to delocalization since the
inhibitors prevent the latter but not the former. Clearly more
studies need to be performed to fully answer this intriguing
finding.
It must not be overlooked that long-term inhibition of HIF-
1a may have a detrimental effect as a tendency to decreased
cell viability was seen in cells treated with YC-1. Indeed being a
central driving force of cellular adaptation it may be important
not to completely block such a beneficial pathway. This raises
the dual nature of HIF-1 modulation—clearly its inhibition is
essential for minimizing barrier disruption however an
exacerbated and extended suppression of its activity may also
reduce cell survival and thereby compromise recovery. Thus
temporal suppression of HIF-1 activity may be essential to
preserve barrier function during injury but basal activity may
also be necessary to augment endothelial survival after insult. In
this regard it is worth noting that development and future use
of small molecule HIF-1 stabilizers (mainly PHD inhibitors) as
therapeutics to improve neuronal/cell survival after injury is
swiftly gaining widespread attention (Harten et al., 2010; Miyata
et al., 2011; Ogunshola and Al-Ahmad, 2012). However,
indications that HIF-1 may disturb barrier function means the
use of such therapeutics must be treated with caution.
Enhanced edema and influx of other blood-borne molecules as
a result of increased BBB permeability will increase intra-
cranial pressure and the transport of potentially detrimental
substances into the brain parenchyma thereby exacerbating
injury. Possible adverse effects of reduced barrier integrity
must be carefully assessed when administering HIF-1 stabilizing
drugs, and duration of HIF-1 stabilization and the regions being
targeted must also be taken into consideration since both will
highly influence the outcome of treatment (Miyata et al., 2011;
Ogunshola and Al-Ahmad, 2012). Indeed the development of
pharmacological agents that limit TJ alterations could
selectively target and prevent detrimental effects of HIF-1 on
barrier function.
In conclusion, we demonstrate that activation of the HIF-
1 pathway mediates hypoxia-induced barrier dysfunction by
delocalization and phosphorylation of TJ proteins and VEGF
secretion (Fig. 6). Our data also suggests that changes in VE-
cadherin may also contribute to BBB alterations. Although
this study focused on the endothelial component of the BBB
we previously highlighted the importance of astrocytes and
pericytes in modulating endothelial cell responses to
hypoxia (Al Ahmad et al., 2009, 2011, 2012). Further
investigation of how temporal–spatial paracrine signaling
between these cells modulates the HIF-1 pathway in brain
endothelial cells is essential to provide information not only
on the possible outcome of HIF-1 stabilizers on barrier
function but also identify new targets to fight injury-induced
barrier disruption.
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ABSTRACT 
Undisturbed functioning of the blood-brain barrier (BBB) crucially depends on paracellular 
signaling between its associated cells namely endothelial cells, pericytes and astrocytes. 
Hypoxia and ischemia are well-known factors causing BBB impairment and the contribution of 
the perivascular cells to hypoxic/ischemic barrier regulation has gained increased attention. 
However, detailed information on hypoxic/ischemic responses of the associated BBB cells is 
rare. We show that the endothelial cell line RBE4 has greater responsiveness and sensitivity 
to oxygen deprivation than astrocytes and pericytes. This higher sensitivity coincided with 
significant stabilization of HIF-1α, early disruption of the actin cytoskeleton and strong 
metabolic impairment at conditions where the other cell types remained largely unaffected. 
Moreover, unlike astrocytes and pericytes RBE4 cells were incapable of inducing autophagy 
as protective mechanism. Both perivascular cells tolerated ischemic conditions well, but 
importantly astrocytes proved to be most resistant. Our data shows that appropriate 
adaptation of proliferation and induction of survival-promoting autophagy likely contribute to 
astrocytic and pericytic tolerance under injury conditions. Thus this study provides important 
information for a better understanding of the cell-specific hypoxic/ischemic responses of BBB 
cells, which is fundamental to unravel the complex cellular interaction between the cells in an 
injury-related context in vivo. 
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INTRODUCTION 
Brain neurons require a stable environment and high nutrient supply for proper functioning 
(Turner and Adamson, 2011). In this regard the well-coordinated teamwork of the cells at the 
blood-brain barrier (BBB) is indispensable. Endothelial cells (EC) that line barrier vessels 
have intimate contact with supporting pericytes (PC) and astrocytes (AC), as well as 
microglia, neurons and a well-defined extracellular matrix to fulfill their gatekeeper function at 
the BBB, crucially controlling nutrient supply and homeostatic balance (Engelhardt et al., 
2014a; Ronaldson and Davis, 2012). It has become very apparent that EC depend on 
inductive signaling of the surrounding cell types to fully develop and maintain their unique 
barrier phenotype (Abbott et al., 2006; Ogunshola, 2011). Recently the important contribution 
of AC and PC to BBB induction and maintenance has received increasing attention (for 
review see (Engelhardt et al., 2014b)).  
Hypoxia (reduced tissue oxygenation) severely impairs BBB function in vivo and in vitro (Al 
Ahmad et al., 2009; Kaur et al., 2006; Lochhead et al.; Schoch et al., 2002) causing 
pathophysiological changes including disturbed energy balance and water/ion homeostasis, 
inflammatory events and leakage of blood-proteins into the brain (Engelhardt et al., 2014b). 
Similarly ischemia, being characterized by impaired nutrient and O2 supply, also results in 
significant BBB breakdown (Liu et al., 2012; Nico and Ribatti, 2012). Clearly, during injury 
conditions specific responses of AC and PC impact BBB maintenance and brain function. 
Both AC and PC have been shown to support barrier function via tight junction retention and 
reduction of endothelial cell death under hypoxic conditions (Al Ahmad et al., 2009; Al Ahmad 
et al., 2011; Brown et al., 2003; Fischer et al., 2000; Hayashi et al., 2004; Zehendner et al., 
2011). On the contrary both cell types up-regulate barrier permeabilizing factors in response 
to hypoxia/ischemia such as vascular endothelial growth factor (VEGF), cytokines, and matrix 
metalloproteinases (MMPs) (Mojsilovic-Petrovic et al., 2007; Nomura et al., 1995; Stamatovic 
et al., 2006; Takata et al., 2011). Currently we do not understand well how, or from where, the 
differential signals that alter BBB characteristics originate, although some evidence suggests 
that injury severity and duration determines the functional outcome of hypoxic/ischemic 
insults on BBB tightness (Chen et al., 2009; Engelhardt et al., 2014b; Halterman and 
Federoff, 1999). In this regard hypoxia-inducible factor 1 (HIF-1), a central regulator of 
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hypoxic/ischemic responses, is of particular importance. HIF-1 constitutes a heterodimeric 
transcription factor composed of the hypoxia-inducible HIF-1α subunit and the constitutively 
expressed HIF-1β subunit (Fandrey and Gassmann, 2009). HIF-1 mediates hypoxic 
adaptation through transcriptional control of more than 100 genes participating in 
angiogenesis, proliferation and cellular metabolism to reduce O2 consumption and increase 
O2 supply but can also trigger cell death (Fandrey and Gassmann, 2009; Ogunshola and Al-
Ahmad, 2012; Wenger et al., 2005). The ability of different cell types to adapt to 
hypoxic/ischemic stress varies considerably. Neurons for example are very sensitive to such 
insults, whereas other brain cells like astrocytes are far more resistant (Turner and Adamson, 
2011). Our previous study showed that AC and PC differentially modulate BBB permeability 
at varying severities of hypoxic insults (Al Ahmad et al., 2009), implying that insult severity 
likely triggers individual cell-specific responses with subsequent consequences on barrier 
modulation.  
To gain better knowledge of cell-specific behavior in terms of overall tolerance as well as 
potential signaling to surrounding cells, we directly compared basal responses of the 
individual BBB cells (brain microvascular endothelial cell line RBE4, primary rat pericytes and 
astrocytes) to hypoxic and ischemic insults in vitro. We analyzed different parameters that 
influence hypoxic and ischemic responses including HIF-1α stabilization and HIF-1 target 
gene expression, actin cytoskeletal alterations, proliferation, and cell survival. Notably the 
responsiveness and tolerance of the three cell types differed considerably and likely underlies 
their ability to maintain and/or modulate BBB integrity. 
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MATERIAL AND METHODS 
Cell culture and isolation of primary cells 
All cell culture media and reagents were obtained from Gibco® (Life Technologies, Zug, 
Switzerland). The rat brain endothelial cell line RBE4 (Roux et al., 1994) was cultivated in 1:1 
α-MEM/Ham’s F-10 medium mixture supplemented with 10% FBS, 300 µg/ml geneticin, and 
1 ng/ml basic fibroblast growth factor (Pepro Tech, Rocky Hill, NJ) on rat tail collagen-coated 
petri dishes. Rat tail collagen was isolated as described in Roll et al. (Roll et al., 1980). 
Primary rat astrocytes were isolated from neonatal pups as described previously (Chow et al., 
2001) and cultured in DMEM supplemented with 10% FBS and 50 µg/ml gentamycin sulfate. 
Primary rat brain pericytes were isolated from male adult rats following an established 
protocol (Asashima et al., 2002) with slight modifications. Briefly, cortices were homogenized 
after removal of meninges. Subsequently microvessels were isolated by centrifugation (20 
min at 3000 g at 4°C) using dextran (final concentration 16%) and digested in DMEM + 0.1% 
Collagenase/Dispase + 125 ug/ml DNAse I (both Roche Diagnostics, Rotkreuz, Switzerland) 
in a water bath for 2h at 37°C. After centrifugation (700 g, 5 min) freshly isolated pericytes 
were plated on rat tail collagen coated dishes and cultured in DMEM supplemented with 20% 
FBS, 50 µg/ml gentamycin sulfate and 2.5 µg/ml amphotericin B until confluency. Subsequent 
passages were maintained on uncoated dishes in astrocyte medium. For all experiments 
astrocytes and pericytes were used at passage 2. 
 
Hypoxic and ischemic exposures 
O2 deprivation experiments were carried out in purpose-built hypoxic glove-box chambers 
(InVivO2 400, Ruskinn Technologies, Pencoed, UK) maintained at 37°C with 5% CO2. O2 
concentration was constantly monitored with an internal O2 sensor. Cells were exposed to 
hypoxia (1% O2) and near anoxia (0.2% O2) for up to 48h. Normoxic controls were maintained 
at 21% O2, 5% CO2 at 37°C. Ischemia was simulated in vitro by oxygen-glucose deprivation 
(OGD). OGD exposures were carried out for astrocytes and pericytes in glucose-free media 
under hypoxia and near anoxia. 
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Western blotting 
Cells were washed with ice-cold PBS and homogenized in cell lysis buffer (50 mM Tris, 150 
mM NaCl, 1% Triton X-100, 1% NP-40) supplemented with protease inhibitor cocktail 
(Calbiochem, Darmstadt, Germany), 1 mM sodium orthovanadate, 1 mM dithiothreitol, 0.5 
mM phenylmethansulfonyl fluoride and 1 mM EDTA. Protein concentration was determined 
with Pierce BCA protein assay (Thermo Fisher Scientific Inc., Rockford, IL). 20 µg of total 
protein were separated on denaturing SDS-Page and transferred onto a nitrocellulose 
membrane. Membranes were blocked at room temperature in 5% non-fat dry milk or 5% BSA 
dissolved in Tris-buffered saline containing 0.1% Tween-20 and subsequently incubated 
overnight at 4°C with primary antibodies against β-actin (1:5000, Sigma–Aldrich, Buchs, 
Switzerland), α-tubulin (1:2000, Sigma–Aldrich), HIF-1α (1:1000, Novus Biologicals, Littleton, 
CO), LC3 (1:2000, Novus Biologicals), Beclin-1 (1:250, Santa Cruz Biotech, Heidelberg, 
Germany), Bax (1:1000, Merck Milipore, Darmstadt, Germany) or BNIP3 (1:1000, Cell 
Signaling Technology, Leiden, The Netherlands). Membranes were washed with 0.1% 
Tween-20 in TBS and incubated with of horseradish peroxidase conjugated secondary 
antibody (ImmunoResearch, Suffolk, UK). Band detection was performed using enhanced 
chemiluminescent substrate and visualized using luminescent image analyzer LAS-3000 
(Fujifilm, Dielsdorf, Switzerland). Blot quantification was performed using ImageJ software 
(ImageJ, NIH, Bethesda, USA). 
 
Quantitative Real-time PCR 
Total RNA was isolated directly from culture dishes using TRIzol® Reagent (Life 
Technologies, Zug, Switzerland) according to the manufacturer`s description. For cDNA 
conversion 1 µg of RNA per sample was reverse transcribed using the ImProm-II 
ReverseTranscriptase kit (Promega, Dübendorf, Switzerland) according to the manufacturer’s 
instructions. Quantitative real-time PCR was performed with an ABI 7500 Fast Real-Time 
PCR System (Applied Biosystems, Zug, Switzerland) using Power Sybr® Green PCR Master 
Mix (Applied Biosystems, Zug, Switzerland). The following primers were used: PHD2 5`-
AAGCCATGGTCGCCTGTTAC-3` and 5`-TGCGTACCTTGTGGCGTATG-3`, VEGF 5`-
CGCAAGAAATCCCGGTTTAA-3` and 5`-CAAATGCTTTCTCCGCTCTGA-3`, GLUT-1 5`-
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GGGCATGATTGGTTCCTTCTC-3` and 5`-CAGGTTCATCATCAGCATGGA-3`, MMP-9 5`-
GGGAACGTATCTGGAAATTCGAC-3` and 5`-CCGGTTGTGGAAACTCACAC-3`, BNIP3 5`-
GCTCCCAGACACCACAAGA-3` and 5`-GCTGAGAAAATTCCCCCTTT-3` and β-actin 5`-
CTGGCTCCTAGCACCATGAAG-3` and 5`-GCCACCGATCCACACAGAGT-3`. All data were 
normalized to β-actin. Fold changes were calculated by the comparative ΔΔCt method.  
 
F-actin staining and microscopy 
RBE4 cells were grown on rat tail collagen-coated coverslips, astrocytes on gelatin-coated 
coverslips and pericytes on uncoated coverslips until confluency. After hypoxic and ischemic 
exposure cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100 in 
PBS and stained for filamentous actin (F-actin) using rhodamine-conjugated phalloidin (Life 
Technologies, Zug, Switzerland). Cell nuclei were counterstained with DAPI (4′,6-Diamidin-2-
phenylindol). Pictures were taken using an inverted fluorescence microscope coupled to an 8-
bit CCD camera (Axiocam HR, Carl Zeiss, Feldbach, Switzerland) and processed using 
ImageJ software (ImageJ, NIH, Bethesda, USA). 
 
BrdU incorporation assay 
Cell proliferation was measured via BrdU incorporation using the colorimetric BrdU Cell 
Proliferation ELISA (Roche Diagnostics, Rotkreuz, Switzerland) according to the 
manufacturer`s instructions. Briefly, 80-90% confluent astrocytes and pericytes were 
subjected to OGD and O2 deprivation for 24h and 48h. For 24h treatments BrdU reagent was 
added simultaneously with onset of OGD/O2 deprivation, whereas for 48h exposures BrdU 
was added 24h before the end of the treatment. After exposure cells were fixed for 30 min 
and incubated for 1.5h at 37°C with a peroxidase conjugated BrdU antibody (anti-BrdU-POD). 
After three PBS washes, peroxidase substrate was added and plates incubated to reach an 
OD405/520 of 0.4-0.5. The colorimetric reaction was stopped by adding 1M H2SO4 and 
absorbance was read at 450/620 nm using a Multiskan RC Microplate Photometer (Thermo 
Labsystems, Helsinki, Finnland). 
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MTT assay 
Cell viability was measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. All cells were cultured in 96-well plates. After ischemic and hypoxic 
exposures a 5 mg/ml MTT solution (Sigma-Aldrich, Buchs, Switzerland) was added to the 
medium to obtain a final concentration 0.5 mg/ml and plates were incubated for 1h at 37°C. 
Subsequently the media was removed, cells were lysed by adding 100 µl dimethyl sulfoxide 
and optical density was measured at 560/670 nm using a Multiskan RC Microplate 
Photometer (Thermo Labsystems, Helsinki, Finnland). 
Statistical analysis 
All results are expressed as mean ± SD of three or more independent experiments. Statistical 
significance was assessed by one-way ANOVA for comparison within one group or two-way 
ANOVA for comparison between different groups using GraphPad Prism 5 software (La Jolla, 
CA). Bonferroni`s post hoc test was used for all analyses. A P-value below 0.05 was 
considered significant. 
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RESULTS 
HIF-1α induction profiles in BBB cells 
Stabilization of HIF-1α protein levels in response to O2 deprivation represents a central 
mechanism of cells to adapt to reduced oxygenation (Semenza, 2011; Wenger et al., 2005). 
HIF-1α expression profiles of the rat endothelial cell line RBE4 (EC), primary rat astrocytes 
(AC) and pericytes (PC) were analyzed after exposure to hypoxia (HX, 1% O2) or near anoxia 
(AX, 0.2% O2) for up to 24h and compared to normoxic baseline expression (NX+Glc) 
indicated by the dashed line (Fig. 1A). In addition AC and PC were subjected to oxygen-
glucose deprivation (OGD) at 1% and 0.2% O2. Since EC were extremely sensitive to O2 
deprivation alone already they did not receive additional OGD treatment. In all cell types HIF-
1α protein was rapidly stabilized within 2 to 6h after onset of exposure and then reduced 
again after 24h (Fig. 1A). However the actual induction profiles differed across the cell types; 
in EC HIF-1α levels reached their plateau already after 2h and remained stable until 6h, 
whereas in AC HIF-1α stabilization peaked at 6h. PC had an intermediate profile showing 
already high HIF-1α expression after 2h that tended to increase after 6h. Moreover, AC and 
PC HIF-1α levels remained elevated after 24h for most exposures, whereas expression levels 
in RBE4 cells had already returned to baseline. Importantly EC and PC did not show any 
difference in total HIF-1α expression between HX and AX at any time point. Similarly OGD did 
not further increase HIF-1α stabilization in PC compared to O2 deprivation alone. AC, in 
contrast showed a clear trend of increased HIF-1α expression depending on the severity of 
the insult (HX versus AX and O2 deprivation versus OGD) (Fig. 1A).  
To directly compare the amount of HIF-1α protein across the three cell types, equal amounts 
of whole cell lysates exposed to HX (Fig.1B) or AX (Fig.1C) in the presence of glucose were 
simultaneously analyzed on the same Western blot membrane. Intriguingly EC showed for 
both O2 concentrations 3-5 times higher HIF-1α expression than AC and PC. Overall these 
results imply that RBE4 cells sense low O2 very rapidly and respond with a strong but short 
lasting HIF-1α stabilization suggesting a greater responsiveness to O2 deprivation than AC 
and PC. The “stereotype” HIF-1α response of EC and PC to mild (HX) and more severe (AX) 
insults indicates an inability to respond in a more fine-tuned manner as observed in AC. 
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Differential regulation of HIF-1 and ischemia-inducible gene expression in BBB cells 
To further characterize the individual BBB cell responses to reduced oxygenation mRNA 
expression profiles of the HIF-1 targets PHD2, VEGF and GLUT-1 as well as the 
hypoxia/ischemia-inducible MMP-9 (Bauer et al., 2010; Wenger et al., 2005) were analyzed 
by qPCR after 24 and 48h of treatment (Fig. 2B-E). A table of the basal normoxic threshold 
cycles (CT) for the individual cell types and analyzed genes is presented in Figure 2A. EC 
had the highest basal expression of PHD2 with a CT of 26.7 compared to AC and PC with a 
CT of about 28 (Fig. 2A). EC showed only weak induction during O2 deprivation of maximal 3-
fold after 24h, whereas the perivascular cells showed an induction of 5 and10-fold after 24h 
HX and AX respectively (Fig. 2B). Interestingly exposure to HX-Glc led to a further very 
pronounced increase in PHD2 mRNA in AC and PC, whereas increased expression after 24h 
AX-Glc was only observed in PC. The PHD2 profiles of 48h exposures were similar to 24h, 
although in general the induction levels were slightly lower and the strong PC induction under 
AX-Glc was lost.   
A different behavior of the cell types was observed for VEGF induction (Fig. 2C). Here PC 
had the highest basal expression during NX with a CT of 26.8, whereas EC and AC had a 
value of about 29 (Fig. 2A). After 24h of HX EC showed a much stronger induction than AC 
and PC, whereas during AX the VEGF expression change was comparable between all cell 
types (Fig. 2C), again suggesting that EC react very strongly to O2 deprivation compared to 
AC and PC. After OGD we detected a very strong increase in VEGF induction in AC and PC 
similarly to PHD2 expression previously. Expression patterns at 48h were similar to 24h with 
the exception that AX levels were much lower in EC than in AC and PC.   
A gradual increase from EC (CT 23) over PC (CT 22) to AC (CT 20) was observed for basal 
GLUT-1 expression (Fig. 2A). For all cell types we observed a good correlation of increased 
GLUT-1 mRNA expression with increased severity and duration of the insult (Fig. 2D). Again 
EC showed the strongest induction (up to 20 fold) during O2 deprivation followed by PC with 
the lowest increase in AC (Fig. 2D). Moreover OGD elevated GLUT-1 mRNA in AC and PC 
compared to O2 deprivation alone.   
Interestingly, basal expression of MMP9 mRNA (CT 33, Fig. 2A) was very low in EC, not 
altered after 24h of O2 deprivation and even decreased after 48h (Fig. 2E). AC and PC 
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showed comparable severity-dependent up-regulation of MMP9 mRNA after 24 and 48h in 
presence of glucose and OGD differed only in HX-Glc where AC showed a remarkable 
increase of MMP-9 compared to PC.  
In conclusion these findings highlight the differential regulation of hypoxic/barrier-modulating 
genes in BBB cells and the consequence of cell-specific responses. 
 
Injury induced actin cytoskeletal rearrangements in BBB cells  
Reduced oxygenation causes a dynamic regulation of the actin cytoskeleton resulting in 
changes of cell contractility, shape and motility (Zieseniss, 2014) thereby providing important 
information on cell state and activation. Changes in F-actin structures were visualized after 
injury using phalloidin staining (Fig. 3). Under normoxic conditions parallel bundles of F-actin 
were observed in EC that localized to cell-cell borders and formed a cortical actin rim, a 
structure being crucial for maintaining endothelial tightness (Prasain and Stevens, 2009) (Fig. 
3A). Already within 6h HX- and AX-mediated disruption of the cortical actin rim was observed 
and characterized by formation of stress fibers (white arrow) while appearance of 
disassembled F-actin (asterisk, Fig. 3A) occurred within 24h. Furthermore large inter-
endothelial gaps were observed after 24h of AX (red arrows, Fig. 3A) and by 48h of AX a 
large number of cells were detached or dead (data not shown). AC and PC present a different 
architecture of F-actin with parallel bundles arranged across the cells so called stress fibers 
(Prasain and Stevens, 2009). In contrast to EC both AC and PC proved to be very insensitive 
to O2 deprivation in presence of glucose as no alterations in F-actin organization were 
observed after 24h in either HX (data not shown) or AX (Fig. 3B) and even prolonged 
treatment for 48h had no effect (data not shown). Although hypoxic OGD was ineffective, 
near anoxic OGD caused appearance of condensed and disorganized stress fibers in both 
cell types after 24h of treatment (Fig. 3B) that was further pronounced after 48h (data not 
shown). Importantly, the effects on AC were less severe as only a small fraction were affected 
and cell shape was largely conserved after 24h AX-Glc, whereas nearly all PC displayed 
significant F-actin disruption and chaotic cell shape changes resulting in very long and thin 
processes (Fig. 3B). These results underline our previous observation that EC are very 
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sensitive to O2 deprivation even in hypoxic conditions, whereas AC and PC tolerate prolonged 
and severe O2 deprivation.  
 
AC and PC adapt their proliferation during O2 deprivation and ischemia  
In addition to cytoskeletal changes controlling cell shape and motility, modulation of 
proliferation represents a crucial factor for survival of hypoxic/ischemic events (Wong et al., 
2013). Proliferation of AC and PC was measured using a BrdU incorporation ELISA. RBE4 
cells were excluded from the proliferation assays, as the immortalized line is characterized by 
excessive proliferative rates. Exposure for 24h in presence or absence of glucose did not 
alter proliferation of AC or PC (Fig. 4A) although a trend towards reduced BrdU incorporation 
under AX-Glc was measured, albeit slightly stronger in PC (Fig. 4A). Prolonged hypoxic 
treatment for 48h significantly reduced proliferation in both cell types and was further 
aggravated by OGD (Fig. 4B). Again a trend of PC being more affected in glucose-free 
conditions than AC was observed, although not significant. For both cell types BrdU 
incorporation was severity dependent resulting in virtually complete proliferation inhibition in 
glucose-free conditions after 48h of treatment (Fig. 4B).  
 
Hypoxic/ischemic exposure differentially affects metabolic activity of BBB cells 
To assess BBB cell viability we performed MTT assays that allow overall evaluation of the 
degree of cellular impairment. After 24h of HX and AX exposure the metabolic activity of EC 
was already severely reduced by about 40%, whereas AC and PC did not show any change 
(Fig. 5A). Notably, glucose withdrawal at normal and hypoxic O2 levels slightly lowered 
metabolic activity of AC and PC. Interestingly AC were able to maintain this activity even in 
AX-Glc, whereas the metabolic rate of PC was significantly reduced. Prolonged treatment for 
48h delineated further important differences (Fig. 5B) with EC showing only 30% of initial 
activity during HX, whereas AC and PC remained largely unaffected (Fig. 5B). AX almost 
completely abolished EC metabolic activity whereas AC were about 30% impaired. 
Surprisingly, during prolonged normoxic glucose withdrawal PC were less affected than AC 
that lost more than 50% of their initial activity. However by 48h of HX-Glc similar degrees of 
AC and PC metabolic impairment that was further accentuated in AX-Glc were observed. In 
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summary EC exhibit severe and early metabolic impairment during O2 deprivation even in 
presence of glucose, whereas both AC and PC remained largely unaffected and tolerate 
periods of up to 24h OGD in HX or AX very well.  
 
Differential regulation of autophagy and cell death in BBB cells 
The effects seen in the MTT assay highlighted interesting differences in cell status and thus 
cell viability during different injury paradigms. However since this assay does not allow direct 
conclusion of survival and cell death pathway activation, prominent apoptotic and autophagy 
markers were analyzed (Fig. 6). Since BNIP3 is a HIF-1 target gene (Wenger et al., 2005) 
and an important signaling molecule at the interface between autophagy and apoptosis (Kubli 
et al., 2007; Tracy and Macleod, 2007) its mRNA and protein expression levels were 
analyzed by qPCR and Western blot respectively (Fig. 6A&B). All three cells upregulated 
BNIP3 transcription in response to O2 deprivation, however their fold induction and temporal 
expression profiles differed strongly (Fig. 6A). An 8-10 fold increase in EC mRNA after 24h of 
HX and AX was measured, whereas prolonged exposure resulted in only 3-fold induction 
(Fig. 6A). In total contrast, the induction range for PC and AC was 50-fold and 150-fold 
respectively with strongly elevated levels of BNIP3 occurring particularly during HX-Glc (Fig. 
6A). Unexpectedly BNIP3 protein levels did not reflect the qPCR data for EC at any time 
point, but instead a significant reduction after 48h of AX was observed (Fig. 6B). In contrast 
AC and PC protein levels correlated well with the induction seen in the qPCR. Moreover the 
reduced fold-change induction of BNIP3 protein in PC compared to AC also correlated well 
with mRNA expression.  
The consequences of increased hypoxic BNIP3 expression are discussed very controversially 
as both cell death/apoptosis promoting (Azad et al., 2008; Kubli et al., 2007) and survival-
promoting functions via induction of autophagy have been reported (Bellot et al., 2009; Tracy 
and Macleod, 2007). The cell death promoting function of BNIP3 has been attributed to Bax 
activation (Kubli et al., 2007). Bax (Bcl-2 associated protein X) is a crucial regulator of 
mitochondria-dependent apoptosis, as it forms pores in the outer mitochondrial membrane 
allowing release of apoptotic proteins such as cytochrome C (Renault and Manon, 2011). We 
did not observe Bax upregulation in any of the BBB cells (Fig. 7A) and levels stayed constant 
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up to 24h of O2 deprivation and/or OGD with prolonged treatment for 48h leading to a 
significant reduction in all cell types. These results suggest that in our model BNIP3 does not 
induce Bax-mediated cell death.  
BNIP3 also regulates autophagy via the activation of Beclin-1 with subsequent formation of 
LC3-II (Bellot et al., 2009). Beclin-1 participates in early autophagosome formation by 
coordinating localization of autophagic proteins and membrane trafficking (Kang et al., 2011). 
Surprisingly, similar to Bax we did not observe increased Beclin-1 expression in any of the 
cell types during injury, but a reduction in total protein levels particularly at AX-Glc treatments 
for AC and PC and at all hypoxic/anoxic for RBE4 cells (Fig. 7B).  
To further investigate this intriguing observation we measured levels of LC3 (microtubule-
associated protein light chain 3), a central protein of the canonical autophagy machinery and 
a down-stream target of Beclin-1 (Kang et al., 2011). LC3 exists in 2 isoforms with LC3-I 
having a cytoplasmic localization whereas LC3-II, though conjugation with 
phosphatidylethanolamine (PE), localizes at membranes of autophagosomes and therefore 
its protein levels reflect formation of autophagosomes (Mizushima and Yoshimori, 2007). In 
all cell types LC3-I levels were only significantly affected after prolonged exposure and severe 
insults (Fig. 8A) although PC already showed a clear trend of reduced levels after 24h (Fig. 
8A). In complete contrast interesting cell-type specific LC3-II profiles were observed. 
Correlating well with the effects observed for BNIP3 expression EC did not upregulate LC3-II 
but significantly downregulated its expression suggesting no ongoing autophagy (Fig. 8B). In 
presence of glucose AC and PC only showed minor changes in LC3-II levels during O2 
deprivation with a mild but significant reduction observed at 48h in both cell types (Fig. 8B). 
However a glucose-dependent increase in LC3-II levels was observed in both AC and PC. AC 
showed a strong increase in LC3-II after 24h at NX-Glc and AX-Glc that were even more 
pronounced after 48h. PC exhibited a significant rise in LC3-II after 24h at all OGD conditions, 
which were also evident after 48h although slightly reduced (Fig. 8B). 
  
! 69 
DISCUSSION  
 
The BBB represents a central component for regulation of proper brain function and therefore 
requires a very tight regulation that depends on signaling inputs of surrounding AC and PC to 
maintain its unique properties and function (Abbott et al., 2006; Engelhardt et al., 2014b; 
Ogunshola and Al-Ahmad, 2012). Similarly AC and PC also modulate BBB tightness during 
hypoxic and ischemic insults, however the critical factors mediating cell-specific responses as 
well as their functional consequences on BBB integrity remain a topic of debate (Al Ahmad et 
al., 2009; Engelhardt et al., 2014b; Hayashi et al., 2004; Kaur et al., 2006; Lu et al., 2009; 
Schroeter et al., 1999). One reason for this is that our understanding about the individual 
responses of the BBB cellular components in terms of proliferation, survival, target gene 
induction and barrier modulation during injury is very limited. This study is the first to directly 
compare hypoxic and ischemic responses of all three major cells types at the BBB and to 
address various aspects of cellular adaptation and survival. We show that the BBB cells differ 
considerably in sensitivity to hypoxic and ischemic insults. All our data points to the fact that 
endothelial cells experience O2 deprivation much more severely than the other cell types and 
show a higher susceptibility. Two publications by Ceruti et al. and Redzic et al. recently 
compared survival of primary rat endothelial cells, AC and PC under OGD (0% O2) and 
similarly concluded that EC are much more susceptible than AC and PC (Ceruti et al., 2011; 
Redzic et al., 2013). Importantly our data further shows that AC tolerate ischemic injury better 
than PC. In this regard it is note worthy that the tolerance of the different BBB cells correlates 
well with the degree of O2 they experience under physiological conditions in vivo. Indeed in 
brain capillaries an O2 content of roughly 8% (pO2 58 mm Hg) has been recorded (Vovenko, 
1999), whereas O2 concentrations in the brain parenchyma are about 4% (pO2 35 mm Hg) 
(Koh and Powis, 2012) thus based on their localization EC are accustomed to higher 
physiological O2 concentrations than PC and AC.  
The HIF-1 signaling pathway crucially controls hypoxic/ischemic gene expression for cell 
survival and energy metabolism but also expression of genes regulating apoptosis and 
autophagy (Bagnall et al., 2014; Fandrey and Gassmann, 2009; Ogunshola and Al-Ahmad, 
2012). Growing evidence suggests that the severity as well as the duration of an insult play a 
crucial role in determination of the pathways becoming activated (Al Ahmad et al., 2009; 
! 70 
Chen et al., 2009; Engelhardt et al., 2014b; Halterman and Federoff, 1999). Indeed we 
observed the more sensitive EC stabilize 3-5 times more HIF-1α protein than the relatively 
resistant AC and PC, suggesting that HIF-1 induction correlates to sensitivity and may 
determine functional outcome for the different cells. In addition rapid stabilization of HIF-1α 
and the observation that O2 deprivation severity did not alter the amount of HIF-1α stabilized 
in either EC or PC points to their greater responsiveness towards hypoxia/ischemia, but a 
less finely tuned response, compared to AC. Other studies have also shown that HIF-1α 
induction is strongly cell-type dependent. A study by Bracken and colleagues showed that 
whereas some cells readily stabilize HIF-1α at 5% O2 others require O2 levels below 1% and 
that HIF-1α transactivation, is also dependent on the severity of hypoxic insults in different 
cell types (Bracken et al., 2006). A direct consequence of HIF-1α stabilization is the induction 
of HIF-1 target genes and accordingly mRNA levels of such HIF-1 target genes revealed a 
cell-specific regulation. Pronounced induction of VEGF (particularly during mild hypoxia) and 
GLUT-1 in EC compared to the other cell types correlated well with their massive HIF-1α 
stabilization, again underlining their strong responsiveness to hypoxic events. Interestingly 
despite an early HIF-1α stabilization similar to EC, PC did not induce VEGF expression in 
comparable strength. As the total levels of HIF-1α stabilization are much lower in PC than in 
EC this suggests that the amount of HIF-1 accounts for the differential regulation of target 
genes. In contrast PHD2 and BNIP3 induction levels were much lower in EC than in AC and 
PC although both are HIF-1 target genes, again suggesting that there is either a cell type-
specific regulation/activation or a severity-dependent regulation of HIF-1 target gene 
expression. Indeed it was shown previously, that mRNA expression of hypoxia-inducible 
genes varies considerably amongst cell types and that cell-type specific induction of target 
genes occurs (Chi et al., 2006). Intriguingly the authors could correlate the amount of HIF-1α 
transcripts and protein abundance to the fold induction of hypoxia responsive genes and most 
importantly to the susceptibility to the cells to hypoxic injury (Chi et al., 2006). Indeed we 
herein present very similar correlations. 
Appropriate adaptation of energy metabolism is a crucial factor for surviving injurious events 
like O2 deprivation and ischemia, thus the transcriptional regulation of the glucose transporter 
GLUT-1 is of particular interest as glucose represents the major brain energy source (Hertz, 
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2008). During O2 deprivation glycolysis becomes crucial for ATP production (Serkova et al., 
2008) and strong induction of GLUT-1 in EC during O2 deprivation agrees with literature 
showing that in EC and cerebral microvessels glucose consumption as well as transport 
increases in response to hypoxia (Loike et al., 1992; Mann et al., 2003). This raises the 
question whether EC are more dependent on glucose uptake to feed their ATP consumption 
during O2 deprivation than AC and PC. A possible reason for this can either be that PC and 
AC exhibit different energy metabolism or that they do not rely as much as EC on glucose per 
se because they can more efficiently use alternate energy sources such as glycogen or 
glutamate. Interestingly GLUT-1 induction in AC was lower than PC. Indeed their versatile 
metabolism i.e. ability to exhibit both high rates of oxidative metabolism but also glycolysis as 
well as to use alternate energy fuels apart from glucose seems to make AC particularly 
resistant to hypoxic/ischemic injuries (Belanger et al., 2011; Bouzier-Sore and Pellerin, 2013; 
Prebil et al., 2011; Turner and Adamson, 2011). In addition it has been long known that AC 
are the major glycogen store within the brain, whereas capillary endothelial cells and PC only 
possess minor reserves (Cataldo and Broadwell, 1986a; Cataldo and Broadwell, 1986b). 
A more global interpretation about the well being of the BBB cells was obtained looking at the 
actin cytoskeletal architecture and metabolic activity using MTT assay. The results of both 
experiments accentuated the rapid impairment of RBE4 cells on different levels of cellular 
function. Firstly the rapid cytoskeletal impairment coincides with loss of BBB function under 
similar conditions (Al Ahmad et al., 2009; Engelhardt et al., 2014a). And EC metabolic 
function rapidly decreased at low O2 concentrations at time points where AC and PC 
remained completely unaffected. Interestingly, changes in cytoskeleton structure preceded 
metabolic suppression in all cell types. AC and PC only showed breakdown of their stress 
fibers and severe inhibition only in severe OGD and prolonged treatments highlighting that 
both cell types are able to cope well with hypoxia/ischemia. Importantly the results obtained 
strongly suggested that AC were more resistant to ischemic conditions than PC. Similarly the 
BrdU proliferation assay suggested higher tolerance of AC to ischemia, as their proliferation 
rate was better maintained compared to PC although not significantly. Importantly both AC 
and PC adapted their proliferative rate depending on duration as well as insult severity, likely 
a crucial reaction to reduce energy consumption and foster cell survival. In line with this a 
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microarray study showed that hypoxia down-regulated genes were mainly linked to 
proliferation (Chi et al., 2006). In contrast increased AC proliferation during hypoxia and 
ischemia has also been reported in vivo and in vitro during acute (6h) OGD and hypoxic 
exposure (Fan et al., 2013; Li et al., 2010; Schmid-Brunclik et al., 2008; Zaidi et al., 2004). In 
our study we did not observe increased proliferation of AC after ischemic treatment, which is 
probably due to the chronic time point selected suggesting differential effects with different 
severities. 
The changes observed in metabolic activity using MTT assay indicated that a crucial 
difference between viability of EC versus PC and AC exists. Particularly the HIF-1 target gene 
BNIP3 represents a point of intersection in regulation of cell viability during O2 deprivation. 
For BNIP3 both pro-apoptotic/cell death promoting functions, via Bax activation (Azad et al., 
2008; Kubli et al., 2007) and survival-promoting functions via autophagy-related proteins 
including Beclin-1 and LC3-II (Bellot et al., 2009) have been observed. We did not detect 
increased Bax levels suggesting that BNIP3 does not promote Bax-mediated cell death in our 
model system. As indicated by the increase in LC3-II expression our data more points 
towards BNIP3-mediated induction of autophagy. This observation is further supported by our 
previous findings, as the resistant AC and PC showed strong BNIP3 expression, whereas the 
susceptible RBE4 cells did not. Unexpectedly the expression profile of LC3-II did not match 
the profile observed for BNIP3, indeed we frequently observed low LC3-II when BNIP3 levels 
were very high. It has been shown that LC3-II represents a good indicator for the number of 
autophagosomes formed, but does not necessarily indicate autophagic flux, as LC3-II itself is 
degraded during the maturation of autophagosomes (Mizushima and Yoshimori, 2007). For 
this reason, a strong activation of autophagy can lead to low LC3-II levels because of its rapid 
degradation, which then may be misinterpreted as lack of autophagy. To combat this problem 
drugs inhibiting autophagosome and lysosome fusion can be used, as well as correlation of 
p62 levels to LC3-II (Mizushima and Yoshimori, 2007). Although our results point towards 
activation of autophagy by AC and PC to modulate their cell survival additional experiments 
would be required to fully understand the underlying mechanism, however this was beyond 
the scope of the current study. In conclusion we can hypothesize that activation of autophagy 
in our model system represents an adaptive mechanism of AC and PC to cope with 
! 73 
hypoxic/ischemic injuries, potentially by removing damaged mitochondria and regeneration of 
ATP by catabolism of existing cytoplasmic precursors (Balduini et al., 2012), whereas RBE4 
cells do not seem to be able to profit from similar responses. Whether the lack of autophagy 
induction in RBE4 cells represents a cell line artifact or whether autophagy induction in brain 
microvascular endothelial cells is not activated in response to hypoxia remains unclear. 
However for peripheral endothelial cells activation of autophagy in response to hypoxia has 
been demonstrated (Chen et al., 2013). Interestingly it has been shown that survival-
promoting BNIP3-mediated mitochondrial autophagy represents a HIF-1 dependent 
mechanism (Zhang et al., 2008) 
In conclusion this study highlights that the BBB cell types vary considerably in their sensitivity 
to O2 deprivation and ischemia. We show on different levels of cellular responses that EC are 
highly susceptible to O2 deprivation, whereas AC and PC are very tolerant to sole O2 
deprivation and even ischemic conditions, although AC tolerate extreme ischemic exposure 
(0.2% O2) better than PC. We advocate that the physiological oxygen concentration that cells 
experience plays a significant role in their sensitivity to insult. Clearly, since differential 
susceptibility underlies BBB alterations better understanding of such causative relationships 
is crucial to combat BBB disturbance during injury.     
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Figure 1: HIF-1α induction profiles in BBB cells. Western blot analysis of HIF-1α protein expression 
in RBE4 cells (EC), pericytes (PC) and astrocytes (AC) exposed to hypoxia (HX) and near anoxia (AX) 
in presence (+) or absence (-) of glucose (Glc) for up to 24h. (A) Densitometric quantification of HIF-1α 
protein expression in EC (upper left panel), PC (upper right panel) and AC (lower left panel). N=3; 
*P<0.05, **P<0.01, ***P<0.001; 1-way ANOVA compared to normoxic baseline. Representative Western 
blots of comparative HIF-1α expression of the different cell types and their densitometric quantifications 
exposed to hypoxia (B) and near anoxia (C). N=3. #P<0.05, ##P<0.01, ###P<0.001; 2-way ANOVA 
compared to EC. 
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Figure 2: Differential regulation of HIF-1 and ischemia inducible gene expression in BBB cells by 
quantitative PCR. (A) Table of basal normoxic expression of the analyzed genes showing threshold 
cycles (CT) ± standard deviation. mRNA expression profiles of PHD2 (B), VEGF (C), GLUT-1(D) and 
MMP-9 (E) after 24h (left panel) and 48h (right panel) of O2 deprivation (solid bars) and oxygen glucose 
deprivation (hatched bars). N=3-4. *P<0.05, **P<0.01, ***P<0.001; 1-way ANOVA compared to 
normoxic baseline. §P<0.05, §§P<0.01, §§§P<0.001; 1-way ANOVA compared to normoxia-glucose. 
#P<0.05, ##P<0.01, ###P<0.001; 2-way ANOVA comparing + to - glucose treatments.!
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Figure 3: O2 deprivation and ischemia induce actin cytoskeleton rearrangements in BBB cells. F-
actin fibers stained with phalloidin (white) and cell nuclei with DAPI (blue). (A) Monolayers of endothelial 
cells exposed to normoxia, hypoxia and near anoxia for 6 and 24h. White arrow shows stress fiber 
formation; red arrows indicate interendothelial gap formation. Asterisk highlights breakdown of F-actin 
resulting in punctuate staining. N=2-3. (B) F-actin staining of stress fibers of astrocytes (upper panel) 
and pericytes (lower panel) exposed to normoxia and near anoxia in presence and absence of glucose 
for 24h. N= 3. !
Figure'3'
A'
B'
A
S
TR
O
C
Y
TE
S
 
Normoxia+Glc Normoxia-Glc Near anoxia+Glc Near anoxia-Glc 
P
E
R
IC
Y
TE
S
 
50 µm 
*
*"
*"
*"
! 81 
!!
Figure 4: Adaptation of proliferation by astrocytes and pericytes during hypoxic and ischemic 
insults. Proliferation of astrocytes (AC) and pericytes (PC) was analyzed using BrdU incorporation 
assay. Proliferation of cells exposed to normoxia, hypoxia and near anoxia in presence (solid bars) and 
absence (hatched bars) of glucose for 24h (A) and 48h (B) was measured and normalized to normoxic 
baseline (NX+Glc). N=3-5. *P<0.05, **P<0.01, ***P<0.001; 1-way ANOVA compared to 
normoxia+glucose. §§§P<0.001; 1-way ANOVA compared to normoxia-glucose. #P<0.05, ##P<0.01, 
###P<0.001; 2-way ANOVA comparing + to - glucose. !!
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Figure 5: Hypoxic/ischemic exposure differentially modulates metabolic activity of BBB cells. 
Viability of endothelial cells (EC), astrocytes (AC) and pericytes (PC) was measured by MTT conversion 
after exposure to normoxia, hypoxia and near anoxia in presence and absence of glucose for 24h (A) 
and 48h (B) and normalized to normoxic baseline (NX+Glc). N=3-5. *P<0.05, **P<0.01, ***P<0.001; 1-
way ANOVA compared to normoxia+glucose. §§P<0.01, §§§P<0.001; 1-way ANOVA compared to 
normoxia-glucose. #P<0.05, ##P<0.01, ###P<0.001; 2-way ANOVA comparing + to - glucose. 
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Figure 6: Differential regulation of autophagy and cell death in BBB cells. Expression of autophagy 
and cell death-related genes was investigated after 24h and 48h exposure to hypoxia (HX), near anoxia 
(AX) and OGD and compared to normoxia (NX). N=4. (A) Table of basal normoxic expression of BNIP3 
showing threshold cycles (CT) ± standard deviation (upper panel). BNIP3 mRNA expression after 24h 
(lower left panel) and 48h (lower right panel) of treatment. Densitometric quantification of protein 
expression (upper panel) and representative Western blots (lower panels) of BNIP3 (B) in endothelial 
cells (EC), astrocytes (AC) and pericytes (PC). N=4. *P<0.05, **P<0.01, ***P<0.001; 1-way ANOVA 
compared to normoxia+glucose. §P<0.05, §§P<0.01, §§§P<0.001; 1-way ANOVA compared to normoxia-
glucose. #P<0.05, ##P<0.01, ###P<0.001; 2-way ANOVA comparing + to - glucose treatment. 
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Figure 7: Differential regulation of autophagy and cell death in BBB cells. Densitometric 
quantification of protein expression (upper panel) and representative Western blots (lower panels) of 
Bax (C), Beclin-1 (D) in endothelial cells (EC), astrocytes (AC) and pericytes (PC). N=4. *P<0.05, 
**P<0.01, ***P<0.001; 1-way ANOVA compared to normoxia+glucose. §P<0.05, §§P<0.01, §§§P<0.001; 
1-way ANOVA compared to normoxia-glucose. #P<0.05, ##P<0.01, ###P<0.001; 2-way ANOVA 
comparing + to - glucose treatment.!
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Figure 8: Differential regulation of autophagy and cell death in BBB cells. Densitometric 
quantification of protein expression (upper panel) and representative Western blots (lower panels) of 
LC3-I (E) and LC3-II (F) in endothelial cells (EC), astrocytes (AC) and pericytes (PC). N=4. *P<0.05, 
**P<0.01, ***P<0.001; 1-way ANOVA compared to normoxia+glucose. §P<0.05, §§P<0.01, §§§P<0.001; 
1-way ANOVA compared to normoxia-glucose. #P<0.05, ##P<0.01, ###P<0.001; 2-way ANOVA 
comparing + to - glucose treatment.!
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3.3 DIFFERENTIAL METABOLIC ADAPTATION OF ASTROCYTES AND 
ENDOTHELIAL CELLS TO HYPOXIC AND ISCHEMIC INJURY 
(additional, unpublished results)  
3.3.1 Introduction 
In my previous work I observed that sensitivity to hypoxic and ischemic insults differs 
considerably between the different cell types at the BBB (Section 3.2). As both hypoxia and 
ischemia require profound metabolic adaptation we hypothesized that differences in cellular 
energy metabolism pathways likely account for these astonishing disparities. To address this 
question experimentally we compared the hypoxic and ischemic metabolic profiles of primary 
rat brain microvascular endothelial cells (RBMEC) and astrocytes (AC) - representing 
hypoxia/ischemia sensitive and tolerant cell types, respectively. To study their metabolic 
adaptation in a global and untargeted way a liquid chromatography-mass spectrometry (LC-
MS) approach was chosen.  
 
3.3.2 Material and Methods 
Primary cell isolation 
All cell culture media and reagents were obtained from Gibco® (Life Technologies, Zug, 
Switzerland) and Sigma-Aldrich (Buchs, Switzerland). Primary rat astrocytes were isolated 
from neonatal pups as described previously (Chow et al., 2001) and cultured in DMEM 
supplemented with 10% FBS and 50 µg/ml gentamycin sulfate. Primary rat brain 
microvascular endothelial cells (RBMEC) were isolated from 8-10 weeks old male Wistar rats 
according to (Coisne et al., 2005) with slight modifications. Briefly, isolated cortices were 
homogenized after removal of meninges in a 40 ml Dounce homogenizer. Microvessels were 
isolated from the homogenate adding an equal volume of 30% Dextran solution and 
subsequent centrifugation at 3000 g for 25 min at 4°C. Then the microvessels were filtered 
through a 60 µm nylon mesh to remove larger vessels and digested in HBSS buffer 
supplemented with 10 mM HEPES, 0.1% BSA, 2 mg/ml collagenase-dispase, 10 µg/ml 
DNAse I and 147 ng/ml TLCK for 45 min at 37°C in a water bath. Digested microvessels were 
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resuspended in endothelial media (DMEM supplemented with 20% calf serum, BME amino 
acids, vitamin solution, 2 mM L-glutamine, 1 ng/ml bFGF, 50 µg/ml gentamycin sulfate) and 
plated on collagen-IV coated culture vessels. 1 day after isolation RBMEC were treated with 3 
µg/ml puromycin-containing media for 24h to reduced pericyte contamination. 
 
O2 deprivation and ischemic treatment  
O2 deprivation experiments were carried out in purpose-built hypoxic glove-box chambers 
(InVivO2 400, Ruskinn Technologies, Pencoed, UK) maintained at 37°C with 5% CO2. O2 
concentration was constantly monitored with an internal O2 sensor. Cells were exposed to 
hypoxia (1% O2) and near anoxia (0.2% O2) for 24h. Normoxic controls were maintained at 
ambient O2 levels, 37°C, 5% CO2. Ischemia was simulated in vitro by oxygen-glucose 
deprivation (OGD). OGD was carried out in glucose-free media at hypoxia and near anoxia. 
 
MTT assay 
Cell viability was measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. All cells were cultured in 96-well plates. After hypoxic/ischemic exposures a 
5 mg/ml MTT solution (Sigma-Aldrich, Buchs, Switzerland) was added to the medium to 
obtain a final concentration 0.5 mg/ml and incubated for 1h at 37°C. Subsequently the media 
was removed, cells were lysed by adding 100 µl dimethyl sulfoxide and optical density was 
measured at 560/670 nm using a Multiskan RC Microplate Photometer (Thermo Labsystems, 
Helsinki, Finnland). 
Metabolite extraction 
For LC-MS metabolite extractions astrocytes (passage 1) and freshly isolated RBMEC 
(passage 0) were cultivated until confluence in 3.5 cm dishes in their respective media. After 
an acclimatization phase of 6h in MS (mass spectrometry) media (DMEM + 10% calf serum + 
BME amino acids, vitamin solution, 2 mM L-glutamine, 1 ng/ml bFGF and 50 µg/ml 
gentamycin sulfate) cells were subjected for 24h to O2 deprivation and OGD as described 
above. Subsequently cells were washed twice with ice-cold 5 mM NH4HCO3 solution and any 
residual liquid was removed. Cells were immediately quenched in 100 µl 80% methanol (-
20°C) containing 20 µg/ml C13/N15 labeled amino acid mixture (Cortecnet, Voisins-Le-
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Bretonneux, France) as internal standard, scraped off the dish using a metal spatula and 
incubated for 10 min on ice for metabolite extraction. After centrifugation (6000 g for 5 min at 
4°C) the supernatant containing the metabolites was lyophilized and stored at -80°C until LC-
MS measurement. All experiments and exposures were carried out four times independently.  
 
LC-MS measurements 
All mass spectrometry measurements and analyses were conducted in cooperation with the 
Functional Genomics Center Zurich (FGCZ), University of Zurich. Lyophilized metabolite 
pellets were resuspended in 20 µl ddH2O and transferred to 96-well plates. Subsequently 
samples were diluted 1:5 in injection solution (90% acetonitrile, 10% methanol, 50 mM 
ammonium acetate, pH 9) and centrifuged. 30 µl of the supernatant were transferred to a 
fresh 96-well plate and directly analyzed on a nanoACQUITY system coupled to a Synapt 
G2HD mass spectrometer (Waters Corp., Milford, USA). The chromatographic separation of 
metabolites was performed on a 0.2 µm x 150 mm BEH amide column using a 10 min linear 
gradient of 90% to 50% acetonitrile. A concentration of 0.5 mM ammonium acetate, pH 9 was 
kept during the whole chromatographic run. All analyses were done in negative mode using 
1.2 kV capillary voltage, 30 V sampling cone voltage and 3 V extraction cone voltage. Source 
temperature was set to 100°C and Nano Flow Gas was applied.  
 
Data analysis and processing 
Data processing and analysis of the LC-MS measurements were carried out by the FGCZ. 
Waters raw data were first converted to centroid mode and further processed into vendor 
independent netCDF format. Mass/retention time peak lists including peak intensities for each 
sample were calculated using the data processing tool cosmiq (Fischer et al., 2014). Signal-
to-noise ratio (SNR) of mass peak detection was set to 3, SNR for chromatographic peak 
detection was set to 10 and a m/z bin size of 0.003 Da was chosen as parameters for cosmiq. 
For metabolite annotation the resulting list was first matched to a list of metabolites with 
known retention time and mass. For additional annotation of unknown metabolites, the list of 
accurate masses was matched to the KEGG database assuming [M-H]- adducts (Ogata et 
al., 1999). Database hits within a mass window of 0.01 Da were considered. 
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Data normalization strategy  
In order to compare the relative metabolite quantities between the different treatments and 
cell types, we performed a normalization approach according to the sum of all detected 
metabolite ion intensities, as previously reported by Katajamaa et al. with slight modifications 
(Katajamaa and Oresic, 2007). This strategy is based on the assumption that the total 
number of cells, which were used for extraction, is reflected by their total amount of 
metabolites and hence can be estimated by the sum of measured ion intensities. One NX+Glc 
RBMEC sample was chosen as reference. The ion intensity for each metabolite was divided 
by the factor Σis/ Σir, where Σis is the summed ion intensity for each individual sample and Σir 
is the summed ion intensity of the reference sample. 
 
Pathway analyses 
Statistically significant metabolites from four independent experiments were analyzed in a 
metabolic pathway context using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
metabolic pathway map (Ogata et al., 1999) and MetaboAnalyst (Xia et al., 2012). The KEGG 
pathway map was retrieved in the KGML data format and imported into cytoscape using the 
KGMLReader tool (Shannon et al., 2003). Fold changes and significance values of the 
annotated metabolites were mapped on this global pathway map. A list of KEGG IDs was 
uploaded to the pathway analysis tool of MetaboAnalyst (Xia et al., 2012; Xia and Wishart, 
2010) and a list of significant pathways was retrieved using following parameters: Rattus 
norvegicus pathway library, hypergeometric test and relative-betweenness centrality. 
MetaboAnalyst2.0 is a web-based free tool and can be accessed via 
http://www.metaboanalyst.ca.  
Statistics 
All results are expressed as mean ± SD. Statistical significance was either assessed using 
unpaired student`s t-test or one-way ANOVA for comparison within one group and two-way 
ANOVA for comparison between different groups using GraphPad Prism 5 software (La Jolla, 
CA). Bonferroni`s post hoc test was used for all ANOVA analyses. A P-value below 0.05 was 
considered significant. 
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3.3.3 Results 
 
Pilot experiments  
Primary cultures of rat brain astrocytes (AC) and microvascular endothelial cells (RBMEC) 
were isolated as described above. Astrocytic cultures were characterized by high expression 
of the astrocyte marker glial fibrillary acidic protein (GFAP), whereas α-smooth muscle actin 
(α-SMA) and PECAM-1 reactivity was absent, implying no contamination with pericytes or 
endothelial cells, respectively (Fig. 3.1A). The phenotype of the RBMEC cultures was 
confirmed by expression of the tight junction proteins occludin, ZO-1 and claudin-5 (Fig. 
3.1B). Only minor contamination with pericytes (less than 5%) was observed, as indicated by 
α-SMA reactivity. Astrocyte contamination was ruled out by complete lack of GFAP 
expression (Fig. 3.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Characterization of primary astrocytes and RBMEC cultures. (A) Astrocyte cultures 
were characterized by strong expression of glial cell marker GFAP (glial fibrillary acidic protein) and 
absence of pericyte and endothelial cell contamination as shown by α-smooth muscle actin and 
PECAM-1 staining, respectively. (B) Rat brain microvascular endothelial cell (RBMEC) phenotype was 
verified by strong expression of the tight junction proteins occludin, ZO-1 and claudin-5 and absence of 
astrocytic GFAP. A pericyte contamination of below 5% was indicated by α-smooth muscle actin 
immunoreactivity. Cell nuclei are shown in blue (DAPI). 
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In order to be able to compare differences in metabolic adaptation between AC and RBMEC 
during O2 deprivation and ischemia the use of an identical culture media was indispensable. 
Typically RBMEC receive a very rich media containing 20% calf serum (CS) and a number of 
additives, such as vitamins, L-Glutamine, amino acids and basic fibroblast growth factor 
(bFGF) (RBMEC media). The astrocyte media (AC media) in contrast consists of DMEM and 
10% fetal bovine serum (FBS) only. However since media composition can strongly influence 
cellular metabolism selection of a media suitable for both cell types, which did not contain too 
rich nutrient conditions but reproduced previous observed effects. The effect of different 
media on metabolic activity/cell viability was measured using MTT assay after 24h of O2 
deprivation and ischemic treatment. AC and RBMEC were exposed for 24h to normoxia (NX), 
hypoxia (HX, 1% O2) and near anoxia (AX, 0.2% O2) in presence and absence of glucose 
(+Glc/-Glc). For each cell type its standard media was compared to two other media namely 
minimal media (DMEM + 10% calf serum + 50 µg/ml gentamycin sulfate) and minimal media 
+ 1 ng/ml bFGF (Fig. 3.2A and Fig. 3.2B). In RBMEC media the endothelial cells hardly 
responded to O2 deprivation and oxygen glucose deprivation (OGD) suggesting the media 
likely contains too much serum and nutrients to observe any major effects of the treatments 
(Fig. 3.2A). For both minimal media with and without bFGF we observed an increase in MTT 
conversion in hypoxic (HX) and near anoxic (AX) exposure compared to normoxic baseline. 
Glucose deprivation during NX led to a reduction of MTT conversion of 30-40%, which was 
further aggravated upon simultaneous OGD during HX and AX (Fig. 3.2A). Importantly the 
presence of bFGF in the minimal media did not have any effect on MTT conversion. Culture 
of AC in either minimal media did not alter metabolic activity under HX or AX compared to the 
conventional AC media (Fig. 3.2B). However during OGD the rate of MTT conversion was 
higher when the minimal media were used. This initial effect of the higher tolerance of AC is 
likely due to the different serum composition in the minimal media, which contains calf serum 
instead of FBS and thus likely different growth factors. The serum effect was however 
abolished after prolonged OGD for 48h, as here all media again showed similar response 
(data not shown). As previously observed for RBMEC the presence of bFGF did not cause 
any alterations in MTT reduction.  
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Figure 3.2C depicts the comparison between the response of AC and RBMEC in minimal 
media without bFGF. Showing the increased activity of RBMEC upon O2 deprivation, which 
may be due to increased proliferation, whereas AC remain unaffected. Similarly in OGD AC 
did not show any dramatic changes in MTT conversion implying their great tolerance for the 
given exposures, in contrast metabolic activity of RBMEC was decreased in a severity-
dependent manner, resulting in about 60% loss of initial activity under AX-Glc (Fig. 3.2C).  
Figure 3.2: Culture media composition affects astrocyte and RBMEC viability. Cell viability of 
RBMEC (A) and astrocytes (AC) (B) cultured in their usual media (RBMEC/AC media), minimal media 
and minimal media + bFGF was measured using MTT assay. Cells were exposed for 24h to normoxia 
(NX), hypoxia (HX) and near anoxia (AX) in presence (+, solid bars) and absence (-, hatched bars) of 
glucose (Glc) and compared to normoxic baseline (NX+Glc). (C) Comparison of RBMEC and AC 
viability in minimal media. N=1-3.  
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Based on these pilot experiments we decided to use the minimal media without bFGF for 
future metabolomics measurements as this gave the closest responses expected from 
previous data as well as avoided the additional complication of bFGF-mediated effects. 
In spite of carefully testing the media in the MTT assay, we encountered difficulties culturing 
the RBMEC in the minimal media over longer periods of time. Although cultivation in 96 well 
plates for the MTT assay did not result in any visual or functional impairment, RBMEC 
cultured in 3.5 cm petri dishes for the metabolite extractions, started to lift off during the 
normoxic incubations. Thus ultimately the media composition for the mass spectrometry 
measurements had to be refined and a media containing similar additives to that of RBMEC 
media with 10% instead of 20% calf serum was used (mass spectrometry/MS media), which 
was tolerated well by both cell types. Prior to the actual exposure RBMEC and AC were 
acclimatized for 6h in the MS media.  
 
Novel insights into cell-specific metabolism of AC and RBMEC during O2 deprivation 
and ischemic stress  
Using a LC-MS based approach we compared the metabolic profiles of primary rat brain 
microvascular endothelial cells (RBMEC) and astrocytes (AC). We could annotate about 500 
metabolites by accurate mass allowing a global overview of cellular metabolism. Due to the 
high complexity of the data set a principal component analysis (PCA) was performed. The 
PCA allows conclusions to be drawn regarding the reproducibility of the data (replicates) and 
importantly gives information about the difference of the metabolome amongst the treatment 
groups. Similarly to the pilot experiments AC and RBMEC were subjected for 24h to NX, HX, 
and AX in presence and absence of glucose. Figure 3.3 is a graphical representation of the 
PCA for all treatments (colors) of AC (stars) and RBMEC (circles). The plot shows that the 
four replicates of similar treatments cluster closely together implying a good reproducibility of 
the observed changes (Fig. 3.3). The three axes represent the major principal components 
(PC) of the data set. The principal components define the directions of the highest 
variance/difference in the data set i.e. where the metabolome is most different. The larger the 
distance between two points the bigger the difference for a certain parameter and the 
percentage of a given axis is the percentage of total variance that this principal component 
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accounts for. On the first axis (PC1) a separation of AC versus RBMEC data points is 
observed showing that the cell type makes the largest contribution to metabolome 
composition whereas the insult severity, shown on the PC2 axis, is the second most 
important parameter affecting metabolome composition. The distribution of the data points on 
the second axis further shows a close clustering of the O2 deprivation groups for both AC and 
RBMEC revealing only minor changes in the metabolome due to O2 deprivation. OGD in 
contrast induces a spread of the different exposures along the second axis and thus 
demonstrates more profound changes induced by ischemic treatment (Fig. 3.3).  
Next we aimed to determine the main metabolites accounting for cell-type specific differences 
presented on the first PC axis to identify differential active metabolic pathways between AC 
 
 
 
 
 
Figure 3.3: Cell type and insult severity chiefly affect metabolome composition. Principal 
component analysis of the metabolomes of AC (stars) and RBMEC (circles) exposed to normoxia (NX), 
hypoxia (HX) and near anoxia (AX) in presence and absence of glucose (+/- Glc). Axes represent the 
principal components (PC) and their contribution to overall metabolome variance in percent (%). As 
indicated by the arrows PC1 reflects the difference between AC and RBMEC, whereas on PC2 the 
different treatment groups separate based on insult severity. N=4. 
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and RBMEC, as these pathways likely account for the differences in hypoxic/ischemic 
sensitivity between the cell types. To do so a list of all detected metabolites was generated in 
which the ratio of metabolite abundance of AC to RBMEC was calculated for physiological 
conditions (NX+Glc). This list was first used for a pathway analysis using the KEGG metabolic 
pathways tool to generate the map presented in Figure 3.4 that depicts an overview of all 
metabolic pathways and the involved metabolites. Metabolites increased in AC, compared to 
RBMEC, are shown in red circles whereas metabolites that are higher in RBMEC are blue. 
The circle size reflects the fold-change with dark colors indicating significant changes 
whereas light colored ones are not significant. It is apparent from the map that in AC many 
metabolites are significantly higher expressed than in RBMEC, particularly in pathways that 
account for carbohydrate metabolism and TCA cycle (purple box). In addition metabolites 
involved in glutathione metabolism (orange box) and creatine metabolism (blue box) were 
strongly elevated in AC. RBMEC in contrast showed an accumulation of metabolites involved 
in nucleotide (red lines) and lipid metabolism (dark green lines). Appendix Table A.1 shows 
fold changes and statistics of the top altered metabolites presented in Fig. 3.4. To further 
characterize the pathways with differential activity in the two cell types, an analysis using the 
MetaboAnalyst tool was performed (Fig. 3.5). The Table depicts the major active pathways in 
AC (upper Table) and RBMEC (lower Table) in relation to each other, showing the number of 
total metabolites involved in the pathway (total), the metabolites found in a pathway just by 
chance (expected), the number of up-regulated metabolites detected in the sample (hits) and 
the calculated p-value (raw p). Correlating well with the results obtained from the KEGG 
analysis we again identified pathways linked to carbohydrate metabolism from top hits for AC 
including galactose, starch and sucrose, amino sugar and nucleotide sugar and fructose 
metabolism, as well as glycolysis and citrate cycle (highlighted in red). It is however 
noteworthy that detection of compounds with similar molecular formula cannot be 
distinguished by the mass spectrometry measurements, which applies for example for the 
hexoses (glucose, fructose and galactose) or D- and L-isomers, like amino acids. For this 
reason the interpretation of glycolysis, fructose and galactose metabolism is difficult as a 
definite metabolite assignation is not possible.  
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Figure 3.4: AC and RBMEC exhibit differential activity of metabolic pathways under 
physiological conditions. The relationship of metabolite abundance between AC and RBMEC under 
physiological conditions (NX+Glc, N=4) was analyzed using the KEGG metabolic pathway tool shown 
as overview of metabolites highly abundant in AC (red) and RBMEC (blue) embedded in their metabolic 
pathways. The size of the circles represents the fold change with dark color depicting significant and 
light color non-significant differences. Purple box: carbohydrate metabolism pathway, red lines: 
nucleotide metabolism, dark green lines: lipid metabolism, orange lines: amino acid metabolism, light 
green lines: terpenoids and polyketides metabolism, light blue lines: glucan biosynthesis blue box: 
creatine metabolism, orange box: glutathione metabolism. 
 
Since our media did not contain any fructose or galactose but only glucose it seems likely that 
the hits we get for these pathways in the pathway analysis might be caused by false 
identification of isomers. Glutathione metabolism was also identified to be very active in AC 
(highlighted in red). In RBMEC however metabolites of the purine metabolism pathway (a 
branch of the nucleotide metabolism) as well as different amino acid pathways, including like 
tyrosine, D-glutamine/D-glutamate and arginine/proline metabolism, were accumulated 
compared to AC (Fig. 3.5 lower panel, highlighted in blue).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: AC and RBMEC exhibit differential activity of metabolic pathways under 
physiological conditions. Top metabolic pathways up-regulated in AC (upper Table) and RBMEC 
(lower Table) compared to each other obtained by pathway analysis using MetaboAnalyst software. 
Total: total number of metabolites involved in pathway, Expected: number of metabolites detected in a 
pathway by chance, Hits: up-regulated metabolites in sample, Raw p: calculated significance, P-value. 
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Next we selected specific pathways elevated in AC for detailed investigation to answer our 
major question, which metabolic pathways may account for their higher tolerance in hypoxic 
and ischemic injury compared to RBMEC. Based on previous literature we selected pathways 
that are known to be important for normal brain function and survival during O2 
deprivation/OGD and compared their activity between AC and RBMEC. The selected 
pathways are creatine/phosphocreatine, glutathione and glycogen metabolism.  
For tissues with high fluctuating energy requirements, like the brain or muscles, the 
creatine/phosphocreatine (CR/pCR) system is of particular importance as it is essential for 
ATP safeguarding and movement, protection against excitotoxicity and has anti-apoptotic and 
antioxidant actions (Perasso et al., 2013). Under conditions of energy shortage pCR donates 
its phosphate group to ADP and thus fosters rapid replenishment of ATP pools in absence of 
glucose or O2 (Perasso et al., 2013; Tachikawa et al., 2007). We compared the abundance of 
metabolites involved in CR biosynthesis and CR/pCR cycle (Fig. 3.6). The biosynthesis 
pathway of CR involves conversion of glycine, L-arginine and S-adenosyl-L-methionine to 
form CR, L-ornithine and S-adenosyl-homocysteine (Fig. 3.6A, upper panel). Indeed we 
observed that the levels of glycine, ornithine and S-adenosyl-L-methionine were higher in AC 
than in RBMEC, suggesting a higher rate of CR biosynthesis (Fig. 3.6A, lower panel) 
Presence of ATP favors the reversible conversion of CR to the highly energetic pCR (Beard 
and Braissant, 2010; Perasso et al., 2013). Supporting the assumption of elevated astrocytic 
CR biosynthesis, pCR was clearly more abundant in AC compared to RBMEC, whereas we 
did not observe any difference in CR levels, which is likely due to the rapid conversion of CR 
to pCR in AC (Fig. 3.6B, lower panel). Interestingly we observed that the ADP levels in 
RBMEC were much higher than in AC, which may explain the low pCR levels although CR is 
present in RBMEC. Unfortunately detection of ATP was not reliable in the mass spectrometry 
measurements preventing this correlation to be established. However, due to its central 
function in cellular protection, and particularly during insults that impair energy generation like 
hypoxia or ischemia, the strong expression of the CR/pCR system represents an excellent 
adaptation of AC to withstand such stress conditions.  
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Figure 3.6: The creatine/phosphocreatine system is more prevalent in astrocytes than in RBMEC. 
The flow charts depict the metabolites involved in creatine biosynthesis (A) and 
creatine/phosphocreatine cycle (B). Lower panels show bar graphs of metabolite abundance (in total ion 
counts) of selected metabolites involved in these pathways comparing between RBMEC and AC under 
physiological conditions (NX+Glc, 24h). N=4. **P<0.01, ***P<0.001; unpaired student`s t-test. 
  
Glycogen represents the major store of glucose equivalents within the brain and thus similarly 
to CR/pCR contributes to replenishment of ATP levels (Belanger et al., 2011; Gruetter, 2003). 
Starch and sucrose metabolism was another major hit in AC pathway analysis and glycogen 
metabolism is an important branch of it. Since UDP-glucose is a direct precursor of glycogen 
we investigated metabolites participating in UDP-glucose formation (Fig.3.7A). Interestingly 
the abundance of hexoses, probably mainly D-glucose, was much higher in AC than in 
RBMEC (Fig. 3.7A). In addition very high levels of UDP-glucose, the major building block of 
glycogen, were detected in AC suggesting a high rate of glycogen biosynthesis, whereas 
RBMEC only showed negligible amounts of UDP-glucose (Fig. 3.7A). Unfortunately glycogen 
itself cannot be directly detected by mass spectrometry, as it is a polymer of glucose that is 
indistinguishable from glucose/hexose monomers. However both high levels of hexoses as 
well as UDP-glucose strongly suggest that AC have more glycogen stores than RBMEC.
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Figure 3.7: High abundance of glycogen- and glutathione-related metabolites in astrocytes. The 
flow charts depict the metabolites involved in glycogen biosynthesis (A) and glutathione redox cycle (B) 
Bar graphs show a comparison of selected metabolites between RBMEC and AC under control 
conditions (NX+Glc, 24h) for the mentioned pathways. N=4. *P<0.05, **P<0.01, ***P<0.001; unpaired 
student`s t-test. 
 
In addition to energy equivalents antioxidants crucially contribute to cellular well-being. 
Glutathione is one of the most important cellular antioxidants that diminishes oxidative stress 
and plays a central role in cell survival during hypoxic and ischemic injury (Juurlink, 1997). As 
predicted by pathway analysis AC indeed contained higher levels of reduced glutathione 
(GSH) and oxidized glutathione (GSSG) than RBMEC (Fig. 3.7B). In addition AC had 
significantly higher levels of Cysteinyl-glycine (Cys-Gly), a compound used as precursor for  
glutathione biosynthesis (Dringen et al., 2001), showing a good correlation with the increased 
glutathione levels.  
Next we investigated whether the above-mentioned differences in the discussed pathways 
could account for the different sensitivities of AC and RBMEC to O2 deprivation and OGD 
(Fig. 3.8). Notably for all treatments pCR levels were consistently and significantly higher in 
AC compared to RBMEC (Fig. 3.8A). The CR/pCR system was modulated in AC in response  
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Figure 3.8: O2 deprivation and ischemia causes changes in phosphocreatine, glycogen and 
glutathione metabolism. Astrocytes and RBMEC were exposed to normoxia (NX), hypoxia (HX) and 
near anoxia (AX) with and without glucose (+/-Glc) for 24h. Abundance of metabolites participating in 
creatine/phosphocreatine cycle (A), glycogen biosynthesis (B) and glutathione turnover (C) were 
compared. N=4. *P<0.05, **P<0.01, ***P<0.001; 1-way ANOVA compared to NX+Glc. §P<0.05, 
§§P<0.01, §§§P<0.001; 1-way ANOVA compared to NX-Glc. #P<0.05, ##P<0.01, ###P<0.001; 2-way 
ANOVA comparing RBMEC versus AC. 
 
to O2 deprivation but particularly during OGD. After 24h of HX and AX pCR was reduced by 
about 30%, in line with this we observed a significant increase of CR under HX. Contrary to 
our expectations the reduced PCR levels in AX did not results in an increase of CR. 
However overall the data indicate that AC use pCR during O2 deprivation to replenish their 
ATP pools. OGD led to a further reduction of pCR in AC concomitantly with an increase in 
CR, highlighting the progressive depletion of the pCR pool to generate ATP. In contrast no 
significant alteration in CR and pCR was observed in RBMEC during O2 deprivation, whereas 
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OGD resulted in a complete exhaustion of pCR during AX. Notably, although we observed 
universal reduction of pCR levels due to OGD AC were still able to maintain some reserves 
after 24h of exposure whereas RBMEC were completely depleted.  
Regarding glycogen metabolism we observed quite stable hexose and UDP-glucose levels 
for both AC and RBMEC during O2 deprivation (Fig 3.8B), suggesting that glycogen synthesis 
can be maintained as long as glucose is available in the culture media. In contrast during 
OGD both hexose and UDP-glucose levels decreased in a severity dependent manner for 
both cell types in line with the fact that glucose becomes a limiting factor. Intriguingly after 
24h of AX-Glc AC display a considerable amount of hexoses (probably from their glycogen 
pool), whereas RBMEC have almost completely depleted their sugar deposits in this 
condition.  
Glutathione levels were, as already observed for normoxic conditions previously (Fig. 3.7B), 
significantly higher in AC than in RBMEC for all treatments (Fig. 3.8C). O2 deprivation alone 
did not alter reduced glutathione levels in AC, whereas in RBMEC a trend for reduction was 
detected, although not significantly (Fig. 3.8C). OGD caused a significant decrease of GSH in 
both cell types in AX but not in HX. Again it is important to note that although for both cell 
types GSH levels declined AC still maintained much higher stores than RBMEC. This 
indicates that only during AX-Glc treatment both cell types consume considerable amounts of 
GSH to deactivate ROS, whereas due to the higher levels AC might be able to withstand the 
oxidative stress longer than RBMEC. Unfortunately we could not make any conclusions on 
GSSG levels due to the fact that it is likely to be rapidly secreted by cells to maintain a 
reduced thiol redox potential during oxidative stress and thus intracellular GSSG levels 
cannot be correlated well to actual GSSG formation (Dringen and Hirrlinger, 2003; Hirrlinger 
et al., 2001).  
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Figure 3.9: O2 deprivation only minorly affects metabolic pathways in astrocytes and RBMEC. 
KEGG pathway analysis of changes in metabolite profile after exposure to AX+Glc (0.2% O2) for 24h in 
astrocytes (A) and RBMEC (B), compared to NX+Glc. Red circles depict up-regulated metabolites, blue 
circles down-regulated metabolites. Circles colored in dark are significantly changed; light colored ones 
are not significant. Green box: glycolysis pathway, purple lines: carbohydrate metabolism, red lines: 
nucleotide metabolism, orange lines: amino acid metabolism, dark green lines: lipid metabolism, light 
green lines: terpenoids and polyketides metabolism, light blue lines: glucan biosynthesis.  
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Figure 3.10: OGD in near anoxia results in profound changes of the cellular metabolome. KEGG 
pathway analysis of changes in metabolite profile after exposure to AX-Glc for 24h in astrocytes (A) and 
RBMEC (B) compared to NX-Glc. Red circles symbolize up-regulated metabolites, blue circles down-
regulated metabolites. Circles colored in dark are significantly changed; light colored ones are not 
significant. Blue box: UDP-glucose/glycogen metabolism, green box: glycolysis. Purple lines: 
carbohydrate metabolism, red lines: nucleotide metabolism, orange lines: amino acid metabolism, dark 
green lines: lipid metabolism, light green lines: terpenoids and polyketides metabolism, light blue lines: 
glucan biosynthesis.  
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In order to obtain a more global overview of the metabolic changes occurring in the individual 
cell types in response to O2 deprivation and OGD additional pathway analyses were 
performed. Although overall O2 deprivation alone did not cause any dramatic metabolome 
alterations comparing AX+Glc exposure to NX+Glc for both AC (Fig. 3.9A) and RBMEC (Fig. 
3.9B) a cell type specific modulation of carbohydrate metabolism was clear from the pathway 
analysis map. In AC metabolites involved in glycolysis were up-regulated (green box), 
whereas intermediates of the TCA cycle were down-regulated, suggesting a shift from 
oxidative metabolism towards a more glycolytic metabolism. In contrast the largely 
unchanged metabolism pathway observed in RBMEC implied a more rigid and less versatile 
metabolic profile of RBMEC. Fold changes and statistics of the top altered metabolites 
presented in the pathway analyses Fig. 3.9 A+B are presented in Appendix Tables A.2 and 
A.3. 
On the other hand glucose deprivation combined with AX caused differential and distinct 
metabolic changes in both cell types (Fig. 3.10A+B, refer to Appendix Table A.4 and A.5 for 
fold changes and statistics). The pathway analysis depicts the changes in the metabolic 
pathways between AX-Glc and NX-Glc after 24h of treatment. Generally a down-regulation of 
metabolites was observed, rather than an up-regulation, with the amino acid metabolism 
(orange lines) pathway being the only one showing an accumulation of metabolites. AC 
showed a marked reduction in metabolites related to UDP-glucose/glycogen metabolism 
(blue box), whereas the down-stream pathways like glycolysis remained largely unaffected 
(green box) (Fig. 3.10A). Similarly to AX+Glc we observed a reduction of metabolites related 
to TCA cycle in AC. In RBMEC the metabolic changes were very profound and many more 
metabolites were reduced compared to AC, particularly in carbohydrate and nucleotide 
metabolism (Fig. 3.10B). The reduction of multiple metabolites of carbohydrate metabolism 
implies that compared to AC the RBMEC are starved of carbohydrates since they do not have 
as high reserves as AC do.  
Finally we compared the metabolic pathways up-regulated during AX-Glc treatment in the two 
cell types relative to each other, to get an idea which pathways are particularly different in this 
condition (Fig. 3.11). Interestingly amino acid metabolism pathway-related metabolites were 
the major elevated ones in AC (highlighted in light red), but again also glutathione metabolism 
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and starch and sucrose metabolism (including glycogen metabolism) were present in the list 
(highlighted in dark red) (Fig. 3.11A). As AC clearly tolerate AX-Glc better than RBMEC, this 
finding again confirms our previous observation that glycogen and glutathione metabolism  
strongly contribute to the tolerance of AC towards these injury conditions. However the Table 
also suggests that AC have a much more active amino acid metabolism under severe injury 
conditions raising the question whether they use amino acid catabolism to feed their energy 
needs. In RBMEC the citrate cycle as well as amino sugar and nucleotide sugar metabolism 
and pyruvate metabolism was increased compared to AC (Fig. 3.11B, highlighted in blue). 
The fact that both TCA cycle as well as pyruvate pathway-related metabolites are 
accumulated in RBMEC suggests a higher oxidative metabolism than for AC. 
 
 
Figure 3.11: Severe ischemic injury causes differential pathway activity in astrocytes and 
RBMEC. Comparison of active metabolic pathways after 24h of AX-Glc exposure in AC (A) and RBMEC 
(B) compared to each other. Total: total number of metabolites involved in pathway, Expected: number 
of metabolites detected in a pathway by chance, Hits: up-regulated metabolites in sample, Raw p: 
calculated significance, P-value. 
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3.3.4 Discussion 
Our own studies (Section 3.2, Figure 3.2C) and others (Ceruti et al., 2011; Redzic et al., 
2013) have clearly demonstrated that endothelial cells are more susceptible to 
hypoxic/ischemic injury than AC. Since adequate adaptation of cell metabolism is a crucial 
parameter for cell survival during such injuries (Ogunshola and Al-Ahmad, 2012), we 
hypothesized that the capability of the different cell types to adapt their metabolism 
accordingly might account for the observed differences in their tolerance and subsequently 
strongly impact barrier integrity. The liquid chromatography-mass spectrometry (LC-MS) 
approach used in this study allowed us to record global changes in cell metabolism in an 
untargeted and very sensitive way. Importantly, a great advantage was that the use of a 
capillary-based system requiring only low amounts of sample material made it possible to 
conduct this study with primary RBMEC instead of an endothelial cell line. A caveat of this 
work was that we had to culture cells in similar media to directly compare the treatment 
effects between the cells. During pilot tests we tested 2 different minimal media (+ and -
bFGF) both of which appeared to be tolerated well by both cell types and reiterated the 
differential sensitivity of AC and RBMEC towards OGD that also has been reported 
previously. Perplexingly however during the actual experiments the RBMEC were clearly 
impaired in the minimal media-bFGF under normoxic conditions. Fortunately this problem was 
solved by using a media that contained supplements similar to the original RBMEC media but 
only 10% calf serum (MS media) for both AC and RBMEC. To really prove that the MS media 
shows the same effects on MTT conversion as previously observed for the pilot experiment 
we plan to repeat these experiment using MS media.  
The second challenge for direct comparison of metabolite abundance between the cell types 
was the normalization of the data. In the metabolomics field a gold standard for robust and 
reliable normalization of cells has not been established (Silva et al., 2013). In general 
normalization to total protein amount, cell number and DNA content are discussed (Silva et 
al., 2013). The study by Silva and co-workers revealed that normalization to protein amount is 
difficult because the metabolite extraction buffers interfere with conventional protein assays 
(Silva et al., 2013), moreover hypoxia and ischemia affect protein synthesis (Koritzinsky and 
Wouters, 2007) and thus might not correlate well to cellular metabolite amounts. Cell number 
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would probably be the most accurate method but again hypoxic/ischemic treatment alters 
proliferation (Ogunshola and Al-Ahmad, 2012; Stanimirovic and Friedman, 2012) and thus we 
could not assume similar cell numbers for the different treatments and would have needed a 
control plate of each treatment for counting, which is not realizable for the RBMEC. More 
importantly AC and RBMEC have a very different cell size, thus it seems likely that the large 
AC would contain more metabolites than the smaller RBMEC, underlining that cell number is 
not a good normalization factor. Measurement of cellular DNA is another possibility, but again 
depending of the degree and mode of cell death (apoptosis versus necrosis) DNA content 
may not be a very reliable measure. The last option, which is widely used in the field and 
which we finally adopted, is to normalize all metabolites based on the total ion count of the 
sample (Katajamaa and Oresic, 2007). The total ion count reflects the total amounts of 
metabolites present in a sample, e.g. comparable to total protein amount in a cell lysate. We 
consider that for our experiments this method represents the most accurate method as it 
expresses the abundance of a given metabolite in correlation to the total metabolites within 
the sample.  
Principal component analysis of the data sets revealed that the cell type determined the major 
difference of the recorded metabolomic profiles suggesting a general difference in the 
metabolism of AC and RBMEC. Indeed pathway analyses showed fundamental differences in 
physiological metabolism between the two cell types. Compared to RBMEC AC accumulated 
large amounts of metabolites involved in sugar and particular glucose metabolism under 
physiological conditions. However, a weak point of choosing an untargeted study approach 
was that the different types of metabolite isomers could not be distinguished from each other. 
This particularly applies for sugar intermediates like hexoses or their phosphorylated 
derivatives and makes an in depth interpretation of sugar metabolism impossible. 
Nevertheless this study has revealed important information regarding differences in 
carbohydrate metabolism between AC and RBMEC and future in depth studies like gas 
chromatography mass spectrometry can be used to distinguishing such isomers and 
investigate sugar metabolism pathways in more detail.   
The high hexose content in AC however correlates very well with the crucial role in supply of 
important energy substrates produced from glucose, like lactate or glycogen, for themselves 
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but also for other brain cells, particularly neurons (Belanger et al., 2011; Prebil et al., 2011; 
Sickmann et al., 2009; Walls et al., 2009). Since endothelial cells at the BBB in contrast 
primarily mediate transport of glucose from the blood across into the brain (Abbott et al., 
2006; Mann et al., 2003), and no role in supply of energetic fuels to other cells has been 
discussed like for AC, it seems logical that AC contain higher concentrations of glucose-
related metabolites than RBMEC. Indeed AC appeared to have high rates of glycogen and 
phosphocreatine biosynthesis, two compounds being crucially involved in maintenance of 
ATP levels under energy demanding conditions (Belanger et al., 2011; Perasso et al., 2013; 
Prebil et al., 2011; Tachikawa et al., 2007). Indeed strong accumulation of UDP-glucose in 
AC approximately 8 times higher than in RBMEC supports this hypothesis. This also agrees 
with studies demonstrating that AC are the major glycogen store within the brain, whereas 
only minor amounts are detected in capillary endothelial cells, neurons, pericytes and 
meningeal cells (Cataldo and Broadwell, 1986a; Cataldo and Broadwell, 1986b). Different 
studies have shown that glycogen is consumed during hypoxia and particularly ischemia by 
AC and represents a central energy source under such conditions (Kahlert and Reiser, 2004; 
Niitsu et al., 1999). This correlates with reduced UDP-glucose observed in our model during 
OGD (Fig. 3.8B and Fig. 3.10A) indicating that glycogen biosynthesis is inhibited. 
Furthermore the fact that metabolites involved in glycolysis remain largely unaffected during 
AX-Glc in AC suggests they degrade glycogen stores to feed glycolysis, in complete contrast 
to RBMEC where a marked reduction of carbohydrate metabolites was observed.  
AC also appear to profit from approximately 10 times higher levels of phosphocreatine 
compared to RBMEC. During O2 deprivation and OGD AC consume pCR, implying they use it 
for ATP generation in stress conditions. Interestingly the expression levels of cytosolic brain 
type creatine kinase, a crucial enzyme for creatine biosynthesis, has been directly correlated 
to resistance of cell types to acute energy loss, e.g. during hypoxia or hypoglycemia 
(Tachikawa et al., 2007). Indeed in the brain mainly AC express high levels of brain type 
creatine kinase, whereas its immunoreactivity was absent in capillaries of the adult mouse 
cortex (Lowe et al., 2013; Tachikawa et al., 2004; Tachikawa et al., 2007), confirming our 
hypothesis that endothelial cells do not synthesize considerable amounts of creatine and thus 
may be protected less during ischemic injuries. 
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Depletion of ATP stores during hypoxia and ischemia represents one important factor that 
has deleterious effects on cell survival, another factor crucially determining cell fate under 
such injury conditions is oxidative stress (Love, 1999; Miyata et al., 2011; Stanimirovic and 
Friedman, 2012). Reduced glutathione (GSH) is considered the major antioxidant within cells 
(Hirrlinger and Dringen, 2010; Wang et al., 2013) and in line with this the resistant AC 
retained about double the amount of GSH than RBMEC. Interestingly GSH slightly decreased 
in RBMEC during O2 deprivation whereas the levels remained stable in AC, which may either 
be due to increased oxidative stress in RBMEC compared to AC or the ability of AC to 
compensate GSH oxidation via regeneration from GSSG or biosynthesis. In AX-Glc treatment 
both cell types exhibited a considerable reduction of GSH levels likely due to increased ROS 
formation under such severe conditions. Overall our data implies that the higher GSH levels 
help AC to better tolerate severe injury conditions than RBMEC. Indeed depletion of 
astrocytic glutathione stores has been correlated to their decreased resistance during 
ischemia (Gabryel and Malecki, 2006; Sims et al., 2004) underlining our hypothesis that the 
amount of glutathione levels correlates to increased ischemic tolerance. 
Overall AC appear to be perfectly equipped for stress conditions of energy depletion and 
ROS, whereas endothelial cells cannot rely on similar protective mechanisms. The high 
tolerance of cultured AC to hypoxic/ischemic conditions appears to be largely reliant on a 
combination of various fine-tuned and versatile metabolic changes including energy 
generation by either glycolysis or oxidative pathways, efficient metabolism of substrates other 
than glucose and a high glutathione content – to name only those revealed in this study. 
However it seems likely that further in-depth analysis of other pathways could reveal 
additional key metabolic adaptations. This perfect adaptation of AC is likely due to their 
important protective role for other brain cells, particularly neurons but also endothelial cells at 
the BBB (Engelhardt et al., 2014b; Schroeter et al., 1999; Turner and Adamson, 2011), during 
injury conditions. It is well known that AC provide energy substrates, such as lactate derived 
from glucose or glycogen, to neurons and also secretion of glutathione by AC has been well 
documented to protect neurons from oxidative stress (Belanger et al., 2011; Bouzier-Sore and 
Pellerin, 2013; Wiesinger et al., 1997). For this reason it would be very interesting to define 
whether AC also provide such metabolic support to endothelial cells in order to improve 
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endothelial function during injury conditions. For example treatment of endothelial cells with 
AC-conditioned media or co-cultivation of EC and AC could give very interesting information 
on whether AC alter endothelial metabolism under injury conditions. In addition a study 
including pericytes and monitoring how their metabolism compares to AC and endothelial 
adaptations would add to our understanding about cell-specific adaptations to hypoxia and 
ischemia.  
In conclusion this study is the first to compare the global metabolism between AC and 
endothelial cells. Unfortunately until now brain researchers have largely disregarded the 
contribution of an intact BBB brain function in disease states. Thus most studies investigating 
brain metabolism exclusively focus on AC and neurons with the importance of endothelial 
cells and pericytes being almost completely neglected. However due to their central role in 
mediating brain homeostasis it is crucial to understand more about the physiological and 
pathophysiological metabolism of the BBB associated cells. In this regard an important open 
question in the field is: which cellular parameters regulate cellular resistance to hypoxic and 
ischemic injury? This study has provided convincing evidence that differences in cellular 
metabolism contribute hypoxic/ischemic tolerance with particularly highly energetic 
metabolites like glycogen or phosphocreatine, and antioxidants being important determinants 
for cellular survival. In the next steps we must assess whether we can take advantage of such 
mechanisms during injury and disease progression to improve barrier stability and, ultimately, 
functional recovery. 
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4 CONCLUSIONS AND PERSPECTIVES 
 
The scope of this work was to improve understanding of the molecular aspects of BBB 
impairment in response to hypoxic and ischemic injury with a special focus on the specific 
responses of the individual BBB cells. Thematically the work was subdivided in two major 
parts. The first part investigated the impact of HIF-1 signaling on hypoxic BBB impairment in 
endothelial cells with a particular focus on tight and adherens junction regulation.  
HIF-1 represents a crucial transcription factor for adaptation to hypoxic/ischemic results. 
Particularly in neurons HIF-1 signaling has been demonstrated to be crucial for cell survival 
during hypoxic and ischemic injury (Baranova et al., 2007; Vangeison et al., 2008). Despite 
the fact that HIF-1 improves cellular adaptation its impact on BBB was only inferred. By 
initiation of angiogenesis e.g. via VEGF signaling, hypoxic signaling provokes barrier opening 
causing brain edema, dysregulation of brain homeostasis, oxidative stress and inflammatory 
events (Ogunshola and Al-Ahmad, 2012; Stanimirovic and Friedman, 2012). Indeed various 
studies modulating HIF-1 activity using HIF-1 stabilizers and inhibitors suggested a negative 
impact of HIF-1 signaling on outcome in ischemic models resulting, increased edema 
formation and infarct volumes, which are both closely related to impaired BBB function (Chen 
et al., 2008a; Yeh et al., 2007). However these studies did not directly investigate the 
mechanisms of BBB disruption on a molecular level. Our study (Engelhardt et al., 2014a) 
showed that normoxic HIF-1α stabilization mimics hypoxic BBB disruption on a temporal and 
mechanistic level exhibiting similar disturbance of barrier function and tight/adherens junction 
modulation, thus substantiating our hypothesis that HIF-1 mediates hypoxic BBB disruption.  
Indeed this observation discloses some caveats regarding the use of HIF-1 stabilizers in 
clinical applications. Particularly in stroke and traumatic brain injury research HIF-1 stabilizers 
are considered for treatment due to their neuroprotective and erythropoiesis-stimulating 
action (Harten et al., 2010; Nagel et al., 2010). However the adverse action of such drugs on 
barrier function should not be disregarded. The increased edema formation and penetration 
of blood-borne molecules that convenes with increased BBB permeability contributes to 
aggravated cerebral damage. This observation clarifies that HIF-1 exerts different outcomes 
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on different cell types: improving cell survival in the case of neurons but promoting loss of 
barrier function in endothelial cells. Therefore the use of HIF-1 stabilizers in therapeutic 
settings needs to be very well defined and potentially requires a very tight time window in 
order to achieve neuroprotection without too severe BBB impairment. In this context more 
knowledge about the action of HIF-1 on different cell types and about the temporal progress 
of diseases will be required. Another potential solution to combat the adverse effects of HIF-1 
on barrier function would be to apply the HIF-1 stabilizers locally into the brain avoiding a 
systemic administration (either orally or via the blood stream), where the drugs would have to 
reach the brain across the vasculature.  
It is also noteworthy that there is also the potential to exploit the barrier-permeabilizing effect 
of HIF-1 to selectively open the BBB for drug delivery. However currently there is insufficient 
information on the mechanistic action of HIF-1 on the endothelial permeability to be able to 
estimate the consequences of such a treatment.  
Importantly we showed in our study that HIF-1 induced displacement of ZO-1, claudin-5 and 
VE-cadherin from the plasma membrane and tyrosine phosphorylation of occludin appears to 
play a more important role in BBB opening than down-regulation of tight/adherens junction 
proteins. In support of this HIF-1 inhibition could partially revert the adverse outcome of 
hypoxia on barrier function and cellular junction rearrangements although not completely. 
With this study we obtained a good insight how HIF-1 signaling affects tight junction and BBB 
modulation. However it seems likely that these effects are not directly exerted by HIF-1 but 
more c clikely via HIF-1 target genes, therefore in future studies it would be very interesting to 
investigate the underlying mechanism of tight junction rearrangements in more depth and to 
identify the players inducing and exerting tight junction displacement. Moreover it would be 
highly attractive to investigate whether HIF-2 signaling contributes to hypoxic barrier 
impairment, particularly since the brain endothelium exhibits strong HIF-2α expression and 
HIF-2 appears to be an important vascular regulator in vivo (Skuli et al., 2009). In addition a 
modulation of HIF-2 signaling by HIF-1 stabilizers and inhibitors is likely because of the 
similar regulation mechanisms of HIF-α proteins. Due to technical limitations of we could not 
directly target HIF-1 using overexpression and knock down in RBE4 cells and thus had to use 
HIF-1 modulating drugs despite the caveat of simultaneously targeting HIF-2α. In addition 
 114 
HIF-2α expression could not be monitored at that time due to the lack of a reliable antibody 
on the market. Certainly as improved methodology becomes available the impact of HIF-2 on 
BBB function needs to be clarified.  
We have previously shown that astrocytes and pericytes protect the endothelial barrier during 
O2 deprivation (Al Ahmad et al., 2009). For this reason it would be enlightening to include 
astrocytes and pericytes in the model and investigate whether they are able to revert the 
negative effects on endothelial HIF-1 signaling. Furthermore investigations of how HIF-1 
signaling in astrocytes and pericytes affects endothelial barrier function and tight junction 
regulation are also required. 
The second part of this work focused on the basal responses of endothelial cells, astrocytes 
and pericytes to hypoxic and ischemic insults. This part of the work did not directly investigate 
BBB modulation but was performed to improve our fundamental comprehension of barrier 
changes that occur during hypoxic and ischemic disease settings. At the basic level, better 
knowledge of individual responsiveness and tolerance of the BBB cells to such insults will 
help to better define their participation in BBB modulation. As expected the barrier cells 
differed considerably in their hypoxic/ischemic tolerance. Endothelial cells (RBE4 cells) were 
very sensitive to O2 deprivation alone and responded with massive induction of hypoxia-
induced gene/protein expression, severe disruption of the actin cytoskeleton and strong 
impairment in viability, whereas astrocytes and pericytes tolerated prolonged O2 deprivation 
without any obvious signs of impairment. Oxygen-glucose deprivation (OGD) in contrast 
affected astrocytes and pericytes particularly when exposed to near anoxia, but nevertheless 
both were able to tolerate these severe insults for a limited period of time, with astrocytes 
being more tolerant than pericytes. Indeed both astrocytes and pericytes were potently able 
to appropriately modulate crucial responses for survival such as cell cycle and autophagy. 
This study aimed to characterize the cell-specific fate and responses in a comprehensive way 
but clearly a more in depth analysis of some particular parameters e.g. activated cell death 
and autophagy pathways would give the study more weight. Similarly the use of primary 
endothelial cells for some crucial experiments would clarify whether RBE4 cells have similar 
responses to primary ECs and importantly whether the cells exhibit similar sensitivities 
towards the treatments. Indeed it is a constant point of discussion in the field how well 
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endothelial cell lines and primary isolated endothelial cells reflect the vascular responses at 
the BBB in vivo. In my point of view, it is desirable to use primary isolated cells over 
endothelial cell lines as they more closely manifest the physiological setting, but as isolation 
of primary brain endothelial cells is very time and cost intense, endothelial cell lines represent 
an appropriate alternative. Indeed depending on the research question endothelial cell lines 
represent a good model system, for example when mechanistic queries are addressed.  
In summary the present study taught us, that particularly endothelial function needs to be 
improved during hypoxic/ischemic injury conditions as the vasculature endothelium clearly 
represents a weak link in such conditions and perivascular cells are considerably more 
tolerant. Our previous study has suggested that at least in terms of barrier function and tight 
junctions HIF-1 signaling exerts rather negative effects on the vasculature and similarly the 
current results indicate that endothelial cells are characterized by elevated HIF-1 stabilization 
compared to the perivascular cells. For this reason it may be worthwhile to investigate 
whether suppression/reduction of HIF-1 signaling can improve endothelial performance and 
revert some of the negative effects observed in the comparative study. Based on the findings 
of the comparative study the reason why some cells are much more resistant to 
hypoxia/ischemia than others remained to be better elucidated. Considering the importance of 
metabolic adaptation for cell survival under these circumstances (see introduction, Section 
1.2.2 and 1.2.3) the hypothesis that some basal differences in the capability of metabolic 
adaptation could account for the varying sensitivities amongst the cell types caught my 
interest. To explore this question in an unbiased and global way an untargeted LC-MS 
approach was chosen, which allowed detection of about 500 annotated metabolites by 
accurate mass. To prevent the initiation of a highly complex study we decided to compare 
only the metabolic footprints of endothelial cells (as rather sensitive cell type) and astrocytes 
(as very robust cells). In order to reduce artifacts that could be caused by the use of a 
transformed cell line, primary rat brain microvascular endothelial cells (RBMEC) and 
astrocytes were isolated and cultured in identical media. In support of our hypothesis we 
observed that indeed RBMEC and astrocytes significantly differed in their metabolic profiles 
and modulation. Astrocytes were particularly equipped for conditions of nutrient shortage and 
oxidative stress as they showed strong glycogen metabolism, high glutathione and high 
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phosphocreatine levels. All these observations agree well with existing literature and support 
the current view about astrocytes providing the “emergency supply” of lactate (generated from 
glycogen) and glutathione for neurons (Belanger et al., 2011; Bouzier-Sore and Pellerin, 
2013; Wiesinger et al., 1997). In this case we could hypothesize that astrocytes may also 
provide substrates to endothelial cells experiencing stressful conditions. Much less is known 
about the metabolism of endothelial cells. Our study is the first to measure the endothelial 
metabolome and show that unlike astrocytes endothelial cells do not build major stores of 
glycogen, glutathione and/or phosphocreatine and thus suffer much more from ischemic 
conditions, although both tolerate hypoxic and near anoxic exposure well when glucose is 
present in the culture media. Overall the metabolomics study gave us very interesting insights 
into metabolic adaptation of endothelial cells and astrocytes and supported our initial 
hypothesis that differences in cellular metabolism could crucially contribute to their sensitivity 
to hypoxia/ischemia. However as for all screening approaches some possible pitfalls need to 
be considered. Although this study gave us important indications about which metabolic 
pathways might account for the differential sensitivities of astrocytes and endothelial cells, it 
remains to be fully experimentally proven. Thus the metabolomics study can be seen as a 
starting point, the initial screen that requires further experimental evidence to really 
corroborate our hypotheses. In addition the results obtained from the LC-MS approach 
regarding isomers like hexoses or amino acids need to interpreted with particular caution. To 
really investigate glycolytic pathways in detail gas chromatography mass spectrometry (GC-
MS) that allows separation of isomers would need to be applied. In addition looking at 
mitochondrial respiration in terms of TCA cycle and electron transport chain activity in the 
individual cell types would add valuable information to our current study. To go a step ahead 
it would be highly interesting to investigate how a co-culture with astrocytes or astrocyte-
conditioned media would affect the metabolic response of RBMEC and whether factors 
released from astrocytes like lactate or glutathione would improve RBMEC outcome. Finally, 
it is apparent that we did not include pericytes in this study, however observing how their 
metabolism compares to astrocytes and whether they similarly possess protective 
metabolites conferring tolerance to ischemia, as the comparative study suggested, would be 
fascinating. 
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In summary this project addressed various aspects of hypoxic and ischemic responses 
occurring at the BBB. We substantiated our hypothesis that HIF-1 signaling indeed exerts 
adverse effects during hypoxic barrier loss and in addition demonstrated that the cells at the 
BBB are considerably different in their tolerance, responses and metabolic adaptation to 
hypoxia and ischemia. Overall this project significantly increased our knowledge about the 
consequences of hypoxia/ischemia on BBB and individual cellular function and opened up 
various new interesting questions and directions. 
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5 APPENDIX 
Table A.1: Relationship of metabolite abundance between AC and RBMEC under 
physiological conditions (NX+Glc) expressed as fold changes. Statistics: *p<0.05, 
**p<0.01, *** p<0.001; 1-way Anova.  
 
 
Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
UDP$glucuronate C00167 580.0343 AC *** 331.56
N$Acetyl$L$aspartate C01042 175.0481 EC * 146.43
N$Carbamoyl$L$aspartate C00438 176.0433 EC * 131.54
Allantoate C00499 176.0546 EC * 131.54
GDP$mannose C00096 605.0772 AC *** 57.57
Naphthalene$1,2$diol C03012 160.0524 AC *** 36.31
AMP C00020 347.0631 EC *** 31.44
dGMP C00362 347.0631 EC *** 31.44
Hypotaurine C00519 109.0197 AC *** 25.66
N$Acetyl$D$glucosamineL6$phosphate C00357 301.0563 EC * 23.97
N$Acetyl$D$mannosamineL6$phosphate C04257 301.0563 EC * 23.97
N$Acetyl$alpha$D$glucosamineL1$phosphate C04501 301.0563 EC * 23.97
Succinyl$CoA C00091 867.1313 AC *** 23.29
(S)$Methylmalonyl$CoA C00683 867.1313 AC *** 23.29
(R)$Methylmalonyl$CoA C01213 867.1313 AC *** 23.29
Malonyl$CoALmethylLester C19673 867.1313 AC *** 23.29
5$Acetylamino$6$formylamino$3$methyluracil C16365 226.0702 AC *** 18.44
Phosphocreatine C02305 211.0358 AC *** 17.21
L$2$AminoadipateLadenylate C05560 490.1213 AC *** 16.68
EthanolamineLphosphate C00346 141.0191 EC ** 12.90
Cys$Gly C01419 178.0412 AC *** 12.75
D$Glucono$1,5$lactone C00198 178.0477 AC *** 12.75
L$Gulono$1,4$lactone C01040 178.0477 AC *** 12.75
2$Dehydro$3$deoxy$D$galactonate C01216 178.0477 AC *** 12.75
1,2$Dihydronaphthalene$1,2$diol C06205 162.0681 AC ** 11.56
Pyruvate C00022 88.016 AC *** 11.47
3$Oxopropanoate C00222 88.016 AC *** 11.47
L$Tyrosine C00082 181.0739 AC *** 11.29
D$Glucose C00031 180.0634 AC *** 11.25
D$Fructose C00095 180.0634 AC *** 11.25
D$Galactose C00124 180.0634 AC *** 11.25
myo$Inositol C00137 180.0634 AC *** 11.25
D$Mannose C00159 180.0634 AC *** 11.25
beta$D$Glucose C00221 180.0634 AC *** 11.25
alpha$D$Glucose C00267 180.0634 AC *** 11.25
beta$D$Fructose C02336 180.0634 AC *** 11.25
D$chiro$Inositol C19891 180.0634 AC *** 11.25
Theobromine C07480 180.0647 AC *** 11.25
1,7$Dimethylxanthine C13747 180.0647 AC *** 11.25
L$erythro$4$Hydroxyglutamate C05947 163.0481 AC *** 10.99
Homovanillate C05582 182.0579 AC *** 9.21
3$Methoxy$4$hydroxyphenylglycolaldehyde C05583 182.0579 AC *** 9.21
UDP$glucose C00029 566.055 AC *** 9.00
UDP$D$galactose C00052 566.055 AC *** 9.00
Biotin C00120 244.0882 AC *** 7.71
Stachyose C01613 666.2219 AC ** 7.56
PyridoxamineLphosphate C00647 248.0562 AC *** 7.53
Cytidine C00475 243.0855 AC *** 7.51
gamma$Glutamyl$beta$cyanoalanine C05711 243.0855 AC *** 7.51
L$2$Aminoadipate C00956 161.0688 AC * 7.25
N$Glycoloyl$neuraminate C03410 325.1009 AC *** 6.74
sn$glycero$3$Phosphocholine C00670 258.1106 AC *** 6.10
cis$Aconitate C00417 174.0164 AC *** 6.03
sn$glycero$3$Phosphoethanolamine C01233 215.0559 AC *** 5.91
GDP$L$fucose C00325 589.0822 AC *** 5.83
D$Sorbitol C00794 182.079 EC ** 5.78
Galactitol C01697 182.079 EC ** 5.78
3$Methylcrotonyl$CoA C03069 849.1571 AC *** 5.63
2$Methylbut$2$enoyl$CoA C03345 849.1571 AC *** 5.63
UMP C00105 324.0359 EC * 5.47
3$Methoxy$4$hydroxyphenylethyleneglycol C05594 184.0736 EC ** 5.45
CholineLphosphate C00588 184.0739 EC ** 5.45
L$Adrenaline C00788 183.0895 EC ** 5.43
L$Normetanephrine C05589 183.0895 EC ** 5.43
(S)$3$Hydroxyoctanoyl$CoA C05266 909.2146 AC *** 5.24
N$Acetyl$L$glutamate C00624 189.0637 EC * 4.86
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Table A.1 (continued): Relationship of metabolite abundance between AC and RBMEC 
under physiological conditions (NX+Glc) expressed as fold changes. Statistics: *p<0.05, 
**p<0.01, *** p<0.001; 1-way Anova. 
 
 
Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
sn#Glycerol+3#phosphate C00093 172.0137 AC *** 4.61
6#Deoxy#L#galactose C01019 164.0685 EC *** 4.51
Cinnavalininate C05640 300.0382 AC *** 4.40
Adenylyl+sulfate C00224 427.0199 EC ** 4.30
ADP C00008 427.0294 EC ** 4.30
Adenosine+3,5#bisphosphate C00054 427.0294 EC ** 4.30
dGDP C00361 427.0294 EC ** 4.30
Sulfate C00059 97.9674 AC *** 4.28
Orthophosphate C00009 97.9769 AC *** 4.28
Uridine C00299 244.0695 EC * 4.25
N#Acetylneuraminate C00270 309.106 AC *** 3.89
O#Acetylneuraminic+acid C03525 309.106 AC *** 3.89
7#Methyluric+acid C16355 182.044 AC * 3.74
1#Methyluric+acid C16359 182.044 AC * 3.74
NAD+ C00003 664.1169 AC *** 3.71
L#Homocysteine C00155 135.0354 EC ** 3.58
Protoporphyrin C02191 562.258 AC *** 3.56
Prunasin C00844 295.1056 EC *** 3.53
D#Glucono#1,5#lactone+6#phosphate C01236 258.0141 AC *** 3.44
2#Deoxyinosine+5#phosphate C06196 332.0522 EC ** 3.27
Sedoheptulose+1,7#bisphosphate C00447 370.0066 EC ** 3.15
3,4#Dihydroxymandelate C05580 184.0372 AC *** 2.97
4#Hydroxybenzoate C00156 138.0317 EC * 2.86
Gentisate+aldehyde C05585 138.0317 EC * 2.86
L#Ornithine C00077 132.0899 AC *** 2.80
D#Ornithine C00515 132.0899 AC *** 2.80
Nicotinamide+D#ribonucleotide C00455 334.0566 EC *** 2.66
Adenosine C00212 267.0968 EC ** 2.65
Deoxyguanosine C00330 267.0968 EC ** 2.65
(1aalpha,2beta,3alpha,11calpha)#1a,2,3,11c#Tetrahydro#6,11#dimethylbenzo[6,7]phenanthro[3,4#b]oxirene#2,3#diolC19559 306.1256 AC ** 2.63
CMP#2#aminoethylphosphonate C05673 430.0655 AC * 2.60
Calcitriol C01673 416.329 EC *** 2.59
Secalciferol C07712 416.329 EC *** 2.59
7alpha,24#Dihydroxy#4#cholesten#3#one C17331 416.329 EC *** 2.59
7alpha,25#Dihydroxy#4#cholesten#3#one C17332 416.329 EC *** 2.59
3beta#Hydroxy#5#cholestenoate C17333 416.329 EC *** 2.59
7alpha,26#Dihydroxy#4#cholesten#3#one C17336 416.329 EC *** 2.59
4#Cholesten#7alpha,12alpha#diol#3#one C17339 416.329 EC *** 2.59
(S)#4#Hydroxymandelonitrile C03742 149.0477 EC *** 2.56
5,6#Dihydroxyindole C05578 149.0477 EC *** 2.56
L#Methionine C00073 149.051 EC *** 2.56
CDP C00112 403.0182 EC *** 2.56
7,8#Dihydroneopterin+3#triphosphate C04895 494.9957 EC ** 2.56
L#Alanine C00041 89.0477 AC *** 2.54
beta#Alanine C00099 89.0477 AC *** 2.54
Sarcosine C00213 89.0477 AC *** 2.54
5#Phosphoribosylglycinamide C03838 286.0566 AC * 2.46
(S)#Malate C00149 134.0215 EC ** 2.46
Raffinose C00492 504.169 AC *** 2.42
D#Gal+alpha+1#>6D#Gal+alpha+1#>6D#Glucose C05404 504.169 AC *** 2.42
4#Aminobutanoate C00334 103.0633 EC *** 2.41
N,N#Dimethylglycine C01026 103.0633 EC *** 2.41
L#3#Amino#isobutanoate C03284 103.0633 EC *** 2.41
3#Aminoisobutyric+acid C05145 103.0633 EC *** 2.41
Decanoyl#CoA C05274 921.251 AC ** 2.38
O#Phospho#L#serine C01005 185.0089 EC ** 2.31
Glycerol C00116 92.0473 EC * 2.31
Ouabain C01443 584.2833 EC * 2.31
L#Glutamate C00025 147.0532 EC *** 2.31
D#Glutamate C00217 147.0532 EC *** 2.31
L#4#Hydroxyglutamate+semialdehyde C05938 147.0532 EC *** 2.31
Anthranilate C00108 137.0477 EC ** 2.23
Isoniazid C07054 137.0589 EC ** 2.23
Pidolic+acid C01879 129.0426 EC *** 2.23
L#1#Pyrroline#3#hydroxy#5#carboxylate C04281 129.0426 EC *** 2.23
1#Pyrroline#4#hydroxy#2#carboxylate C04282 129.0426 EC *** 2.23
3#Sulfino#L#alanine C00606 153.0096 AC *** 2.18
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Table A.1 (continued): Relationship of metabolite abundance between AC and RBMEC 
under physiological conditions (NX+Glc) expressed as fold changes. Statistics: *p<0.05, 
**p<0.01, *** p<0.001; 1-way Anova. 
 
 
Table A.2: Top altered metabolites in AC upon exposure to AX+Glc compared to 
normoxic baseline (NX+Glc). Statistics: *p<0.05, **p<0.01, *** p<0.001; 1-way Anova. 
 
 
Table A.3: Top altered metabolites in RBMEC upon exposure to AX+Glc compared to 
normoxic baseline (NX+Glc). Statistics: *p<0.05, **p<0.01, *** p<0.001; 1-way Anova. 
 
 
Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
5"Methoxyindoleacetate C05660 205.0739 AC * 2.17
Deoxyribose C01801 134.0579 EC * 2.17
2"(S"Glutathionyl)acetylGglutathione C14863 654.1625 EC *** 2.14
Formyl"N"acetyl"5"methoxykynurenamine C05642 264.111 AC ** 2.11
CDP"choline C00307 488.1073 EC * 2.10
Xylitol C00379 152.0685 EC * 2.08
L"Arabitol C00532 152.0685 EC * 2.08
Pantothenate C00864 219.1107 AC * 2.03
AflatoxinGB1exo"8,9"epoxide"GSH C11278 635.1421 AC ** 2.02
Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
(")"Ureidoglycolate C00603 134.0328 NX *** 6.60
(S)"Malate C00149 134.0215 NX * 6.40
SedoheptuloseD7"phosphate C05382 290.0403 AX *** 5.08
Succinyl"CoA C00091 867.1313 NX ** 4.19
(S)"Methylmalonyl"CoA C00683 867.1313 NX ** 4.19
(R)"Methylmalonyl"CoA C01213 867.1313 NX ** 4.19
Malonyl"CoADmethylDester C19673 867.1313 NX ** 4.19
Fumarate C00122 116.011 NX *** 3.63
L"Aspartate C00049 133.0375 NX *** 2.85
D"Aspartate C00402 133.0375 NX *** 2.85
Pantetheine C00831 278.13 AX *** 2.81
Protoporphyrin C02191 562.258 AX ** 2.78
Ouabain C01443 584.2833 AX * 2.76
GlyceroneDphosphate C00111 169.998 AX ** 2.69
D"GlyceraldehydeD3"phosphate C00118 169.998 AX ** 2.69
N"Acetyl"L"glutamate C00624 189.0637 AX * 2.65
CMP"2"aminoethylphosphonate C05673 430.0655 NX * 2.46
3"Sulfino"L"alanine C00606 153.0096 AX *** 2.42
D"Sorbitol C00794 182.079 AX *** 2.26
Galactitol C01697 182.079 AX *** 2.26
3"Methoxy"4"hydroxyphenylethyleneglycol C05594 184.0736 AX ** 2.17
CholineDphosphate C00588 184.0739 AX ** 2.17
L"Adrenaline C00788 183.0895 AX *** 2.11
L"Normetanephrine C05589 183.0895 AX *** 2.11
Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
Stachyose C01613 666.2219 AX ** 14.16
Sedoheptulose:7<phosphate C05382 290.0403 AX *** 8.64
(S)<3<Hydroxyoctanoyl<CoA C05266 909.2146 AX * 4.12
Cytidine C00475 243.0855 AX *** 4.02
gamma<Glutamyl<beta<cyanoalanine C05711 243.0855 AX *** 4.02
Biotin C00120 244.0882 AX *** 4.00
cis<Aconitate C00417 174.0164 AX *** 3.79
sn<glycero<3<Phosphocholine C00670 258.1106 AX *** 3.64
(<)<Ureidoglycolate C00603 134.0328 NX ** 3.53
sn<Glycerol:3<phosphate C00093 172.0137 AX *** 3.10
sn<glycero<3<Phosphoethanolamine C01233 215.0559 AX *** 3.04
Raffinose C00492 504.169 AX * 2.70
D<Gal:alpha:1<>6D<Gal:alpha:1<>6D<Glucose C05404 504.169 AX * 2.70
L<Homocysteine C00155 135.0354 NX * 2.67
2,5<Dioxopentanoate C00433 130.0266 AX *** 2.19
2<Oxoglutaramate C00940 145.0375 AX *** 2.07
L<Aspartate C00049 133.0375 NX ** 2.04
D<Aspartate C00402 133.0375 NX ** 2.04
11beta,21<Dihydroxy<5beta<pregnane<3,20<dione C05475 348.2301 AX ** 2.04
3alpha,21<Dihydroxy<5beta<pregnane<11,20<dione C05478 348.2301 AX ** 2.04
17alpha,21<Dihydroxypregnenolone C05487 348.2301 AX ** 2.04
 121 
Table A.4: Top altered metabolites in AC upon exposure to AX-Glc compared to NX-
Glc. Statistics: *p<0.05, **p<0.01, *** p<0.001; 1-way Anova. 
 
 
 
 
 
Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
UDP$glucose C00029 566.055 NX *** 236.62
UDP$D$galactose C00052 566.055 NX *** 236.62
UDP$glucuronate C00167 580.0343 NX ** 66.28
Biotin C00120 244.0882 NX *** 42.84
Cytidine C00475 243.0855 NX *** 30.62
gamma$Glutamyl$beta$cyanoalanine C05711 243.0855 NX *** 30.62
GDP$mannose C00096 605.0772 NX * 29.78
sn$glycero$3$Phosphocholine C00670 258.1106 NX *** 26.77
cis$Aconitate C00417 174.0164 NX *** 18.86
sn$glycero$3$Phosphoethanolamine C01233 215.0559 NX *** 17.67
sn$GlycerolI3$phosphate C00093 172.0137 NX *** 16.37
Succinyl$CoA C00091 867.1313 NX * 13.67
(S)$Methylmalonyl$CoA C00683 867.1313 NX * 13.67
(R)$Methylmalonyl$CoA C01213 867.1313 NX * 13.67
Malonyl$CoAImethylIester C19673 867.1313 NX * 13.67
2$Oxoglutaramate C00940 145.0375 AX ** 11.24
L$2$AminoadipateIadenylate C05560 490.1213 NX *** 10.98
UMP C00105 324.0359 NX *** 9.93
FAD C00016 785.1571 AX *** 9.56
CMP$2$aminoethylphosphonate C05673 430.0655 NX *** 8.81
(S)$3$Hydroxyoctanoyl$CoA C05266 909.2146 NX ** 7.51
5$Phosphoribosylamine C03090 229.0351 AX *** 5.95
L$Homocysteine C00155 135.0354 NX *** 4.98
($)$Ureidoglycolate C00603 134.0328 NX *** 4.61
6$ThioguanosineImonophosphate C16619 379.0352 NX *** 4.50
(S)$Malate C00149 134.0215 NX *** 4.43
3$Methylcrotonyl$CoA C03069 849.1571 NX *** 4.40
2$Methylbut$2$enoyl$CoA C03345 849.1571 NX *** 4.40
Creatine C00300 131.0695 AX ** 4.17
GDP$L$fucose C00325 589.0822 NX *** 3.72
Phosphocreatine C02305 211.0358 NX ** 3.54
3,5$CyclicIGMP C00942 345.0474 NX ** 3.48
5$Acetylamino$6$formylamino$3$methyluracil C16365 226.0702 NX *** 3.42
11beta,21$Dihydroxy$5beta$pregnane$3,20$dione C05475 348.2301 AX *** 3.36
3alpha,21$Dihydroxy$5beta$pregnane$11,20$dione C05478 348.2301 AX *** 3.36
17alpha,21$Dihydroxypregnenolone C05487 348.2301 AX *** 3.36
Decanoyl$CoA C05274 921.251 NX *** 3.03
N$Acetylneuraminate C00270 309.106 AX * 2.96
O$AcetylneuraminicIacid C03525 309.106 AX * 2.96
Sulfate C00059 97.9674 NX *** 2.88
Orthophosphate C00009 97.9769 NX *** 2.88
Cys$Gly C01419 178.0412 NX *** 2.81
D$Glucono$1,5$lactone C00198 178.0477 NX *** 2.81
L$Gulono$1,4$lactone C01040 178.0477 NX *** 2.81
2$Dehydro$3$deoxy$D$galactonate C01216 178.0477 NX *** 2.81
16$Glucuronide$estriol C05504 464.2046 AX ** 2.81
Pantetheine C00831 278.13 AX ** 2.76
L$Tyrosine C00082 181.0739 NX *** 2.67
D$Glucose C00031 180.0634 NX *** 2.65
D$Fructose C00095 180.0634 NX *** 2.65
D$Galactose C00124 180.0634 NX *** 2.65
myo$Inositol C00137 180.0634 NX *** 2.65
D$Mannose C00159 180.0634 NX *** 2.65
beta$D$Glucose C00221 180.0634 NX *** 2.65
alpha$D$Glucose C00267 180.0634 NX *** 2.65
beta$D$Fructose C02336 180.0634 NX *** 2.65
D$chiro$Inositol C19891 180.0634 NX *** 2.65
Theobromine C07480 180.0647 NX *** 2.65
1,7$Dimethylxanthine C13747 180.0647 NX *** 2.65
Protoporphyrin C02191 562.258 AX * 2.62
Pyruvate C00022 88.016 NX *** 2.60
3$Oxopropanoate C00222 88.016 NX *** 2.60
Homovanillate C05582 182.0579 NX *** 2.60
3$Methoxy$4$hydroxyphenylglycolaldehyde C05583 182.0579 NX *** 2.60
PresqualeneIdiphosphate C03428 586.3188 AX ** 2.55
Ouabain C01443 584.2833 AX * 2.54
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Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
D"Glucosamine.6"phosphate C00352 259.0457 NX ** 2.53
GMP C00144 363.058 NX ** 2.43
Precursor.Z C18239 363.058 NX ** 2.43
Fumarate C00122 116.011 NX *** 2.40
L"erythro"4"Hydroxyglutamate C05947 163.0481 NX *** 2.36
Adenosine C00212 267.0968 NX * 2.33
Deoxyguanosine C00330 267.0968 NX * 2.33
Arachidonate C00219 304.2402 NX * 2.30
D"Ribose.5"phosphate C00117 230.0192 NX ** 2.29
D"Ribulose.5"phosphate C00199 230.0192 NX ** 2.29
D"Xylulose.5"phosphate C00231 230.0192 NX ** 2.29
alpha"D"Ribose.1"phosphate C00620 230.0192 NX ** 2.29
7"Hydroxymethyl"12"methylbenz[a]anthracene.sulfate C19562 352.0769 AX * 2.29
Acetyl"CoA C00024 809.1258 NX ** 2.29
S"Adenosyl"L"methionine C00019 398.1372 AX ** 2.16
4"(2"Aminophenyl)"2,4"dioxobutanoate C01252 207.0532 NX ** 2.15
1"Nitro"5,6"dihydroxy"dihydronaphthalene C14801 207.0532 NX ** 2.15
L"Glutamate C00025 147.0532 AX *** 2.02
D"Glutamate C00217 147.0532 AX *** 2.02
L"4"Hydroxyglutamate.semialdehyde C05938 147.0532 AX *** 2.02
dADP C00206 411.0345 AX ** 2.01
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Metabolite)Name KEGG)ID Monoisotopic)mass Up)in Significance Fold)change
UDP$N$acetyl$D$glucosamine C00043 607.0816 NX * 193.59
UDP$N$acetyl$D$galactosamine C00203 607.0816 NX * 193.59
N$Acetyl$D$glucosamineB6$phosphate C00357 301.0563 NX ** 58.70
N$Acetyl$D$mannosamineB6$phosphate C04257 301.0563 NX ** 58.70
N$Acetyl$alpha$D$glucosamineB1$phosphate C04501 301.0563 NX ** 58.70
N$Acetylneuraminate C00270 309.106 AX *** 46.55
O$AcetylneuraminicBacid C03525 309.106 AX *** 46.55
UDP$glucose C00029 566.055 NX *** 46.00
UDP$D$galactose C00052 566.055 NX *** 46.00
UMP C00105 324.0359 NX ** 40.15
Phosphocreatine C02305 211.0358 NX * 24.00
GlutathioneBdisulfide C00127 612.152 NX *** 19.62
Sulfate C00059 97.9674 NX * 14.27
Orthophosphate C00009 97.9769 NX * 14.27
N$Glycoloyl$neuraminate C03410 325.1009 AX *** 12.57
Biotin C00120 244.0882 NX *** 9.88
Succinyl$CoA C00091 867.1313 NX ** 9.64
(S)$Methylmalonyl$CoA C00683 867.1313 NX ** 9.64
(R)$Methylmalonyl$CoA C01213 867.1313 NX ** 9.64
Malonyl$CoABmethylBester C19673 867.1313 NX ** 9.64
2$Methyl$1$hydroxypropyl$ThPP C15976 497.1025 NX ** 8.35
sn$glycero$3$Phosphoethanolamine C01233 215.0559 NX *** 7.46
Cytidine C00475 243.0855 NX *** 7.14
gamma$Glutamyl$beta$cyanoalanine C05711 243.0855 NX *** 7.14
D$Glucono$1,5$lactoneB6$phosphate C01236 258.0141 NX *** 7.08
D$FructoseB6$phosphate C00085 260.0297 NX *** 6.85
D$GlucoseB6$phosphate C00092 260.0297 NX *** 6.85
D$GlucoseB1$phosphate C00103 260.0297 NX *** 6.85
D$MannoseB6$phosphate C00275 260.0297 NX *** 6.85
alpha$D$GalactoseB1$phosphate C00446 260.0297 NX *** 6.85
D$MannoseB1$phosphate C00636 260.0297 NX *** 6.85
alpha$D$GlucoseB6$phosphate C00668 260.0297 NX *** 6.85
D$FructoseB1$phosphate C01094 260.0297 NX *** 6.85
D$TagatoseB6$phosphate C01097 260.0297 NX *** 6.85
beta$D$GlucoseB6$phosphate C01172 260.0297 NX *** 6.85
InositolB1$phosphate C01177 260.0297 NX *** 6.85
beta$D$FructoseB2$phosphate C03267 260.0297 NX *** 6.85
myo$InositolB4$phosphate C03546 260.0297 NX *** 6.85
1D$myo$InositolB3$phosphate C04006 260.0297 NX *** 6.85
beta$D$FructoseB6$phosphate C05345 260.0297 NX *** 6.85
NicotinamideBD$ribonucleotide C00455 334.0566 NX *** 6.77
sn$glycero$3$Phosphocholine C00670 258.1106 NX *** 5.79
(1aalpha,2beta,3alpha,11calpha)$1a,2,3,11c$
Tetrahydro$6,11$dimethylbenzo[6,7]phenanthro[3,4$
b]oxirene$2,3$diol
C19559 306.1256 AX *** 5.53
3,5$CyclicBGMP C00942 345.0474 NX *** 5.46
sn$GlycerolB3$phosphate C00093 172.0137 NX *** 5.45
Porphobilinogen C00931 226.0954 NX ** 5.08
Uridine C00299 244.0695 NX * 5.00
AflatoxinBB1exo$8,9$epoxide$GSH C11278 635.1421 NX ** 4.98
cis$Aconitate C00417 174.0164 NX *** 4.96
SedoheptuloseB1,7$bisphosphate C00447 370.0066 NX *** 4.91
L$Tyrosine C00082 181.0739 NX *** 4.61
AMP C00020 347.0631 NX *** 4.29
dGMP C00362 347.0631 NX *** 4.29
Homovanillate C05582 182.0579 NX *** 4.24
3$Methoxy$4$hydroxyphenylglycolaldehyde C05583 182.0579 NX *** 4.24
D$Glucose C00031 180.0634 NX *** 4.23
D$Fructose C00095 180.0634 NX *** 4.23
D$Galactose C00124 180.0634 NX *** 4.23
myo$Inositol C00137 180.0634 NX *** 4.23
D$Mannose C00159 180.0634 NX *** 4.23
beta$D$Glucose C00221 180.0634 NX *** 4.23
alpha$D$Glucose C00267 180.0634 NX *** 4.23
beta$D$Fructose C02336 180.0634 NX *** 4.23
D$chiro$Inositol C19891 180.0634 NX *** 4.23
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Theobromine C07480 180.0647 NX *** 4.23
1,78Dimethylxanthine C13747 180.0647 NX *** 4.23
NAD+ C00003 664.1169 NX *** 4.20
Pyruvate C00022 88.016 NX *** 4.17
38Oxopropanoate C00222 88.016 NX *** 4.17
2,58Dioxopentanoate C00433 130.0266 NX *** 4.01
(1R,2S)8NaphthaleneL1,28oxide C14786 144.0575 NX ** 3.73
CMP828aminoethylphosphonate C05673 430.0655 NX ** 3.67
N8Acetyl8L8glutamate C00624 189.0637 NX *** 3.65
28Oxoadipate C00322 160.0372 AX *** 3.63
38Oxoadipate C00846 160.0372 AX *** 3.63
28Oxoglutarate C00026 146.0215 NX ** 3.53
28(alpha8Hydroxyethyl)thiamineLdiphosphate C05125 469.0712 AX *** 3.52
68ThioguanosineLmonophosphate C16619 379.0352 NX *** 3.42
Glutathione C00051 307.0838 NX ** 3.41
L8FucoseL18phosphate C02985 244.0348 NX *** 3.31
Adenosine C00212 267.0968 NX *** 3.23
Deoxyguanosine C00330 267.0968 NX *** 3.23
28Oxosuccinamate C02362 131.0219 AX *** 3.20
Pantetheine C00831 278.13 NX * 3.19
D8RiboseL58phosphate C00117 230.0192 NX * 3.01
D8RibuloseL58phosphate C00199 230.0192 NX * 3.01
D8XyluloseL58phosphate C00231 230.0192 NX * 3.01
alpha8D8RiboseL18phosphate C00620 230.0192 NX * 3.01
AdenylylLsulfate C00224 427.0199 NX * 2.93
ADP C00008 427.0294 NX * 2.93
AdenosineL3,58bisphosphate C00054 427.0294 NX * 2.93
dGDP C00361 427.0294 NX * 2.93
Linamarin C01594 247.1056 AX * 2.91
L8Aspartate C00049 133.0375 AX *** 2.82
D8Aspartate C00402 133.0375 AX *** 2.82
D8Xylonolactone C02266 148.0372 NX *** 2.82
28Hydroxyglutarate C02630 148.0372 NX *** 2.82
gamma8L8Glutamyl8L8cysteine C00669 250.0623 NX ** 2.82
D8GlucosamineL68phosphate C00352 259.0457 NX *** 2.73
48(28Aminophenyl)82,48dioxobutanoate C01252 207.0532 NX *** 2.68
18Nitro85,68dihydroxy8dihydronaphthalene C14801 207.0532 NX *** 2.68
Thymidine C00214 242.0903 AX ** 2.67
Phenylacetaldehyde C00601 120.0575 NX ** 2.59
Glycerol C00116 92.0473 NX *** 2.55
Anthranilate C00108 137.0477 NX *** 2.51
Isoniazid C07054 137.0589 NX *** 2.51
N8Acetylserotonin C00978 218.1055 AX * 2.49
CMP8N8acetylneuraminate C00128 614.1473 AX ** 2.47
Cys8Gly C01419 178.0412 NX ** 2.43
D8Glucono81,58lactone C00198 178.0477 NX ** 2.43
L8Gulono81,48lactone C01040 178.0477 NX ** 2.43
28Dehydro838deoxy8D8galactonate C01216 178.0477 NX ** 2.43
Hypotaurine C00519 109.0197 NX * 2.40
GMP C00144 363.058 NX *** 2.27
PrecursorLZ C18239 363.058 NX *** 2.27
L8erythro848Hydroxyglutamate C05947 163.0481 NX * 2.27
28Oxobutanoate C00109 102.0317 NX ** 2.27
Acetoacetate C00164 102.0317 NX ** 2.27
SuccinateLsemialdehyde C00232 102.0317 NX ** 2.27
(S)8MethylmalonateLsemialdehyde C06002 102.0317 NX ** 2.27
L8Alanine C00041 89.0477 AX *** 2.24
beta8Alanine C00099 89.0477 AX *** 2.24
Sarcosine C00213 89.0477 AX *** 2.24
48Hydroxybenzoate C00156 138.0317 AX * 2.21
GentisateLaldehyde C05585 138.0317 AX * 2.21
PresqualeneLdiphosphate C03428 586.3188 AX ** 2.20
Deoxyribose C01801 134.0579 NX ** 2.10
5,68Dihydrothymine C00906 128.0586 NX *** 2.09
Raffinose C00492 504.169 AX ** 2.09
D8GalLalphaL18>6D8GalLalphaL18>6D8Glucose C05404 504.169 AX ** 2.09
Inosine C00294 268.0808 NX * 2.08
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9"Hydroxybenzo[a]pyrene C14556 268.0888 NX * 2.08
Benzo[a]pyrene"7,8"oxide C14850 268.0888 NX * 2.08
Benzo[a]pyrene"4,5"oxide C14851 268.0888 NX * 2.08
Urocanate C00785 138.0429 AX *** 2.07
Prunasin C00844 295.1056 NX *** 2.07
Hydroquinone C00530 110.0368 NX *** 2.05
Imidazole"4"acetaldehyde C05130 110.048 NX *** 2.05
Thymine C00178 126.0429 NX ** 2.05
Imidazole"4"acetate C02835 126.0429 NX ** 2.05
O"Phospho"L"serine C01005 185.0089 NX *** 2.04
Adenine C00147 135.0545 AX *** 2.03
Hypoxanthine C00262 136.0385 NX *** 2.03
4"Hydroxyphenylacetaldehyde C03765 136.0524 NX *** 2.03
PhenylaceticQacid C07086 136.0524 NX *** 2.03
(R)"Mevalonate C00418 148.0736 NX *** 2.03
7,8"DihydroneopterinQ3"triphosphate C04895 494.9957 NX * 2.03
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The blood–brain barrier (BBB) is a complex vascular structure consisting of microvascular endothelial cells that line the vessel
wall, astrocyte end-feet, pericytes, as well as the basal lamina. BBB cells act in concert to maintain the characteristic
impermeable and low paracellular flux of the brain vascular network, thus ensuring a homeostatic neuronal environment.
Alterations in BBB stability that occur during injury have dire consequences on disease progression and it is clear that BBB
cell-specific responses, positive or negative, must make a significant contribution to injury outcome. Reduced oxygenation, or
hypoxia, is a characteristic of many brain diseases that significantly increases barrier permeability. Recent data suggest that
hypoxia-inducible factor (HIF-1), the master regulator of the hypoxic response, probably mediates many hypoxic effects either
directly or indirectly via its target genes. This review discusses current knowledge of physiological cell-specific regulation of
barrier function, their responses to hypoxia as well as consequences of hypoxic- and HIF-1-mediated mechanisms on barrier
integrity during select brain diseases. In the final sections, the potential of current advances in targeting HIF-1 as a therapeutic
strategy will be overviewed.
Abbreviations
BBB, blood–brain barrier; HIF-1, hypoxia-inducible factor-1; TJ, tight junction; ECs, endothelial cells; TEER,
transendothelial electrical resistance
The maintenance of CNS homeostasis is performed largely by
the blood–brain barrier (BBB), which together with neurons
and microglia form an organization referred to as the neuro-
vascular unit (NVU). The BBB is dynamic performing both
passive and active features of the brain endothelium essen-
tially acting as a vascular gatekeeper that controls movement
of substances from the circulating blood into the brain paren-
chyma – a role crucial for neuronal, and therefore CNS,
homeostasis. Accumulating experimental evidence supports
the hypothesis that opening of the BBB triggers a chain of
events leading to neuronal dysfunction and damage resulting
in neurological disease, and when coupled with previous
insults BBB disruption could have serious detrimental conse-
quences for patient outcome. Despite this knowledge, our
understanding of physiological barrier function, as well as
during disease, is very limited. In addition, the contribution
of the perivascular cells that modulate barrier characteristics
and their individual responses to injury is poorly character-
ized. This review will discuss the mechanisms through which
hypoxia, a characteristic state of many brain diseases, dis-
rupts barrier function and the importance of BBB cell-specific
responses to barrier integrity. Additionally, consequences of
hypoxia-mediated barrier modulation during brain disease
and future therapeutic use of hypoxia-inducible factor-1
(HIF-1) modulators in the clinics will be reviewed.
Physiology
BBB organization and cell-specific function
The BBB is a complex structure consisting of microvascular
endothelial cells (ECs) that line the vessel wall, astrocyte
end-feet, pericytes, as well as the basal lamina (see Figure 1),
which together with neurons and microglia form an organi-
zation referred to as the NVU. The basal lamina is an essential
part of the BBB that surrounds the capillaries thereby anchor-
ing the cells in place and providing a link with the resident
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brain cells. The brain ECs are in direct contact with brain
pericytes (Abbott et al., 2010; Ogunshola and Al-Ahmad,
2012) and separated from the brain parenchyma by two
layers of extracellular matrices (ECM). The inner layer is
formed by the vascular basement membrane (BM) localized at
the EC basolateral side and is shared with neighbouring peri-
cytes (Hallmann et al., 2005). The outer layer is formed by the
glia limitans as a result of glial end-feet processes that sur-
rounds or ensheaths the cerebral vascular tree (Paolinelli
et al., 2011). Perivascular glial end-feet form a direct interface
between the vascular compartment and the brain paren-
chyma (see Figure 1) and are therefore thought to represent
key checkpoints of brain metabolism and function (Wolburg
et al., 2009a).
BBB cells act in concert to maintain the characteristic
impermeable and low paracellular flux of the vascular
network that is chiefly mediated via high expression levels
and localization of tight junction (TJ) proteins, namely,
occludins, claudins, junctional adhesion molecules and their
adaptor protein zonula occludens-1 (ZO-1; reviewed in
Förster, 2008; Abbott et al., 2010). TJs are elaborate structures
that function as both a ‘zipper’ that separates the apical and
basolateral cell membranes thus enabling asymmetric distri-
bution of membrane constituents, and a ‘fence’ that limits
paracellular permeability (see Figure 1 inset). Thus, stringent
regulation of CNS homeostasis by severe restriction of the
paracellular diffusional pathway between the ECs and sub-
stances and/or cells within the circulating blood is ensured.
TJs are highly dynamic structures that rapidly undergo sub-
cellular redistribution, expression level alterations as well as
post-translational modifications, all of which affect protein–
protein interactions (reviewed in Förster, 2008; Ogunshola,
2011). Cellular interactions and local release of factors (dis-
cussed in detail later), in addition to signals from circulating
Figure 1
The BBB protects neurons and glial cells from systemically circulating agents as brain microvessels form a very tight barrier clearly distinct from
vessels in other organs. The barrier is formed by ECs (red), which line the blood vessels, surrounded by pericytes (light blue), BM (grey) and
astrocytic (dark blue) end-feet. Astrocytes provide the cellular link to the adjacent neurons (pink). The illustration also shows microglial cells (grey)
in contact with astrocytes. Inset (black box) shows the cell–cell contact that takes place between two adjacent ECs at the BBB and demonstrates
the basic organization of the BBB tight and adherens junctional proteins. Note the interactions of the junctional proteins with the cytoskeleton.
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substances, have marked effects on TJ expression and there-
fore barrier integrity. Brain ECs do not seem to spontaneously
express high TJ levels but are induced by the surrounding
perivascular cells, astrocytes and pericytes (Ballabh et al.,
2004; Abbott et al., 2006; Ogunshola, 2011). Astrocytes are
the most abundant cell in the brain and their long filamen-
tous end-foot processes extend towards and envelope the
vascular network. Astrocytes have long been known to play a
central role in inducing expression of TJ proteins in micro-
vascular ECs (Abbott, 2002; Ogunshola, 2011). Although peri-
cytes have very close contact with ECs, lying juxtaposed to
the capillary and sharing a BM, for a long time, the function
of this cell in barrier maintenance was largely unknown.
Scientific advances in tools and methodologies, however,
have provided recent evidence from both in vitro and in vivo
studies that pericytes also significantly contribute to barrier
stability during development and adulthood.
Barrier effectiveness is directly related to the ability of the
perivascular cells to maintain their normal functional activi-
ties. As such, alterations or modifications of perivascular cell
properties per se, as a result of disease progression or signal-
ling pathway activation, will compromise barrier integrity
and increase permeability. Despite this fact, the highly coor-
dinated signalling mechanisms and dynamic interactions
that exist between individual cells of the BBB remain largely
unknown. Such knowledge is key to better understand barrier
function under physiological as well as pathological condi-
tions. This implies possible future development of cell-
specific therapies and targeted treatments that could indeed
represent an important way to stabilize barrier function
during injury. The following sections deal with some of the
cell-specific responses that occur particularly during oxygen
deprivation and diseases characterized by hypoxia in more
detail. Notably, because of the complexity related to studying
BBB in vivo, much of the data comes from in vitro model
systems, however, where possible reference to in vivo studies
will also be given.
Astrocytes at the BBB
Similar to neurons and other glial cells astrocytes originate
from the neuroectoderm (Allen and Barres, 2009). To date, 11
different types of astrocytes are known of which eight are
specifically associated with blood vessels (Abbott et al., 2006).
Astrocytes are crucially involved in control of neuronal func-
tion through regulation of brain homeostasis, supply of
neuronswith energy and substrates for neurotransmission and
recycling of neurotransmitters. Furthermore, they represent
the connection between neurons and the brain vasculature,
which they cover with their end-feet. Almost 50 years ago, the
close proximity of the astrocytic end-feet to the brain endothe-
lium raised the hypothesis that astrocytes contribute to BBB
regulation (Davson and Oldendorf, 1967). Since then, a
number of in vivo (Stewart and Wiley, 1981; Janzer and Raff,
1987; Willis et al., 2004) and particularly in vitro studies have
demonstrated the importance of astrocytes to BBB induction
and regulation. Model systems using astrocyte-endothelial
co-cultures (Dehouck et al., 1990; Rist et al., 1997; Fischer
et al., 2000; Al Ahmad et al., 2009) as well as astrocyte-
conditioned media (ACM) (Rubin et al., 1991; Raub et al.,
1992) demonstrated the inductive potential of astrocytes on
barrier tightness by increased transendothelial electrical resist-
ance (TEER) and reduced permeability to low molecular
weight tracers (for detailed review, refer to the excellent article
by Deli et al., 2005). There is now good evidence that barrier
induction through astrocytes is mainly mediated via changes
in the number, length and complexity of endothelial TJs
(Tao-Cheng et al., 1987), expression levels of TJ and associated-
proteins like occludin and ZO-1, respectively (Siddharthan
et al., 2007; Colgan et al., 2008), and the redistribution of
junctional proteins such as platelet endothelial cell adhesion
molecule-1, ZO-1 and claudin-5 at endothelial junctions
(Colgan et al., 2008; Al Ahmad et al., 2011). In addition, astro-
cytes modulate expression and polarized localization of
endothelial transporters, such as P-glycoprotein (P-gp) or
multi-drug resistance protein (MRP) (Berezowski et al., 2004;
Al Ahmad et al., 2011) as well as BBB-specific enzyme-systems
such as γ-glutamyl transpeptidase (Meyer et al., 1991; Hayashi
et al., 1997) and thus crucially regulate EC function.
Major efforts have been made to unravel how astrocytes
modulate TJs, transporters and enzyme systems. Astrocytes
are known to secrete a large number of substances including
peptides, growth factors and chemokines (Nico and Ribatti,
2012) several of which modulate barrier function, such as
basic fibroblast growth factor (bFGF), TGF-β1, glial cell-
derived neurotrophic factor and src-suppressed C-kinase sub-
strate (SSeCKS) (Igarashi et al., 1999; Sobue et al., 1999; Lee
et al., 2003; Reuss et al., 2003; Dohgu et al., 2004; Walshe
et al., 2009; Shimizu et al., 2012). For instance, bFGF has
demonstrated barrier-tightening effects in vitro by reducing
barrier permeability (Sobue et al., 1999) and increasing
endothelial γ-glutamyl-transpeptidase and alkaline phos-
phatase activity (Hafny et al., 1996). In vivo bFGF knockout
increases BBB permeability to albumin and reduces the
expression of ZO-1 and occludin, and coincides with reduced
astrocyte differentiation (Reuss et al., 2003). The effect of
astrocyte-secreted TGF-β1 on barrier function is controversial.
While some studies observed reduced BBB permeability and
increased TJ expression in the presence of TGF-β1/TGF-β
(Dohgu et al., 2004; 2005; Walshe et al., 2009), others
reported adverse effects (Shen et al., 2011). This discrepancy
may be explained by the fact that TGF-β effects on the
endothelium are highly dependent on the endothelial acti-
vation state and the tissue environment, especially the ECM
as it mediates TGF-β activation (Cambier et al., 2005).
Over the past 20 years, our understanding of the impor-
tance of astrocytes as regulators of BBB physiology and how
they modulate barrier characteristics has dramatically
increased but, realistically, unravelling of the complex path-
ways has just begun.
Pericytes at the BBB
The origin of CNS pericytes remains unclear with derivation
from the mesoderm and neuroectoderm as well as from the
monocyte lineage under general discussion (Sa-Pereira et al.,
2012). Diverse functions within the brain have been attrib-
uted to pericytes including regulation of brain homeostasis,
angiogenesis, blood flow, immune and phagocytic activity, as
well as being a source of pluripotent stem cells (Sa-Pereira
et al., 2012). The effect of pericytes on BBB induction and
maintenance is less well characterized than astrocyte-induced
responses. During development pericytes fulfil central roles
in vessel stabilization through inhibition of EC proliferation
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and migration as well as regulation of vessel maturation
(Antonelli-Orlidge et al., 1989; Hellström et al., 2001; Al
Ahmad et al., 2011; Sa-Pereira et al., 2012). Recent in vivo
studies using platelet-derived growth factor (PDGF) receptor β
(PDGFRβ) knockout mice have significantly improved our
understanding. During embryonic angiogenesis, pericytes are
recruited to the vessels via EC-derived PDGF-β. The impaired
recruitment of pericytes to the brain microvasculature caused
by inhibition of PDGF-β signalling, induced either by PDGF-β
or PDGFRβ knockout, resulted in severe vascular conse-
quences such as increased vessel diameter, formation of
microaneurysms, endothelial hyperplasia and increased
vessel permeability (Lindahl et al., 1997; Hellström et al.,
2001; Daneman et al., 2010). These alterations in vessel tight-
ness were attributed to enhanced caveolae formation and
transcytosis, abnormal TJ alignment and increased expression
of permeability inducing factors like VEGF and angiopoietins
(ANG) −2 (Hellström et al., 2001; Daneman et al., 2010). Cor-
responding studies in adult mice revealed that pericytes are
also crucial for adult BBB maintenance, as reduced pericytic
vessel coverage resulted in increased BBB permeability,
altered endothelial gene expression and loss of astrocyte
end-feet polarization (Armulik et al., 2010). Age-dependent
pericyte loss in PDGFRβ+/− mice elevated parenchymal accu-
mulation of blood proteins and leakage of neurotoxic and
vasculotoxic substances into the brain parenchyma and a
reduction in the expression of ZO-1 and occludin protein
(Bell et al., 2010). In vitro studies using cells of human,
murine, bovine and porcine origin further underlined the
positive effect of pericytes on BBB tightness (Hayashi et al.,
2004; Dohgu et al., 2005; Nakagawa et al., 2007; Al Ahmad
et al., 2009; Daneman et al., 2010). Similar to astrocytes, peri-
cytes are capable of secreting factors that modulate BBB per-
meability under normal conditions, like ANG-1 (Hori et al.,
2004; Wang et al., 2007), TGF-β1 (Dohgu et al., 2005) and
GDNF (Shimizu et al., 2012) that increase ZO-1, claudin-5 or
occludin in vitro (Hori et al., 2004; Wang et al., 2007; Shimizu
et al., 2011). Therefore, similar to astrocytes, pericytes seem
capable of modulating TJs. In contrast, a few in vitro studies
report that co-culture of ECs with pericytes reduces TEER via
induction of matrix metalloproteinases (MMP)-2 and -9 activ-
ity and activation of VEGF-mediated signalling (Zozulya
et al., 2008; Thanabalasundaram et al., 2010). Interestingly,
this negative effect of pericytes seems to be dependent on
their differentiation state (Thanabalasundaram et al., 2011).
Tricellular interactions – ECs,
pericytes, astrocytes
How ECs, astrocytes and pericytes influence each other and
concertedly modulate barrier function is a highly interesting
but challenging question. Due to the complexity of the BBB
in vivo data on this topic is limited, but some in vitro studies
have investigated the effect of simultaneous astrocyte and
pericyte co-culture on ECs. The majority of these studies
report increased TEER in triple cultures compared with
co-culture or monoculture models (Nakagawa et al., 2007;
2009; Al Ahmad et al., 2009); however, decreased TEER in
triple cultures due to the presence of pericytes was also
reported (Hatherell et al., 2011). Interestingly, only Hatherell
et al. used human ECs. Importantly, the permeability to
sodium-fluorescein, sucrose or 40 kDa FITC-dextran was not
significantly altered in triple cultures compared with contact
astrocyte co-cultures (Al Ahmad et al., 2009; Nakagawa et al.,
2009). Nakagawa et al. indeed observed that claudin-5 and
ZO-1 protein expression is increased and more restricted to
cell–cell borders in triple cultures compared with endothelial
monocultures (Nakagawa et al., 2009). Using a novel three-
dimensional culture model, our group showed that co-culture
of ECs with astrocytes and pericytes also induces polarized,
luminal localization of the ABC transporters P-gp and MRP-2
and that astrocytes and pericytes are indispensable for P-gp
activity (Al Ahmad et al., 2011). However, it is patently
evident that many more studies and wider use of triple
culture model systems is invaluable for understanding the
multicellular crosstalk at the BBB.
Basement membrane
The BM represents an important but often neglected compo-
nent of the BBB. Although the BM does not act as a diffusion
barrier per se, it fulfils important functions for the BBB by
providing structural support for the cells by anchoring them
in place. Moreover, the BM provides an important platform
for mediating signalling events that regulate cell differentia-
tion, proliferation, migration and adhesion (Baeten and
Akassoglou, 2011) and thus BBB function. The BM consists of
structural matrix proteins that are secreted by the BBB cells
with cell-specific differences (a detailed list is presented in
Baeten and Akassoglou, 2011). BBB cells are anchored to the
BM via ECM receptors, of which the best understood ones are
the integrins and dystroglycan (Baeten and Akassoglou,
2011). More than just providing a physical link between the
BM and the cells, the matrix receptors represent important
modulators of signalling pathways that allow cellular adap-
tation to environmental changes. Perlecan, the dominating
proteoglycan in the endothelial BM (Engelhardt and Sorokin,
2009), has been shown to interact with a number of different
growth factors like VEGF, PDGF or TGF-β and retain them in
the ECM thereby regulating cellular signal transduction to
control cell responses and BBB maintenance (Roberts et al.,
2012).
Composition of the BM can also regulate BBB tightness
(Tilling et al., 1998). P-gp expression is increased when ECs
are cultured on brain-derived ECM (Tatsuta et al., 1994).
ECMs derived from pericytes or astrocytes exhibit differential
effects on EC impedance in vitro compared with controls
grown on their endogenous ECMs (Hartmann et al., 2007).
Interestingly, ECs cultured on astrocyte-derived ECM dis-
played a higher resistance than those cultured on pericyte-
derived ECM. Astrocyte-derived ECM has been shown to
up-regulate the expression of endothelial-specific γ-glutamyl-
transpeptidase and activity (Mizuguchi et al., 1994; Hayashi
et al., 1997). Several BM-associated proteins have been shown
to be important for BBB maintenance in vivo. Depletion of
perlecan in vivo is lethal due to deterioration of brain vesicles
and myocardial BM (Baeten and Akassoglou, 2011), whereas
specific depletion of perlecan in the endothelial BM results in
microvessel bleeding and endothelial dilations (Hallmann
et al., 2005). Agrin, another proteoglycan, accumulates at
brain microvessels at the time of BBB tightening (Wolburg
et al., 2009b) and its depletion results in TJ disruption
(Rascher et al., 2002) and depolarization of astrocytic end-feet
mainly through redistribution of aquaporin 4 (AQP4;
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Wolburg et al., 2009b). Osada et al. showed that blocking of
β1-integrin using a neutralizing antibody results in altered
claudin-5 localization and increased endothelial permeability
in vitro and in vivo (Osada et al., 2011).
Taken together, these data indicate that the BM compo-
sition participates in BBB regulation; however, the mecha-
nisms are only poorly understood and need to be better
addressed.
Hypoxia and the BBB
Mechanisms of hypoxic BBB disruption
Hypoxia, when the oxygen demand of tissues is not met, acts
as an initial trigger for pathophysiological changes at the BBB
such as altered distribution of water and ions, inflammatory
events and oxidative stress, oedema formation, infiltration of
peripheral immune cells and leakage of blood proteins into
the brain. In addition, hypoxia induces major alterations in
vessel structure as it stimulates proliferation of ECs leading to
formation of new blood vessels and furthermore promotes
activation and proliferation of astrocytes (reviewed by
Ogunshola and Al-Ahmad, 2012; Stanimirovic and Friedman,
2012). A large number of in vivo and in vitro studies have
demonstrated that hypoxia is a major stress factor inducing
BBB disruption (Schoch et al., 2002; Kaur et al., 2006; Al
Ahmad et al., 2009; Lochhead et al., 2010). Regarding the
temporal course of hypoxic barrier opening, detailed in vivo
studies are rare. Increased BBB permeability to Evans blue was
observed in mice 6 h after onset of hypoxia (7% O2; Li et al.,
2011). After 24 and 48 h of hypoxic exposure to 8% O2,
increased BBB leakage to sodium fluorescein was demon-
strated in mice (Schoch et al., 2002; Bauer et al., 2010).
Another study by Witt and colleagues demonstrated that
exposure to 6% O2 for 1 h with subsequent re-oxygenation in
a rat model resulted in a biphasic opening of the BBB within
the first hour and again after 6–24 h of re-oxygenation (Witt
et al., 2008). For in vitro models, a generalized statement
about the course of barrier opening is almost impossible due
to different culture systems, cell sources, oxygen concentra-
tions and read-outs. However, decreased endothelial tight-
ness has been observed from the first 30 min of hypoxic
exposure for up to 48 h (Abbruscato and Davis, 1999a; Fischer
et al., 1999; Yamagata et al., 2004; Fleegal et al., 2005;
Kuhlmann et al., 2007; Al Ahmad et al., 2009).
The mechanisms of hypoxic barrier disruption have been
studied intensively and it is evident that disruption of the
BBB occurs on many different molecular levels. TJ complexes
are major targets of hypoxic BBB disruption. At the molecular
level, hypoxia modulates protein expression levels and sub-
cellular redistribution of occludin, ZO-1 and claudin-5
(Fischer et al., 2002; Mark and Davis, 2002; Koto et al., 2007;
Bauer et al., 2010; Willis et al., 2010). The redistribution criti-
cally regulates TJ integrity and is probably mediated via phos-
phorylation changes at serine, threonine and tyrosine
residues and by caveolae-mediated endocytosis that deter-
mines their localization at the plasma membrane and inter-
action with other proteins at the TJ (Luissint et al., 2012). PKC
enzymes, myosin light chain kinase, and RhoA regulate TJ
protein phosphorylation and contribute to hypoxic or
inflammatory barrier disruption (for review, refer to Luissint
et al., 2012). Increased transcellular and pinocytic activity of
brain ECs represent additional events contributing to aug-
mented barrier permeability during hypoxia (Plateel et al.,
1997; Cipolla et al., 2004). Hypoxia-mediated alterations and
breakdown of the BM also aggravate BBB opening and are
particularly important during ischaemic events (Candelario-
Jalil et al., 2009; Stanimirovic and Friedman, 2012). Direct
and indirect contribution of pericytes and astrocytes to
hypoxic-mediated BBB permeability is discussed below.
HIFs as mediators of the hypoxic response
Hypoxia requires an immediate response of the affected
tissues/cells to sustain their function and prevent cell death.
The most important tasks of the adaptation process are to
decrease energy consumption and increase oxygenation. This
is mainly achieved through metabolic adaptation and tem-
poral cell cycle arrest as well as induction of angiogenic and
erythropoietic genes to increase oxygen delivery to the
hypoxic tissues (Wenger et al., 2005). Different signalling
pathways are involved in these events including the unfolded
protein response, mammalian target of rapamycin signalling,
and HIF-mediated gene regulation (Majmundar et al., 2010).
HIFs are considered master regulators of the hypoxic response
and are heterodimeric transcription factors composed of an
oxygen-sensitive α-subunit and a constitutively expressed
β-subunit. Under normoxia, the HIFα subunits are constitu-
tively transcribed but constantly targeted for proteasomal
degradation through a cascade of hydroxylation of conserved
proline residues via prolyl hydroxylases (PHDs), subsequent
recognition by the Von Hippel–Lindau (VHL) protein, ubiq-
uitination and degradation by the proteasome. As oxygen
tension drops, the PHD enzymes are inhibited and the lack of
hydroxylation results in cytoplasmic stabilization of the
α-subunits. After phosphorylation, HIFαs translocate to the
nucleus and dimerize with ARNT (also known as HIF-β) and
co-activators forming a functional HIF transcription factor
(Wenger et al., 2005; Fandrey and Gassmann, 2009). By
binding to hypoxia-responsive elements in promoter regions,
HIFs induce the expression of target genes involved in cellular
adaptation to hypoxic stress-regulating erythropoiesis, angio-
genesis, proliferation and cellular metabolism (Ogunshola
and Al-Ahmad, 2012; see Figure 2).
Three different HIFs have been identified, namely, HIF-1,
-2 and -3 of which HIF-1 is the most widely studied. More
than 100 HIF-1 target genes are known to date (Semenza,
2003). HIF-1 signalling is considered essential for cellular
adaptation and survival during hypoxia. Several HIF-1 target
genes are neuroprotective and act as pro-survival factors such
as erythropoietin and VEGF. Moreover, HIF-1 signalling regu-
lates the expression of several proteins implicated in glycoly-
sis such as phosphofructokinase or enolase-1 and glucose
transporter 1 (GLUT1), thus regulating metabolic adaptation
to low oxygenation. Besides its positive effects, HIF-1 also
accounts for detrimental effects observed during hypoxia/
ischaemia by activation of prodeath genes, such as BNIP3,
COX2 or p53 stabilization (reviewed in Singh et al., 2012). At
present, it is not clear what determines whether the initiated
HIF-1-mediated response is protective or detrimental.
However, it is likely that the severity of the insult and its
duration, as well as cell type-specific differences and paracrine
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signalling play a critical role. Thus, HIF-1 signalling is a key
determinant of functional outcome.
HIF-1 regulates BBB permeability
Growing evidence suggests that HIF-1 could play a
pivotal role in the changes that occur at the BBB during
hypoxia. Good insights have been obtained from cerebral
ischaemia and reperfusion studies as well as in vitro work
(reviewed by Ogunshola and Al-Ahmad, 2012). The HIF-1
inhibitors 2-methoxyestradiol and YC-1 reduce oedema
formation (directly correlating to BBB permeability) and
infarct volumes after ischaemia or ischaemia reperfusion
(Yeh et al., 2007; Chen et al., 2008a), whereas rapid
DMOG (dimethyloxalylglycine)-induced HIF-1α stabilization
increased oedema formation. In both studies, these effects
were attributed to modulation of VEGF production (Chen
et al., 2008a). Our own in vitro work using brain ECs also
suggest that HIF-1 stabilization is directly linked to barrier
disruption and that inhibition of HIF-1 can significantly
improve barrier stability (Engelhardt et al. unpubl. data).
Likewise, HIF-1 inhibition using siRNA in a rat focal ischae-
mia model showed less BBB disruption and a better outcome
for the animals and is correlated with decreased VEGF levels,
as well as reduction of caspase-3 and p53 expression (Chen
et al., 2009). These studies suggest that HIF-1 stabilization is
likely to trigger increased BBB permeability through activa-
tion of its multiple target genes and signalling cascade.
Contribution of astrocytes and pericytes to
hypoxic BBB regulation
The importance of non-neuronal cells in brain diseases asso-
ciated with hypoxia has long been neglected. The next
section discusses the response of BBB cells to hypoxia/
ischaemia and their subsequent effect on BBB function.
Astrocytes
Information on the basal responses of astrocytes to reduced
oxygenation is limited and far from complete. We know that
astrocytes are more resistant to hypoxia and ischaemia than
neurons, which is probably due to their higher capacity to
metabolically adapt to hypoxia/ischaemia by using alterna-
tive energy sources and switching to anaerobic glycolysis
thereby ensuring maintenance of the ATP levels (Schmid-
Brunclik et al., 2008; Turner and Adamson, 2011). Astrocytes
are activated in vivo (Kaur et al., 2006) and in vitro
(Schmid-Brunclik et al., 2008) following hypoxic/ischaemic
injury and secrete elevated levels of a large number of factors
that can be neurotoxic as well as neuroprotective (reviewed in
Trendelenburg and Dirnagl, 2005; Vangeison and Rempe,
2009). Modulation of a variety of proteins suggests a highly
Figure 2
Schematic diagram illustrating the mechanism of HIF-1 regulation under normoxic and hypoxic conditions. HIFs are heterodimeric transcription
factors composed of an oxygen-sensitive α-subunit and a constitutively expressed β-subunit. Under normoxia (white gradient), the HIF-1α subunit
is constitutively transcribed but constantly targeted degradation through hydroxylation of conserved proline residues by PHDs leading to
recognition by VHL protein, ubiquitination and subsequent degradation by proteasome. As oxygen tension drops (red gradient), the PHD enzymes
are inhibited and the lack of hydroxylation results in cytoplasmic stabilization of the α-subunits. After phosphorylation, HIF-1α translocates to the
nucleus and dimerizes with HIF-1β (also known as ARNT) and co-activators such as p300/CBP forming a functional HIF-1 transcription factor. HIF-1
then binds to hypoxia-responsive elements (HREs) in the promoter regions of its many targets inducing expression of genes involved in cellular
adaptation to hypoxic stress by regulating erythropoiesis, angiogenesis, proliferation and cellular metabolism in order to reduce O2 consumption
and increase O2 delivery to tissues.
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complex tempering of barrier status. Indeed, a microarray
study recorded more than 1100 hypoxia-responsive genes in
human astrocytes with five times more genes up-regulated
than suppressed. Notably, many of the up-regulated genes
were glycolytic enzymes and angiogenic molecules (Mense
et al., 2006). Astrocytes co-cultured with ECs results in
mutual up-regulation and preservation of antioxidant enzy-
matic activity and reduced radical-induced EC injury (lipid
peroxidation) compared with endothelial monocultures
(Schroeter et al., 1999; Ogunshola and Al-Ahmad, 2012).
Different in vitro studies have shown that astrocyte
co-culture or treatment of ECs with ACM improves EC per-
formance and maintenance of barrier function during
hypoxic insults (Fischer et al., 2000; Brown et al., 2003; Al
Ahmad et al., 2009). Consistent with these observations
astrocytes/ACM preserve the junctional localization of TJ pro-
teins, like ZO-1 or claudin-5 (Fischer et al., 2000; Al Ahmad
et al., 2011) and hypoxia/glycaemia-dependent down-
regulation of the adherens junction protein E-cadherin is
partially reversed in the presence of astrocytes (Abbruscato
and Davis, 1999b). Media from hypoxic and re-oxygenated
astrocytes contain ANG-1 that increases occludin expression
and reduces endothelial proliferation thereby stabilizing the
vasculature (Song et al., 2002). In addition, co-culture with
astrocytes attenuates endothelial caspase-3 activation during
hypoxia (Al Ahmad et al., 2009) thereby reducing cell death
and caspase-3-mediated TJ disruption (Zehendner et al.,
2011).
Astrocytes are the major source of VEGF in the brain and
respond to hypoxic stimuli with increased induction and
secretion of VEGF that acts as an endothelial survival factor
(Chow et al., 2001; Kaur et al., 2006; Mense et al., 2006;
Schmid-Brunclik et al., 2008). However, VEGF is also a promi-
nent angiogenic molecule and thus a strong inducer of vas-
cular permeability in vitro and in vivo (Fischer et al., 1999;
Schoch et al., 2002). Our group has shown that despite a
beneficial effect of astrocyte co-cultures on hypoxic barrier
maintenance, inhibition of VEGF signalling (with the VEGF
receptor inhibitor SU1498) further improved maintenance of
barrier characteristics (Al Ahmad et al., 2011). In agreement
with this result, astrocyte-derived VEGF was also shown to
drive BBB disruption after hypoxic exposure (Kaur et al.,
2006) and in CNS inflammatory disease (Argaw et al., 2012).
Thus, the effect of VEGF secretion during insult is multifac-
eted. VEGF binds and activates two TK receptors, namely,
VEGFR1 (also known as FLT1) and VEGFR2 (also known
as KDR or FLK1). Hypoxia-induced endothelial hyper-
permeability seems to be mediated predominantly by activa-
tion of VEGFR1 (Vogel et al., 2007), in agreement with the
finding that hypoxia up-regulates both the expression of
VEGFR1 and the binding of VEGF to VEGFR1 (Fischer et al.,
1999). Excellent reviews on hypoxia- and HIF-1-mediated
VEGF permeability have been published (Fan et al., 2009;
Nakayama and Berger, 2013). However, it has also been
shown that VEGF splicing in the terminal exon results in
variants, termed VEGFxxxb (VEGF165b), that act as anti-
angiogenic dominant negative splice isoforms (Ladomery
et al., 2007; Nowak et al., 2008). Notably, high homology
means these anti-angiogenic isoforms may have been mistak-
enly identified as the more canonical species in many studies.
Although the ratio of the b-isoforms to the canonical species
could be highly relevant, investigations on the effects of
stimuli such as hypoxia on these splice variants are yet to be
performed. Astrocytic secretion of MMPs during hypoxia also
causes BM reorganization and weakens barrier function.
Increased activity of MMP-2, MMP-9 and MMP-13 was
detected in hypoxic astrocyte supernatants and treatment of
ECs with those supernatants led to MMP-13-dependent delo-
calization and proteolysis of ZO-1 and disruption of
VE-cadherin (Lu et al., 2009).
Astrocytes additionally express various cytokines in
response to hypoxic stimulation. For example, IL-1β is a
HIF-1 target gene (Zhang et al., 2006) that can activate HIF-1α
and VEGF expression in a NFκB-dependent manner in astro-
cytes and cause down-regulation of the vessel-stabilizing
factor SSeCKs (Argaw et al., 2006). Also, large amounts of
the monocyte chemoattractant proteins (MCP) MCP-1 and
MCP-5 are produced by hypoxic astrocytes in a HIF-1-
dependent manner (Mojsilovic-Petrovic et al., 2007). Apart
from its main function of recruiting leukocytes at sites of
inflammation, MCP-1 was shown to increase the paracellular
permeability of endothelial monolayers via TJ redistribution
mediated by Rho signalling (Stamatovic et al., 2003) and is
involved in formation of vasogenic oedema in vivo
(Stamatovic et al., 2005). Clearly, hypoxic responses of astro-
cytes are critical during injury and disease and particularly
affect the stability of the BBB.
Pericytes in hypoxic BBB regulation
Only a few studies have investigated the survival of pericytes
after hypoxic and ischaemic insults. Our in vitro data suggest
that pericytes have comparable sensitivity to astrocytes. We
did not observe any impairment of mitochondrial activity in
pericytes exposed for up to 48 h in 0.2% oxygen reflecting no
loss of viability, whereas ischaemic conditions reduced mito-
chondrial function only after 24 h of exposure (Engelhardt
et al., unpubl. obs.). Likewise, it was shown that ECs are much
more susceptible to ischaemia than astrocytes and pericytes
in vitro (Ceruti et al., 2011). In vivo pericytes were observed to
migrate away from microvessels in response to traumatic
brain injury (TBI; Dore-Duffy et al., 2000) and hypoxic
stimuli already 2 h after onset of the insult and preceding any
changes in vessel structure (Gonul et al., 2002). Furthermore,
a reduction of pericyte-to-EC ratio was reported after 1 week
of hypobaric hypoxia (Dore-Duffy et al., 2007). Although the
cell status during these events remains unclear, the changes
occurring during pathologies associated with increased BBB
permeability suggest that pericyte loss per se could contribute
to augmented barrier leakage. Indeed, in vitro models have
shown that the presence of pericytes protects endothelial
monolayers from hypoxic barrier disruption (Hayashi et al.,
2004; Al Ahmad et al., 2009), particularly during prolonged
and severe oxygen deprivation, by maintaining TJ protein
localization and reducing endothelial caspase-3 activation (Al
Ahmad et al., 2009; 2011). Interestingly, under severe condi-
tions, co-culture of pericytes with ECs maintained TEER and
reduced paracellular flux of labelled substances better than
astrocyte co-cultures (Al Ahmad et al., 2009).
Like astrocytes, pericytes respond to hypoxia by up-
regulating various growth factors. Park et al. demonstrated
that in retinal pericytes ANG-1, but not ANG-2, mRNA is
significantly elevated (Park et al., 2003) again suggesting a
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vessel-stabilizing effect. Interestingly, the induction of ANG-1
could be mimicked through treatment of the pericytes with
recombinant VEGF (Park et al., 2003). An in vivo study sug-
gested that hypoxic pericytes rapidly increase VEGF levels
within 24 h, whereas astrocytic VEGF production was
observed after 4 days (Dore-Duffy et al., 2007). In our studies,
we observed different outcomes when inhibiting VEGF sig-
nalling using SU1498; inhibition was only beneficial in EC
pericyte co-cultures during 1% O2 but not during more severe
oxygen deprivation (0.1% O2; Al Ahmad et al., 2009).
Although temporal-spatial VEGF-mediated induction of
ANG-1 may be a plausible explanation for some of the
barrier-stabilizing effects of pericytes during hypoxia, it is
unlikely that elevated VEGF expression does not largely con-
tribute to hypoxic barrier disruption, indeed VEGF signalling
by other brain cells may also have an effect. Like astrocytes,
pericytes also secrete MMPs and their expression is aug-
mented through pro-inflammatory cytokines like TNF-α
(Takata et al., 2011). Additionally, pericytes can induce MMP
expression in ECs, although the link between pericyte MMP
expression and hypoxic barrier disruption is still to be prop-
erly demonstrated. Taken together, however, the data indi-
cate that timing, severity and cellular crosstalk is likely to be
very complex.
Overall, despite limited information, similar to astrocytes,
pericytes appear to fulfil important barrier-stabilizing func-
tions but in response to stress also secrete molecules that can
cause BBB remodelling and increased permeability. Thus,
more studies are required to understand the multiple roles of
this elusive perivascular cell.
Pathophysiology
Hypoxia-mediated BBB dysfunction is associated with many
neurological diseases such as stroke, TBI and Alzheimer’s
disease (AD) (Ballabh et al., 2004). As discussed earlier, parac-
rine interactions between brain ECs, astrocytes and pericytes
play a crucial role in maintaining the BBB. However, their
contribution to various brain diseases by secreting factors
that modulate the barrier during injury is frequently over-
looked. The next section of this review will focus on direct or
indirect influences of hypoxic, and particularly HIF-1-
mediated BBB cell-specific responses to progression of select
diseases namely stroke, TBI and AD (see Figure 3).
Stroke/cerebral ischaemia
Stroke is a major cause of morbidity and mortality across all
industrialized countries. The most commonly occurring type
of stroke is ischaemic (Bamford et al., 1990), which accounts
for approximately 80% of the total incidences. Ischaemic
stroke results from occlusion of a major cerebral artery either
by thrombosis or an embolus. In either case, this restricts the
delivery of substrates to the tissue, particularly oxygen and
glucose, which leads to a cascade of ischaemic events (Dirnagl
et al., 1999). Within the core of the ischaemic region, deficits
in blood flow, decreased energy stores (ATP levels), metabolic
failure and ionic imbalance are severe and cell death pro-
gresses within minutes. The region surrounding the compro-
mised area, called the ischaemic penumbra, suffers milder
insults and is salvageable if blood flow is restored quickly.
However, the reperfusion of ischaemic tissue can also lead to
secondary damage caused by the rapid re-exposure to oxygen
and inflammatory responses in the damaged tissue. Restora-
tion of blood flow also increases the pressure on the damaged
ECs and their TJs (Sandoval and Witt, 2008). Additionally,
reperfusion results in a fresh supply of leukocytes that trans-
locate into the parenchyma triggering a cascade of cytokine
release (Dirnagl et al., 1999). Activated astrocytes and peri-
cytes modulate blood flow, maintain ion homeostasis and
contribute to water homeostasis, as well as participate in the
inflammatory cascade and release a number of substances
that may be either neuroprotective or harmful during ischae-
mia. This wide variety of responses results in a number of
effects including loss of TJ expression and localization,
increase in permeability, degradation of BM, loss of integrins,
oedema and further inflammation (Sandoval and Witt, 2008;
Kwon et al., 2009), all of which contribute to BBB disruption
(see Figure 3). Although the trigger for the pathological
changes is hard to establish they are probably interdepend-
ent. Cerebral ischaemia induced by transient occlusion of
middle cerebral artery evokes a marked biphasic opening of
the BBB. Early opening of the BBB takes place within the first
half hour of reperfusion and is followed by partial closing.
This initial acute opening is described as a ‘haemodynamic’
BBB opening resulting in cytotoxic oedema (reviewed by
Nagy et al., 1979; Kuroiwa et al., 1985). Subsequently, a
second delayed, but progressive, opening occurs between 24
and 48 h post-reperfusion and results in vasogenic oedema
(Huang et al., 1999). Notably, taking advantage of this later
progressive BBB opening may aid the delivery of low perme-
ability neuroprotective therapeutic agents.
Brain ECs maintain impermeability of the BBB largely
through their TJs. Notably, ZO-1 and occludin expression
were reduced in a microsphere-induced cerebral embolism
model of cerebral ischaemia (Kago et al., 2003). Although not
many studies have evaluated TJ changes post-ischaemia,
some reports have demonstrated changes in BBB cell contacts
partly due to BM degradation. Astrocyte end-feet are well
known to swell post-ischaemia (Kimelberg, 2005) and degra-
Figure 3
Flow chart of the events leading to BBB disruption and the following
events occurring later in stroke, TBI and AD.
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dation of BM also causes their detachment from the vessel
wall leading to increased permeability (Kwon et al., 2009). In
addition to swelling, surviving astrocytes in the vicinity of
the ischaemic damage also undergo a process of hypertrophy
referred to as reactive astrogliosis. Similarly, pericytes have
also been shown to migrate away from vessels in animal
models of ischaemia by breaking through the BM that
ensheaths them (Dore-Duffy et al., 2000; Melgar et al., 2006).
This indicates that in addition to changes in BBB permeabil-
ity induced by TJ alterations, contact with BBB-supportive
cells is also modified and probably enhances BBB disruption.
It is reported that ischaemia followed by reperfusion in rats
results in BBB disruption and breakdown of BM collagen
IV (Hamann et al., 2002; Scholler et al., 2007). Likewise,
ischaemic/reperfusion injury also results in a decrease in
laminin and fibronectin (Hamann et al., 1995). Other BM
proteins, such as agrin and perlecan are also degraded after
ischaemia (Fukuda et al., 2004; Baumann et al., 2009). Fukuda
and group were the first to provide direct evidence that active
proteases, which are known to degrade the BM are generated
in ischaemic cerebral tissue (Fukuda et al., 2004). The most
widely studied proteases, MMPs, are released by astrocytes
(Zhang et al., 2004) and microglia (Del Zoppo et al., 2007)
post-ischaemic injury. MMP-9 and -2, in particular, are major
contributors of ischaemic pathology. Many groups have dem-
onstrated the detrimental role of MMP-9 in ischaemic models
by using inhibitors of MMP-9 or MMP-9 knockout animals
and reported reduction in BBB damage, brain water content,
infarct size and neurological deficit (Romanic et al., 1998;
Asahi et al., 2001; Jiang et al., 2001; Park et al., 2009; Cui
et al., 2012). Therefore, inhibiting MMPs may be highly ben-
eficial for treating cerebral ischaemia, as reviewed elsewhere
(Cunningham et al., 2005; Morancho et al., 2010).
BBB disruption after ischaemia increases permeability to
macromolecules allowing fluid movement from intravascular
to extravascular spaces and leading to vasogenic oedema
(Sandoval and Witt, 2008). Aquaporins (AQPs) are highly
permeable water channels that play a crucial role in fluid
balance. AQP4 in particular participates in the maintenance
of brain water homeostasis and is highly concentrated on
astrocyte end-feet (Nielsen et al., 1997). The role of AQP4 has
been explored in various models of ischaemic stroke where it
contributes to the formation of cerebral oedema. In disease
models, such as acute cerebral ischaemia and water intoxica-
tion (Manley et al., 2000), water moves into the cell resulting
in cytotoxic brain oedema. Deletion of AQP4 was shown to
prevent cellular water uptake in these models, as demon-
strated by reduced brain water content, lower intracranial
pressure values, infarct size and lesion volume (Manley et al.,
2000; Zeng et al., 2012). In chronic ischaemia or TBI models
that result in vasogenic oedema due to BBB disruption, dele-
tion of AQP4 exacerbated cerebral oedema formation assessed
by water content measurements and intracranial pressure
(Papadopoulos et al., 2004). Based on these findings it can be
concluded that AQP4 plays a differential role in modulating
brain water homeostasis and is dependent on the duration
and type of insult.
VEGF, one of the most important factors induced by
hypoxia, performs a major role in driving BBB disruption
leading to oedema formation in the acute phase following
ischaemia (Zhang et al., 2000; Chi et al., 2007; 2008). Elevated
VEGF expression appears as early as 1 h after the onset of
cerebral ischaemia (Abumiya et al., 1999; Plate et al., 1999b).
Indeed, early administration of VEGF increases BBB perme-
ability, increases infarct size and worsens neurological
outcome following an ischaemic insult (Zhang et al., 2000).
Similarly, inhibition of endogenous VEGF in the acute phase
reduces BBB permeability (Mayhan, 1999; Valable et al., 2005;
Yeh et al., 2007). This is in line with findings that suggest
VEGF is not only an angiogenic factor but also a permeability
factor (Plate, 1999a). Apart from its role at the vasculature,
there are several studies that have also examined the effect of
VEGF on cerebral infarct size. Van Bruggen et al. reported that
antagonism of VEGF reduces ischaemia reperfusion-related
brain oedema and injury in mice (van Bruggen et al., 1999).
Similarly, VEGF administered i.v. increased infarct size when
given early after ischaemia in rats but, in contrast, improved
neurological function when given at later stages 2 days post-
ischaemia (Zhang et al., 2000). These studies suggest that
despite enhancing angiogenesis and reducing neurological
deficits during late-stage stroke recovery, inhibition of VEGF
at the acute stage of injury may reduce BBB compromise. The
negative side of VEGF could perhaps be achieved partly by
counteracting its permeabilizing effect in the acute phase
of ischaemia. Indeed, systemic adenoviral gene delivery of
ANG-1, a known anti-permeability factor that maintains and
stabilizes mature vessels by promoting interaction between
ECs and surrounding support cells (Hori et al., 2004), causes
resistance to vascular leakage induced by VEGF in the brain
after cerebral ischaemia (Zhang et al., 2002). Conversely,
ANG-2 that leads to de-stabilization of vessels and dissocia-
tion of pericytes, is up-regulated by hypoxia and cytokines
including VEGF (Mandriota and Pepper, 1998; Valable et al.,
2005). Thus, the co-ordination of VEGF and the ANG is
crucial for maintaining the integrity of existing vessels and
modulating growing vessels for better outcome following
ischaemia.
In summary, the exact mechanisms causing brain vascular
disruption are hard to establish but factors like VEGF and
MMPs released from BBB-supportive cells are likely to play an
instrumental role. Further confirmation of these conclusions
using cell-specific conditional knockout animal experiments
is necessary for better understanding of the role of these cells
at the BBB post-ischaemia.
Traumatic brain injury
TBI results from an outside force causing instant mechanical
disruption of brain tissue and delayed pathogenic events
that collectively mediate widespread neurodegeneration
(reviewed by Gaetz, 2004). Subsequently, the traumatized
brain is highly susceptible to secondary brain injuries, which
can be caused by hypoxia (Hellewell et al., 2010) and seizures
(Bao et al., 2011). Reports from animal model studies and
significant clinical data both suggest a central role for vascu-
lar integrity in TBI outcome, especially BBB breakdown which
can last from minutes to several days to weeks, or even years
after the acute event (Unterberg et al., 2004; Hawkins and
Davis, 2005; Abbott et al., 2006; Tomkins et al., 2008). This
kind of disruption might also influence the progression of
long-term TBI complications, such as AD, which include
delayed neuronal dysfunction and cell death (see Figure 3).
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Studies of animal models of TBI have also demonstrated a
biphasic increase in BBB permeability to albumin and other
high molecular weight proteins peaking at 4 to 6 h as well as
2–3 days after injury (Bas¸kaya et al., 1997; Hicks et al., 1997).
The first peak in BBB permeability generally overlaps with
increased production of a number of secretory factors that
include chemokines, cytokines, MMPs and VEGF, which con-
tribute to BBB dysfunction and also invasion of neutrophils.
A thorough review on molecular pathogenesis of BBB break-
down in TBI has been recently published (Nag et al., 2011).
Chemokines not only play a key role in post-traumatic
recruitment of leukocytes, but may also modify the perme-
ability of the BBB. After injury recruitment of leukocytes into
the brain parenchyma releases a number of inflammatory
cytokines that worsen the outcome of the disease state. For
example, as stated earlier MCP-1 is up-regulated post-hypoxia
and very recently, Semple et al. reported its important role in
reducing lesion size and secondary damage and improving
functional outcome in mice following TBI (Semple et al.,
2010). This improvement may be attributed to decreased
leukocyte accumulation resulting in an environment more
advantageous for neuronal survival. Increased levels of
cytokines are correlated to poorer clinical outcomes. TNF-α
mRNA and protein is elevated acutely after experimental TBI
(Bermpohl et al., 2007) as well as in clinical settings (Csuka
et al., 1999) and is known to exacerbate BBB disruption post-
TBI (Bermpohl et al., 2007). Similarly, a rapid increase of IL-1β
is observed early enough after experimental TBI (Wang and
Shuaib, 2002). Patel et al., using intracerebral or intraven-
tricular administration of exogenous IL-1β, demonstrated sig-
nificant exacerbation of injury (Patel et al., 2003). In
addition, transgenic mice, in which the IL-1β is overexpressed
in astrocytes alone, were observed to have a leaky BBB
(Shaftel et al., 2007). Thus, BBB dysfunction mediated via
cytokines released from BBB cells can worsen injury outcome
in the acute stages and may be hypoxia-dependent. In con-
trast, the mechanisms involved in the delayed (second phase)
opening of the BBB are presently unclear and require further
investigation.
Although the role of VEGF and its receptors has been
studied extensively in ischaemia over the last years, only a
few groups have performed studies elucidating the role of this
molecule post-TBI. Using different models of TBI, it was
reported that astrocytes as well as inflammatory cells react to
injury by increasing VEGF expression (Papavassiliou et al.,
1997; Sköld et al., 2002). In contrast, pericytes were shown to
undergo cell death post-TBI using TUNEL assay (Dore-Duffy
et al., 2007). Morgan et al. demonstrated a substantial
increase in angiogenesis, based on BrdU-positive nuclei
within the endothelium post-TBI via increased expression of
VEGF and its receptor (Morgan et al., 2007). This induction of
angiogenesis could be mediated by the up-regulation of astro-
cytic VEGF, which in turn increases both astrocyte prolifera-
tion and facilitates the expression of other growth factors,
which support late-stage recovery (Krum et al., 2008). Corti-
costeroids that are usually used for treating early vasogenic
oedema after acute BBB compromise have been demonstrated
to stabilize the BBB by decreasing the expression of VEGF
(Kim et al., 2008). Again, the data suggest that during disease
early VEGF release from glial cells can be harmful to BBB
function and further worsen the outcome post-TBI. Similarly,
MMPs, in particular MMP-2, MMP-3 and MMP-9, are
up-regulated following TBI (Shigemori et al., 2006; Vilalta
et al., 2008; Hayashi et al., 2010). As found in cerebral ischae-
mia, genetic deletion of MMP-9 or pharmacological inhibi-
tion of the activity of MMPs using TIMPs significantly
reduced the extent of tissue damage and improved functional
outcome in murine models of TBI (Wang et al., 2000). In
addition, mice overexpressing the human TIMP1 gene sub-
jected to TBI showed reduced levels of MMP-9 synthesis and
a less leaky vasculature accompanied by decreased brain
tissue damage compared with control animals (Tejima et al.,
2009). All these observations indicate that secretion of VEGF
and MMPs by BBB cells could indeed represent a potential
target for pharmacological intervention in TBI and ischae-
mia. Nonetheless, it should be emphasized that as these
factors also play an important role in the repair process at
later stages, delayed inhibition of their activity may actually
have adverse therapeutic effects (Nag et al., 1997; Zhao et al.,
2006).
AQP4 expression is markedly modified in both experi-
mental and clinical TBI (Manley et al., 2000; Papadopoulos
and Verkman, 2007; Tang et al., 2010; Fukuda and Badaut,
2012). Initial studies implied that induction of AQPs in a
model of TBI promoted oedema formation (Manley et al.,
2000) and that therapeutic inhibition of AQP4 could be ben-
eficial in controlling oedema (Taya et al., 2008). Indeed,
Fukuda et al. used siRNA against AQP4 to demonstrate
improvements that were associated with decreased oedema
formation, increased microglial activation and decreased BBB
disruption post-TBI (Fukuda et al., 2013). However, it subse-
quently became apparent that the modifications in AQP4
expression are dependent on the type of oedema and its
regional distinction (Sun et al., 2003; Papadopoulos et al.,
2004). For instance, in an ischaemic model that results in
cytotoxic oedema, inhibition of AQP4 expression was associ-
ated with decreased oedema, reduced infarct area and an
improvement in functional outcome (Fazzina et al., 2010). In
contrast, in a cold lesion injury model of vasogenic brain
oedema, AQP4-deficient mice had a markedly worse clinical
outcome (Papadopoulos et al., 2004). These findings suggest
that AQP4 is mainly essential for the clearance of vasogenic
oedema but its other effects depend on the type of injury and
the time point being measured.
Finally, BBB disruption also triggers a chain of events that
not only affects vascular cells but also neuronal cells by
causing epilepsy (Tomkins et al., 2007; 2008). This theory
seems plausible since the studies cited suggest that damage to
the microvasculature might result in the extravasation of
serum proteins such as albumin, which leads to the activation
of astrocytes as the first step in the epileptogenic process. This
interaction suggests a key functional role of activated astro-
cytes in neuronal excitability. Hardly any work has been
performed on the specific role of pericytes in TBI, although
endothelin-1-induced pericyte-mediated vasoconstriction
was recently reported (Dore-Duffy et al., 2011). Many more
studies on cell-specific responses to TBI are surely warranted.
Alzheimer’s disease
AD is a progressive and irreversible neurodegenerative disor-
der characterized by the accumulation of amyloid β-peptide
(Aβ) in the CNS, the presence of hyper-phosphorylated tau
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filaments and cerebrovascular changes that lead to cerebral
amyloid angiopathy (Greenberg et al., 2004). AD is another
neurodegenerative disease that is characterized by hypoxia, a
state that is believed to only aggravate disease progression
(Ogunshola and Antoniou, 2009; Peers et al., 2009; Figure 3).
At present, the cellular and molecular basis by which
systemic hypoxia influences AD are not completely under-
stood. However, the emerging evidence indicates that pro-
longed hypoxia induces formation of Aβ that accumulates
over years and probably contributes to vascular alterations
(Selkoe, 2001). Hypoxia induces Aβ processing through
mechanisms that increase the activity of two enzymes crucial
for Aβ formation, β-secretase and γ-secretase (Sun et al., 2006;
Zhang et al., 2007; Li et al., 2009). HIF-1α mediates a tran-
scriptional increase in β-secretase expression (Zhang et al.,
2007) and presenilin-1 levels – presenilin being the major
protein of the γ-secretase complex (Pluta, 2007). In addition,
hypoxia also promotes down-regulation of neprilysin, an
Aβ-degrading enzyme (Nalivaevaa et al., 2004), which can
lead to alterations in the expression of vascular-specific genes
in brain ECs (Wu et al., 2005). All of these effects can be
considered pro-amyloidogenic, that is, would predispose to
increased Aβ levels either through increased production or
reduced degradation. Recently, Wilcock and colleagues used a
transgenic mouse model to demonstrate that during progres-
sion of an AD-related pathology the numbers of astrocytic
processes in apparent contact with cerebral vasculature were
reduced. Furthermore, amyloid accumulation caused signifi-
cant reductions in AQP4 and potassium channels associated
with cerebral vessels in both the mouse model and individu-
als with AD (Wilcock et al., 2009). This observation seems to
agree with studies performed in cerebral ischaemia or TBI
models during the vasogenic phase suggesting that the pres-
ence of AQP4 is beneficial for functional outcome. Clearly,
AQ4 plays a significant role in controlling brain water
homeostasis; however, many more studies are required to
define how its modulation will affect functional outcome of
disease progression in different pathologies. An excellent
review on aquaporins and AD has been published (Foglio and
Rodella, 2010). Emerging evidence suggests that the Aβ accu-
mulation that causes vascular alterations ultimately leads to
hypo-perfusion (Sagare et al., 2012). Pericytes could probably
influence this hypo-perfusion in conditions of severe ischae-
mia and oxidative stress, as they contract not only during the
hypoxic insult but remain contracted even after reperfusion
(Yemisci et al., 2009). Hypoxia also promotes phosphoryla-
tion of tau through the MAPK pathway (Fang et al., 2010).
Tau is a microtubule-associated protein that plays a major
role in stabilizing microtubules, found mainly in neurons but
has also been shown in low levels in astrocytes (Lee et al.,
2001). Aβ and/or hypo-perfusion can induce hyper-
phosphorylation of tau, leading to the protein structural
changes found in AD patients, which affects its binding with
tubulin and causes destabilization of the cytoskeleton
(Michaelis et al., 2002). This leads to formation of neurofibril-
lary tangles and suggests that tau pathology develops second-
ary to Aβ injury and can be modulated via hypoxia-mediated
signalling.
Alterations in vascular permeability and BBB disruption
are detected in the brains of AD patients (Claudio, 1996).
However, deposition of Aβ aggregates in cerebrovasculature
and the brain is less understood and the mechanisms that
cause changes in permeability are not clear. The BBB regulates
the entry of plasma-derived Aβ into the brain and clears
brain-derived Aβ through the receptor for advanced glycation
end-products (RAGE) and low-density lipoprotein receptor-
related protein respectively (Shibata et al., 2000; Deane et al.,
2003). Previous reports showed increased levels of free Aβ in
plasma of AD patients or mouse models (Kawarabayashi et al.,
2001; Zhou et al., 2012). Through these studies, one can
speculate that Aβ may disrupt the TJs of BBB via interaction
with RAGE as a specific mediator. In agreement with this
hypothesis, a recent study performed by Kook et al. using
cultured ECs showed Aβ-induced structural alterations and
reduction in protein levels of ZO-1 as well as increased per-
meability. Furthermore, a neutralizing antibody against the
extracellular domain of RAGE effectively blocked Aβ-induced
alterations in ZO-1 distribution suggesting that Aβ–RAGE
interactions are critical for TJ integrity (Kook et al., 2012). It is
well known that calcium influx is induced by Aβ in the cells
(Kawahara et al., 2000) and increased intracellular calcium
also leads to TJ alterations as well as inducing MMP expres-
sion (Stuart et al., 1996; Rosenberg, 2009; Kook et al., 2012).
Thus, MMP activation could further accelerate degradation of
the BM as observed post-ischaemia and worsen the outcome
of AD.
Thus, although the amyloid hypothesis for the pathogen-
esis of AD suggests this peptide initiates a cascade of events
leading to neuronal injury and loss and eventually dementia,
from the studies mentioned above, vascular alteration may
significantly contribute to the disease as well. Recently,
Zlokovic presented an alternative, two-step vascular hypoth-
esis as discussed in the review (Zlokovic, 2011). The hypoth-
esis suggests that in the first step, the primary damage to
brain vasculature initiates a non-amyloidogenic pathway of
neuronal dysfunction and injury, which is mediated by BBB
dysfunction. This is correlated with leakage and secretion of
multiple toxic molecules and/or reduced blood flow, which
causes multiple focal ischaemic or hypoxic injuries. In the
second step, BBB dysfunction also leads to increased Aβ gen-
eration and impairment of Aβ clearance. Both these processes
contribute to accumulation of Aβ species in the brain and
toxicity. It is clear from this hypothesis that phenomena like
vascular regression and hypo-metabolism occur secondary to
vascular and/or Aβ injury but also that BBB alterations prob-
ably make a sizeable contribution to disease progression.
Temporal-spatial BBB disruption in senescence-accelerated
mouse prone 8 mice, considered by some researchers as a
model of AD, was recently reported (Del Valle et al., 2009).
However, the role of the perivascular cells, astrocytes and
pericytes, and the mechanisms that caused the changes in
permeability are not clear and require further investigation.
Vascular regression is a phenomenon observed in AD
patients (Zlokovic, 2005; Grammas, 2011) as well as in APP
transgenic mice – a model for late-stage AD (Paris et al., 2004).
For example, reduction in brain capillary length in the hip-
pocampus correlated well with increased clinical dementia
rating scores in AD patients (Bouras et al., 2006). The reason
for this phenomenon is unclear but could be explained partly
by the anti-angiogenic activity of Aβ (Thomas et al., 1996). Aβ
counteracts the pro-angiogenic effects of VEGF and bFGF in
ECs by sequestering VEGF in the plaques (Yang et al., 2004).
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Reduced angiogenic effects in AD are also caused by TGF-β1
(Tesseur and Wyss-Coray, 2006). Transgenic overexpression
of TGF-β1 in astrocytes stimulates Aβ deposition in brain
vessels, along with alterations in regional cerebral blood flow
and AD-like vascular degeneration and brain metabolic activ-
ity. Furthermore, elevated levels of TGF-β1 in human AD
correlate with increased Aβ deposition in brain vessels
(Wyss-Coray et al., 2001). However, it is noteworthy that
TGF-β1 can also be neuroprotective and promote Aβ clear-
ance as shown in microglia (Wyss-Coray et al., 2001). These
findings raise an interesting question of whether vascular
regression and/or degeneration in AD results from unsuccess-
ful vascular repair and/or remodelling.
Another phenomenon that occurs during AD progression
that may be modulated by BBB cells is hypo-metabolism.
Neurons are incapable of synthesizing or storing glucose and
are dependent on glucose transport across the BBB, a process
that is mediated by glucose transporters (GLUTs). GLUT1 is
also located on cerebrovascular ECs and astrocytes (Vannucci
et al., 1997). In AD, dysfunctional cerebral ECs express less
GLUT1 as well as HIF-1, a major regulator of GLUT1, thereby
reducing glucose uptake in the brain (Liu et al., 2008). Fur-
thermore, studies using 18F-fluorodeoxyglucose PET have
identified reductions in glucose uptake in individuals with a
high risk of dementia (Herholz, 2010). Decreased glucose
uptake across the BBB, as seen by PET, may also precede brain
atrophy (Herholz, 2010). This suggests that hypo-metabolism
due to BBB dysfunction is a contributing factor for disease
progression and occurs at a later stage after vascular and/or
Aβ injury. Whether swelling and retraction of astrocyte end-
feet inhibits glucose transport to neurons and thereby facili-
tates neuronal hypo-metabolism needs further study.
It is clear that many more studies are needed to fully
understand the effect of hypoxia-mediated changes on neu-
rodegenerative pathologies with respect to BBB function and
contribution of astrocytes and pericytes. And the question
remains, are we missing important mechanistic roles of the
BBB under pathophysiological conditions by studying the
nervous system in isolation from the influence of the vascular
system? The likely answer is yes. Thus, more research based
on the BBB and the NVU as a whole is warranted to provide
important insights in the future.
Pharmacology
HIF modulators as therapeutic targets
The important role for HIF-1 in the mediation of the adaptive
processes to hypoxia means that it could potentially repre-
sent an important target to prevent cellular damage during
disease progression. Targeting HIF-1 now represents a poten-
tial therapeutic strategy in numerous physiological including
myocardial ischaemia and cerebrovascular diseases. In this
regard, a wide variety of PHD inhibitors that cause stabiliza-
tion of HIF-1 have been developed as erythropoiesis
stimulating agents and neuroprotective drugs. Additionally,
activity relating to development of HIF-1 inhibitors to
prevent solid tumour angiogenesis has also exponentially
increased in the last years but may also be useful to prevent
BBB alterations during injury conditions. Some promising
advances in these areas are discussed below.
HIF stabilizers
The therapeutic potential of development and use of small
molecule HIF stabilizers to improve cell survival after injury is
gaining popularity in many different fields. In particular
PHDs, the enzymes that regulate HIF-1 stabilization, are now
being recognized as important targets for future medical
intervention. PHD enzymes require iron and 2-oxyglutarate
(2-OG) in order to catalyse HIF prolyl hydroxylation
(Jaakkola et al., 2001). hus iron chelators and competitive
inhibitors impair the activity of PHD enzymes and other
iron-dependent enzymes. deferoxamine, an iron chelator,
and cobalt chloride (CoCl2), a competitive inhibitor of iron,
are routinely used both in vitro and in vivo to inhibit PHD
enzyme activity and thus stabilize HIF. Both seem to be pro-
tective in preconditioning preclinical models of cerebral
ischaemia (Prass et al., 2002; Siddiq et al., 2005; Aminova
et al., 2008; Jones et al., 2008). Indeed, in vivo high concen-
trations of iron, stored in the cytoplasmic protein ferritin, are
released during ischaemia (Harten et al., 2010) and could lead
to radical-mediated damage of cellular components (Sorond
and Ratan, 2000). Thus, sequestration of iron in general may
be beneficial in certain injuries as well as making a major
contribution to the neuroprotective action of iron chelators
such as CoCl2. The 2-OG analogues L-mimosine, DMOG and
3,4-dihydroxybenzoate can also be used to inhibit PHD
enzymes (reviewed by Harten et al., 2010). Some small-
molecule activators have also been identified. A potent and
effective activator of the HIF pathway is tilorone. Tilorone
appears to be able to cross the BBB, stabilize HIF-1α protein
and confer significant resistance to stroke and spinal cord
injury by an as yet unknown mechanism (Ratan et al., 2008).
However, as its use is associated with the accumulation gly-
cosaminoglycans, its future use in humans is debatable
(Harten et al., 2010). Finally, the race is on for development of
novel PHD inhibitors, particularly for the treatment of ischae-
mic diseases such as stroke, and a number of compounds has
been developed by Fibrogen (reviewed by Harten et al., 2010).
A selection of the most promising PHD inhibitors currently
being considered for therapeutic strategies has recently been
reviewed (Nagel et al., 2010; Karuppagounder and Ratan,
2012). However, it must be emphasized that, although HIF
stabilizers mimic the neuroprotective effects of precondition-
ing in both in vitro and in vivo ischaemic models, the use of
PHD inhibition as a post-injury treatment remains somewhat
controversial. In mice, post-ischaemic PHD inhibition offered
less protection than pre-ischaemic treatments (Baranova
et al., 2007) and early activation of HIF-1α using DMOG
accentuated brain oedema and BBB disruption compared
with ischaemia alone (Chen et al., 2008b). Importantly, in
both cases, these effects were attributed to increased VEGF
levels with astrocytes being the most likely culprits
(Vangeison et al., 2008).
HIF inhibitors
Although identification of agents that specifically increase
hydroxylation activity of PHDs – and thus HIF-1 degradation
– is relatively unexplored, the fact that HIF-1 induction is
closely linked to BBB permeability means putative inhibitors
may have a relevant application preventing barrier changes
associated with hypoxic and/or ischaemic-induced injury
progression. Indeed, in the cancer field, targeting of HIF-1 in
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hypoxic cells is an attractive therapeutic strategy that is
already being actively pursued, since HIF-1 is tightly linked to
the metastatic potential of many tumours, treatment resist-
ance and poor prognosis (Hu et al., 2012; Meijer et al., 2012;
Xia et al., 2012). To date, a number of molecules that inhibit
the HIF-1 pathway have been identified predominantly using
cell-based screening systems and research of HIF-1 activity in
cancer cell lines. Supraphysiological supplementation of iron
and ascorbate enhances PHD activity and results in HIF-1
degradation (Harten et al., 2010) and has already been used in
the clinics. In addition, both are considered relatively safe,
inexpensive and readily available. 2-OG and its derivatives,
the rate-limiting co-substrate for PHDs, stimulate PHD activ-
ity and reduce basal HIF-1α protein levels suggesting they
may also have a therapeutic role (Ban et al., 2011). More-
over, targeted screening recently identified a compound,
KRH102053, as a PHD2 activator and showed it reduced levels
of HIF-1 and its downstream target genes, leading to inhibi-
tion of hypoxia-induced responses including metastasis and
glucose metabolism in vitro (Choi et al., 2008). A number of
other inhibitors have also been developed – for excellent
overviews of putative HIF-1 inhibitors in development as well
as clinical and preclinical trials see Ban et al. (2011); Xia et al.
(2012). Although various small molecules have been devel-
oped as HIF-1 inhibitors, the mechanisms by which they
work are still unclear in many cases. The fact that none of
them seem to exclusively target HIF-1α signalling suggests
they can also have multiple off-target effects. Perhaps an
exception is EZN-2968, an RNA antagonist that targets HIF-1α
mRNA and thereby directly inhibits HIF-1α expression
(Greenberger et al., 2008). Tumour reduction was found in
nude mice implanted with DU145 human prostate cancer
cells treated with EZN-2968 and a phase I clinical study in
patients with advanced malignancies revealed that EZN-2968
was well tolerated (Ban et al., 2011). EZN-2968 is currently
discussed as the best potential for specific HIF-1α inhibition
and promising results of the clinical studies are expected (Ban
et al., 2011).
In conclusion, the future looks bright for the use of HIF
inhibitors as therapeutics, but overall, it is apparent that
future design of more specific agents is required for better
drugs to be developed. Perhaps such drugs will also be useful
to prevent BBB disruption particularly during the acute phase
after injury in the future.
Targeted BBB cell-specific treatment
The major focus of therapeutic targets has always been neu-
ronal mechanisms of injury. Notably, attention to dysfunc-
tion or loss of non-neuronal cell types, that is, the cells that
maintain the neuronal homeostatic environment, are
avenues not well explored even though they may signifi-
cantly increase the chances of success. As discussed above,
HIF stabilization, and/or PHD inhibition, compromises
barrier stability and as such targeting HIF-1 may be a way to
maintain barrier stability during injury. Using therapeutic
targets that activate a broad programme of genes in different
cell types, as discussed above, may stimulate biological effects
better than the separate application of growth factors or other
repair proteins (reviewed by (Ratan et al., 2007), especially in
this case as an endogenous programme of adaptation is aug-
mented. However, the wide range of HIF targets could have
the caveat that modulation of multiple processes could
potentially have a negative outcome on whole body physiol-
ogy. For example, clinical syndromes associated with exces-
sive activation of the HIF pathway exist (Gassmann et al.,
2003) and whereas some studies indicate that HIF-1 is neu-
roprotective, others demonstrate negative outcomes. Clearly,
the effects on the NVU in particular must be better under-
stood to ascertain the general widespread application of such
therapeutics. Since different cell types of the BBB and CNS
show diverse and sometimes opposing responses to HIF-1
modulation, targeting the pathway in a cell-specific manner
will circumvent adverse side effects that can be expected of
general HIF-1 modulators. Cell-specific therapeutics (e.g.
endothelial-, astrocyte- or pericyte-specific drugs) may also
result in more efficacious treatment and better tailoring to the
injury in question. Targeting and augmenting vascular EC
function directly will provide the significant advantage that
such drugs would not be required to cross the BBB, that is, be
easier targets than current neuron-directed research. Thus,
detailed knowledge of cell-specific responses during injury is
required to support development of more specific therapeutic
agents. Additionally, in-depth knowledge of the side effects of
long-term or high-dose treatments must be well defined prior
to their clinical implementation. It must also be emphasized
that the consequence of increased levels of HIF-1 in different
cell types is highly divergent and dependent on the type of
injury. Indeed, it is now becoming clear that the PHDs may
also have specific endogenous substrates as well as divergent
cell-specific roles (Smirnova et al., 2012). Thus, an additional
challenge will be whether development of isoform-specific
inhibitors will be more efficacious and safe than a more
global approach. Clearly, BBB cell-specific responses and their
contribution to injury progression are instrumental factors
that need to be carefully considered, and the balance of HIF-1
neuroprotective effects with the putative negative outcome
on BBB function must be weighed before implementing any
treatment strategy.
Conclusion
Overall, hypoxia and HIF-1 significantly contribute to BBB
dysfunction in various neurological diseases. The influence of
BBB cell specificity to outcome remains very unclear but
deserves significantly more investigation since this knowl-
edge will enable development of more effective therapeutic
strategies to combat disease progression. Clearly, balancing
HIF-1 beneficial and deleterious effects with cell-specific
responses, disease profiles, and windows of opportunity will
be very difficult.
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8 ABBREVIATIONS 
2ME2   2-Methoxyestradiol 
α-SMA   α-smooth muscle actin 
AC   Astrocyte 
acetyl-CoA  Acetyl coenzyme A 
AF-6   Afadin  
AJ   Adherens junction 
ANG   Angiopoietin 
ARNT   Aryl hydrocarbon receptor nuclear translocator 
ATP   Adenosine triphosphate 
AX   Near anoxia 
BBB   Blood-brain barrier 
bFGF   Basic fibroblast growth factor 
BHS   Bluthirnschranke 
BNIP3   BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
BrdU   Bromodeoxyuridine 
CNS   Central nervous system 
CoCl2   Cobalt chloride 
CR   Creatine 
DFO   Deferoxamine mesylate salt 
DMOG   Dimethyloxalylglycine 
DNA   Deoxyribonucleic acid 
EC   Endothelial cell 
ELISA   Enzyme-linked immunosorbent assay 
FADH2   Flavin adenine dinucleotide  
GFAP   Glial fibrillary acidic protein 
GLUT   Glucose transporter 
GSH   Glutathione 
GSSG   Glutathione disulfide 
HIF   Hypoxia-inducible factor 
HX   Hypoxia 
LC-MS   Liquid chromatography-mass spectrometry 
LC3   Microtubule-associated protein light chain 3 
MMP   Matrix metalloproteinase 
MS   Mass spectrometry 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADH   Nicotinamide adenine dinucleotide 
NX   Normoxia 
OGD   Oxygen-glucose deprivation 
PC   Pericyte 
PCA   Principal component analysis 
pCR   Phosphocreatine 
PCR   Polymerase chain reaction 
PDGF   Platelet-derived growth factor 
PHD   Prolyl hydroxylase 
RBE4   Rat brain endothelial 4 
RBMEC  Rat brain microvascular endothelial cell 
ROS   Reactive oxygen species 
TCA   Tricarboxylic acid 
TEER   Transendothelial electrical resistance 
TJ   Tight junction 
UDP-glucose  Uridindiphosphate-glucose 
VEGF   Vascular endothelial growth factor 
YC-1   3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole  
ZO-1   Zonula occludens 1 
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